General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) by United States Advisory Committee on Immunization Practices.
Please note: An erratum has been published for this issue. To view the erratum, please click here.
Centers for Disease Control and Prevention
MMWR Morbidity and Mortality Weekly Report
Recommendations and Reports /  Vol. 60 / No. 2 January 28,2011
General Recommendations on Immunization
Recommendations of the Advisory Committee 
on Immunization Practices (ACIP)
Continuing Education Examination available at http://www.cdc.gov/m m wr/cm e/conted.htm l
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
CONTENTS
Introduction........................................................................................... 3
Methods..............     4
Timing and Spacing of Immunobiologies............................................4
Contraindications and Precautions.....................................................10
Preventing and Managing Adverse Reactions................................... 11
Vaccine Administration........................................................................13
Storage and Handling of Immunobiologies.......................................17
Altered Immunocompetence............................................................. 19
Special Situations.................................................................................23
Vaccination Records.............................................................................30
Vaccination Programs.......................................................................... 31
Vaccine Information Sources.............................................................. 34
Acknowledgments ..........................................  35
References.............................................................................................52
Abbreviations.......................................................................................59
Glossary.................................................................................................60
CDC, our planners, and our content experts wish to disclose that they have no financial 
interests or other relationships w ith  the manufacturers o f commercial products, sup­
pliers o f commercial services, or commercial supporters. This report w ill not include 
any discussion o f the unlabeled use o f a product or a product under investigational 
use w ith  the exception o f the following situations:
1. The nonsimultaneous administration o f yellow fever (YF) vaccine and inactivated 
vaccines.
2. Simultaneous administration o f an inactivated and live vaccine (e.g., pneumococcal 
polysaccharide vaccine [PPSV] and zoster [Zos] vaccine).
3. Interchangeability o f combination vaccines and single-component vaccines (e.g., 
using single-component Haemophilus influenzae type b [H ib ], diphtheria and 
tetanus toxoids and acellular pertussis (DTaP), and inactivated poliovirus [IPV] 
for later doses in series, after a series has begun w ith  DTaP-IPV/Hib).
4. Interchangeability o f brands o f combination vaccines and single-component 
vaccines (e.g., using D TaP-IPV/H ib and single-component hepatitis B [Hep B] 
vaccine for later doses in series that m ight have previously included DTaP-IPV- 
HepB and H ib).
5. Rotarix and RotaTeq need not be repeated i f  an infant spits up or regurgitates a dose.
6. Contact allergy to latex is neither a contraindication nor a precaution to the use 
o f quadrivalent meningococcal conjugate vaccine (M CV4) in the absence o f an 
anaphylactic allergy.
7. No need to  repeat a dose o f M C V 4 vaccine given subcutaneously.
8. Revaccination w ith  M CV4.
9. Appropriate storage and handling for the following vaccines at 35°F—46°F:
Disclosure o f Relationship
DTaP 
Hib
Hepatitis A  
Hepatitis B
Human papillomavirus (HPV) 
PPSV
Measles, mumps, and rubella (M M R) 
Pneumococcal conjugate vaccine (PCV) 
Rotavirus (RV)
Tetanus toxoid, reduced diphtheria toxoid, 
and acellular pertussis (Tdap) vaccine 
Trivalent inactivated influenza vaccine (TIV)
10. Initiation o f live Zos vaccine in immunocompetent patients 3 months after remission 
from chemotherapy.
11. Avoiding conception for 1 month after vaccination w ith  M M R  or varicella (Var) 
vaccine.
12. A  m inimum age o f 12 months for the fourth dose o f DTaP.
13. Use o f pneumococcal conjugate vaccine and Haemophilus influenzae b vaccine in 
persons receiving hematopoietic cell transplant or who are infected w ith human 
immunodeficiency virus, regardless o f age.
There is no commercial support for this activity.
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Summary
This report is a revision o f  the General Recommendations on Immunization a?id updates the 20 0 6  statement by the Advisory 
Committee on Immunization Practices (ACIP) (CDC. General recommendations on immunization: recommendations o f  the Advisory 
Committee on Immunization Practices [ACIP], M M W R  2006;55[No. RR-15J), The report also includes revised content from previ­
ous AC IP  recommendations on thefollowing topics: advdt vaccination (CDC. Update on adult immunization recommendations o f  the 
immunization practices Advisory Committee [ACIP], M M W R  1991;40[No. RR-12]); the assessment and feedback strategy to increase 
vaccination rates (CDC. Recommendations o f  the Advisory Committee on Immunization Practices: programmatic strategies to increase 
vaccination rates— assessment and feedback o f  provider-based vaccination coverage information. M M W R  1996;45:219—20); linkage 
o f  vaccination services and those o f  the Supplemental Nutrition Program fo r  Women, Infants, and  Children (W IC  program) (CDC. 
Recommendations o f  the Advisory Committee on Immunization Practices: programmatic strategies to increase vaccination coverage by 
age 2  years— linkage o f  vaccination and W IC  services. M M W R  1996;45:217-8); adolescent immunization (CDC. Immunization  
o f  adolescents: recommendations o f  the Advisory Committee on Immunization Practices, the American Academy o f  Pediatrics, the 
American Academy o f  Family Physicians, and the American Medical Association. M M W R  1996;45[No. RR-13J); and combination 
vaccines (CDC. Combination vaccines for childhood immunization: recommendations o f  the Advisory Committee on Immunization  
Practices [ACIP], the American Academy o f  Pediatrics [AAPJ, and the American Academy ofFamily Physicians [AAFP], M M W R  
1999:48[No. RR-5J).
Notable revisions to the 2 0 0 6 recommendations include 1 ) revisions to the tables o f  contraindications andprecautions to vaccination, 
as well as a separate table o f  conditions that are commonly misperceived as contraindications andprecautions; 2) reordering ofthe report 
content, with vaccine risk-beneft screening, managing adverse reactions, reporting o f  adverse events, and the vaccine injury compensation 
program presented immediately after the discussion ofcontraindications andprecautions; 3) stricter criteria fo r  selecting an appropriate 
storage unitfor vaccines; 4) additional guidancefor maintaining the cold- chain in the event o f  unavoidable temperature deviations; and  
5) updated revisions fo r  vaccination o f  patients who have received a hematopoietic cell transplant. The most recent AC IP  recommenda­
tions for each specific vaccine should be consulted fo r  comprehensive details. This report, AC IP  recommendations fo r  each vaccine, and  
additional information about vaccinations are available from CD C a t http://www.cdc.gov/vaccines.
clinicians and other health-care providers about concerns that 
com m only arise w hen vaccinating persons o f  various ages. 
Providers and patients encounter num erous issues, such as 
the tim ing o f  each dose, screening for contraindications and 
precautions, the num ber o f  vaccines to be adm inistered, the 
educational needs o f  patients and parents, and interpreting 
and responding to adverse events. Vaccination providers help 
patients understand the substantial, occasionally conflicting, 
inform ation about vaccination. These vaccination recom ­
m endations are intended for clinicians and other health-care 
providers w ho vaccinate patients.
Introduction
C D C  recom m ends ro u tin e  vaccination  to  p reven t 17 
vaccine-preventable diseases that occur in infants, children, 
adolescents, or adults. T his report provides inform ation for
T h e  m ateria l in  th is  re p o rt o r ig ina te d  in  the N a tio n a l C en te r fo r 
Im m u n iz a t io n  and  R e sp ira to ry  Diseases, A n n e  S chuchat, M D ,  
D irecto r.
C o rre sp o n d in g  preparer: A n d re w  Kroger, M D ,  N a tio n a l C en te r fo r 
Im m u n iza tio n  and R espira tory Diseases, 1600 C lif to n  R d., M S  E-52, 
A tlan ta , G A  30333. Telephone: 40 4-63 9-1 958 ; Fax: 404-639-8828 ; 
E -m a il: aok2@cdc.gov.
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T he guidance in this report will help vaccination provid­
ers to assess vaccine benefits and risks, use recom m ended 
adm inistration and storage practices, understand the m ost 
effective strategies for ensuring that vaccination coverage in the 
population remains high, and com m unicate the im portance 
o f  vaccination to reduce the effects o f  vaccine-preventable 
disease. These recom m endations are intended for use in the 
U nited States; vaccine availability, use, and epidemiologic cir­
cumstances m ight differ in o ther countries and m ight warrant 
different recom m endations.
Methods
T he Advisory Com m ittee on Immunization Practices (ACIP) 
General Recommendations W ork Group (GRWG) revises the 
General Recommendations on Immunization every 3 to 5 years. 
Relevant topics are those identified by ACIP as topics that relate 
to all vaccines, including timing and spacing o f doses, vaccine 
administration, and vaccine storage and handling. New topics 
often are added when ACIP decides that previous ACIP state­
ments on general issues such as combination vaccines, adolescent 
vaccination, or adult vaccination should be revised and combined 
with the General Recommendations on Immunization.
T h e recom m endations in this report are based no t only 
on available scientific evidence bu t also on expertise that 
comes directly from a diverse group o f  health-care providers 
and public health  officials. G RW G  includes professionals 
from  academ ic m edicine (pediatrics, fam ily practice, and 
pharmacy); international (Canada), federal, and state public 
health professionals; and a m em ber from the nongovernmental 
Im m unization Action Coalition. GRW G, which met m onthly 
beginning June 2007, formed subgroups on the basis o f  in ter­
est in topics such tim ing and spacing, vaccine adm inistration, 
and storage and handling. These subgroups also m et monthly, 
conducted literature reviews, and contributed expert opinion 
on the need for revisions to specific language. In O ctober 2008, 
G RW G  consulted A C IP to determ ine the best m echanism  for 
approving the resulting docum ent. A CIP concluded that the 
docum ent could be approved and finalized increm entally with 
a final vote on the entire docum ent.
Revisions to the following sections were approved through con­
sensus vote in October 2008 (i.e., were approved as a part o f  the 
entire document and not through separate votes on each section): 
l)T im ing and Spacing oflmmunobiologics; 2) Contraindications 
and Precautions; 3) Preventing and Managing Adverse Reactions; 
4) Reporting Vaccine Adverse Events; 5) the National Vaccine 
Injury Compensation Program; and 6) Vaccine Administration. 
In February 2009, revisions were made to Storage and Handling 
o f Immunobiologies, and ACIP approved the section. In June
2009, ACIP voted to incorporate the contents of a 1999 ACIP 
statement on combination vaccines. The statement was revised 
by GRW G and the ACIP Com bination Vaccines W ork Group. 
ACIP also approved m inor changes to the section on Special 
Situations and the section on Vaccination Records. In October 
2009, ACIP voted to revise the entire General Recommendations 
on Immunization, which incorporated ACIP recommendations on 
adolescent vaccination (1996) and adult vaccination (1991) into 
the section on Vaccination Programs. Three votes were taken to 
approve various sections of the document, and one vote was taken 
to approve the entire document. At this final meeting, ACIP also 
discussed concerns about the lack o f  evidence that supports use o f 
antipyretics before or at the time o f vaccination for the prevention 
o f fever. Consequently, C D C  added information highlighting 
the lack o f evidence for the use o f antipyretics to the section on 
Methods for Alleviating Discomfort and Pain Associated with 
Vaccination. The last meeting o f GRW G was held on December 
2, 2009. This meeting served solely to update the work group 
regarding the discussions and vote of the October 2009 meeting 
and C D C  deliberations on changes to the recommendations on 
the use o f  antipyretics.
Timing and Spacing 
of Immunobiologies
General Principles for Vaccine Scheduling
O ptim al response to a vaccine depends on m ultiple factors, 
including the type o f  vaccine, age o f the recipient, and im m une 
status o f  the recipient. Recom m endations for the age at which 
vaccines are adm inistered are influenced by age-specific risks 
for disease, age-specific risks for complications, age-specific 
responses to vaccination, and potential interference w ith the 
im m une response by passively transferred maternal antibodies. 
Vaccines are recom m ended for m embers o f  the youngest age 
group at risk for experiencing the disease for w hich efficacy 
and safety have been dem onstrated.
Certain products, including inactivated vaccines, toxoids, 
recombinant subunit vaccines, polysaccharide conjugate vaccines, 
and live vaccines, require >2 doses to elicit an adequate antibody 
response. Tetanus and diphtheria toxoids require booster doses 
to maintain protective antibody concentrations. Unconjugated 
polysaccharide vaccines do not induce T-cell memory, and addi­
tional doses (although they elicit the same or a lower antibody 
concentration) might increase the level o f protection. Conjugation 
with a protein carrier improves the effectiveness o f polysaccharide 
vaccines by inducing T-lymphocyte—dependent immunologic 
function. M any vaccines that stim ulate bo th  cell-mediated 
im m unity and neutralizing antibodies (e.g., live, attenuated virus
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vaccines) usually can induce prolonged immunity, even if antibody 
titers decline over time (7). Subsequent exposure to such viruses 
usually results in a rapid anamnestic antibody response without 
viremia.
Approxim ately 90% —95%  o f recipients o f  a single dose o f 
certain live vaccines adm inistered by injection at the recom ­
m ended age (i.e., measles, rubella, and yellow fever vaccines) 
develop protective antibodies, generally w ithin 14 days o f  the 
dose. For varicella and m um ps vaccines, 80% —85%  o f  vac- 
cinees are protected after a single dose. However, because a 
limited proportion (5% —15%) o f  measles, m um ps, and rubella 
(M M R) or varicella vaccinees fail to respond to 1 dose, a sec­
ond dose is recom m ended to provide another opportun ity  to 
develop im m unity  (2). O f  those who do not respond to the 
first dose o f  M M R  or varicella vaccine, 97% —99%  respond to 
a second dose (3,4).
T he Recommended Im m unization Schedules fo r  Persons Aged 
0 Through 18 Years and the Recommended A dult Im m unization  
Schedule are revised annually. Physicians and other health-care 
providers should ensure that they are following the m ost up- 
to-date schedules, w hich are available from C D C  at h ttp :// 
www.cdc.gov/vaccines.
Spacing of Multiple Doses 
of the Same Antigen
Vaccination providers should adhere as closely as possible to 
recom m ended vaccination schedules (Table 1). A dm inistration 
at recom m ended ages and in accordance w ith recom m ended 
intervals between doses o f m ultidose antigens provide optim al 
protection.
A dm inistration o f doses o f  a multidose vaccine using inter­
vals that are shorter than recom m ended m ight be necessary in 
certain circumstances, such as im pending international travel 
or w hen a person is behind schedule on vaccinations but needs 
rapid protection. In these situations, an accelerated schedule 
can be im plem ented using intervals between doses that are 
shorter than intervals recom m ended for routine vaccination. 
T he accelerated or m inim um  intervals and ages for schedul­
ing catch-up vaccinations are available at http://www.cdc.gov/ 
vaccines. Vaccine doses should not be administered at intervals 
less than these m inim um  intervals or at an age that is younger 
than the m inim um  age.*
* D uring  measles outbreaks, i f  cases are occurring among infants aged <12 months, 
measles vaccination o f  infants as young as 6 months can be used as an outbreak 
control measure. However, doses administered at ages <12 months should no t be 
counted as part o f  the series (Source: C D C . Measles, mumps, and rubella vaccine 
use and strategies for elim ination o f  measles, rubella, and congenital rubella syn­
drome and control o f  mumps: recommendations o f  the Advisory Comm ittee on 
Im m unization Practices [ACIP]. M M W R  1998;47[No. RR-8]).
Before adm inistering a vaccine dose, providers m ight need 
to verify that all previous doses were adm inistered after the 
m in im um  age and in accordance w'ith m in im um  intervals 
(Table 1). In clinical practice, vaccine doses occasionally are 
adm inistered at intervals less than the m inim um  interval or at 
ages younger than the m inim um  age. Doses adm inistered too 
close together or at too young an age can lead to a suboptim al 
im m une response. However, adm inistering a dose a few days 
earlier the m inim um  interval or age is unlikely to have a sub­
stantially negative effect on the im m une response to that dose. 
Vaccine doses administered <4 days before the m inim um  inter­
val or age are considered valid; however, local or state mandates 
m ight supersede this 4-day guideline.1 (Day 1 is the day before 
the day that marks the m inim um  age or m inim um  interval for 
a vaccine.) Because o f  the unique schedule for rabies vaccine, 
the 4-day guideline does no t apply to this vaccine (5). Doses 
o f  any vaccine adm inistered >5 days earlier than the m inim um  
interval or age should not be counted as valid doses and should 
be repeated as age appropriate. T he repeat dose should be 
spaced after the invalid dose by the recom m ended m inim um  
interval (Table 1). For example, if  the first and second doses o f 
Haemophilus influenzae type b (Hib) were adm inistered only 
14 days apart, the second dose would be invalid and need to be 
repeated because the m inim um  interval from  dose 1 to dose 2 
is 4 weeks. T h e  repeat dose should be adm inistered >4 weeks 
after the invalid dose (in this case, the second). T he repeat dose 
is counted as the valid second dose.
If  the first dose in a series is given >5 days before the recom ­
m ended m inim um  age, the dose should be repeated on or after 
the date when the child reaches at least the m in im um  age. If  
the vaccine is a live vaccine, ensuring that a m inim um  interval 
o f  28 days has elapsed from  the invalid dose is recom m ended. 
For example, if  the first dose o f  varicella vaccine were inadver­
tently  adm inistered at age 10 m onths, the repeat dose would 
be adm inistered no earlier than the child’s first birthday (the 
m inim um  age for the first dose). I f  the first dose o f  varicella 
vaccine were adm inistered at age 11 m onths and 2 weeks, the 
repeat dose should be adm inistered no earlier than 4 weeks 
thereafter, w hich would occur after the first birthday.
Certain vaccines (e.g., adult tetanus and diphtheria toxoids 
[T d], pediatric diphtheria and tetanus toxoids [DT]; and teta­
nus toxoid) produce increased rates o f  local or systemic reac­
tions in certain recipients w hen adm inistered more frequently 
than recommended (6, / ) .  Careful record keeping, maintenance
In  certain situations, local or state requirements m ig h t mandate tha t doses o f  
selected vaccines be administered on or after specific ages. For example, a school 
entry requirement m igh t n o t accept a dose o f  M M R  o r varicella vaccine ad­
m inistered before the ch ild ’s firs t birthday. A C IP  recommends tha t physicians 
and other health-care providers com ply w ith  local or state vaccination require­
ments when scheduling and adm inistering vaccines.
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of patient histories, use o f  im m unization inform ation systems 
(IISs), and adherence to recom m ended schedules can decrease 
the incidence o f  such reactions w ithout adversely affecting 
im m unity
Simultaneous Administration
Sim ultaneous ad m in is tra tio n  o f  vaccines is defined as 
adm inistering more than one vaccine on the same clinic day, 
at different anatom ic sites, and not com bined in the same 
syringe. Experimental evidence and extensive clinical experi­
ence provide the scientific basis for adm inistering vaccines 
sim ultaneously Sim ultaneously adm inistering all vaccines for 
w hich a person is eligible at the tim e o f a visit increases the 
probability that a child, adolescent, or adult will be vaccinated 
fully by the appropriate age (8). A study conducted during a 
measles outbreak dem onstrated that approxim ately one third 
o f  measles cases am ong unvaccinated bu t vaccine-eligible 
preschool children m ight have been prevented if  M M R  had 
been adm inistered at the same visit w hen another vaccine was 
adm inistered (9). Simultaneous adm inistration also is criti­
cal when preparing for foreign travel and w hen a health-care 
provider is uncertain that a patient will return for additional 
doses o f  vaccine.
W ith  some exceptions, sim ultaneously adm inistering the 
m ost widely used live and inactivated vaccines has produced 
seroconversion rates and rates for adverse reactions similar to 
those observed w hen the vaccines are adm inistered separately 
{10—13). R outine adm inistration o f  all age-appropriate doses 
o f vaccines sim ultaneously is recom m ended for children for 
w hom  no specific contraindications exist at the time o f the 
visit. M M R  and varicella vaccine can be adm inistered sim ul­
taneously. Live, attenuated  influenza vaccine (LAIV) does 
not interfere w ith  the im m une response to M M R  or varicella 
vaccines administered at the same visit. N o data exist about 
the im m unogenicity  o f  oral Ty21a typhoid  vaccine w hen 
ad ministered concurrently or w ithin 30 days o f  live virus vac­
cines. In the absence o f  such data, if  typhoid vaccination is 
warranted, adm inistration should not be delayed because o f 
recent adm inistration o f  live, attenuated virus vaccines (14). 
Simultaneous ad m inistration of pneumococcal polysaccharide 
vaccine (PPSV) and inactivated influenza vaccine elicits a satis­
factory antibody response w ithout increasing the incidence or 
severity o f adverse reactions (75). Simultaneous adm inistration 
o f  PPSV and inactivated influenza vaccine is recom m ended 
for all persons for w hom  both vaccines are indicated. Tetanus 
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) 
and trivalent inactivated influenza vaccine (TIV) can be adm in­
istered sim ultaneously (76). H epatitis B vaccine administered 
w ith yellow fever vaccine is as safe and im m unogenic as when
these vaccines are adm inistered separately (77). Measles and 
yellow fever vaccines have been adm inistered safely at the same 
visit and w ithout reduction o f im m unogenicity o f  either o f 
the com ponents (18,19).
D epending on w hich vaccines are adm inistered during the 
first year o f  life, a child m ight receive up to nine injections 
at the 12- through 15-m onth  visit (M M R , varicella, H ib, 
pneum ococcal conjugate vaccine [PCV], pediatric diphtheria 
and tetanus toxoids and acellular pertussis [DTaP], inacti­
vated poliovirus [IPV], hepatitis A, hepatitis B, and influenza 
vaccines). A lthough there is no exact lim it on the num ber o f  
injections, w ith a little flexibility, a provider can ensure that 
the prim ary series doses are given w ithout adm inistering too 
m any injections at each visit. To reduce the num ber o f  injec­
tions at the 12- through 15-m onth visit, the hepatitis B series 
and 3 doses o f  IPV  (20) can be adm inistered before the child’s 
first birthday.
T here are m any other examples o f  ways the vaccination 
schedule provides flexibility. T he m ajority o f  children aged 1 
year w'ho have received 2 H ib vaccine doses (polyribosylribitol 
phosphate-m eningococcal ou ter m em brane p ro tein  [PRP- 
O M P]) or 3 H ib vaccine doses (PRP-tetanus ' PR P-T  ) and 3 
previous doses o f  DTaP and PC V  have protection against H ib, 
diphtheria, pertussis, tetanus, and pneum ococcus, w hich lasts 
throughout infancy (21,22). T he  third (PR P-O M P) or fourth 
(PRP-T) dose o f the H ib  series and the fourth  doses o f DTaP 
and PC V  are critical in boosting antibody titer and ensuring 
continued protection (22—25). The fourth dose o f  DTaP is rec­
om m ended at age 15—18 m onths bu t may be adm inistered as 
early as age 12 m onths if  6 m onths have elapsed since the third 
dose and if  there is concern that the child m ight not return by 
age 18 m onths (23). For infants at low risk for infection w ith 
hepatitis B virus (i.e., m other tested negative for hepatitis B 
surface antigen [HBsAg] at the tim e o f  delivery and is not in 
a high risk group), the hepatitis B series can be com pleted at 
any tim e for children aged 6—18 m onths (26). T he  m inim um  
age for adm inistration o f  com bination vaccines is the oldest 
m inim um  age for any o f  the individual com ponents; the m ini­
m um  interval between doses is equal to the greatest m inim um  
interval o f  any o f  the individual com ponents. W ith  use o f  the 
com bination H ib-hepatitis B vaccine, the m inim um  age o f 
adm inistration o f the final dose is 12 m onths because o f the 
m inim um  age requirem ent for the last dose o f  the H ib series 
(26). Recommended spacing o f  doses should be m aintained 
(Table 1).
Combination Vaccines
C om bination vaccines merge equivalent com ponent vac­
cines into single products to prevent more than one disease
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or to pro tect against m ultip le strains o f  infectious agents 
causing the same disease. Licensed com bination vaccines can 
be used whenever any com ponents o f  the com bination are 
indicated and its o ther com ponents are no t contraindicated 
and if  licensed by the Food and D rug A dm inistration (FDA) 
for that dose in the series. Use o f  com bination vaccines can 
reduce the num ber o f  injections patients receive and alleviate 
concern associated w ith the num ber o f injections (20,27,28). 
Studies have dem onstrated that parents and providers m ight 
be uncom fortable w ith m ultiple injections during single visits 
(29—31). Potential advantages o f  com bination vaccines include 
1) improved vaccine coverage rates (32), 2) timely vaccination 
coverage for children who are behind the schedule (33,34), 
3) reduced shipping and stocking costs, 4) reduced costs for 
extra health-care visits necessitated by deferral o f  vaccination, 
and 5) facilitation o f  additional new vaccines into vaccination 
programs.
Potential disadvantages o f  com bination vaccines include the 
following: 1) adverse events that m ight occur more frequently 
after adm inistration o f  a com bination vaccine compared w ith 
adm inistration o f  separate antigens at the same visit, such 
as those that occur w ith the com bination measles, m um ps, 
rubella, and varicella (M M RV) vaccine and com bination  
DTaP-hepatitis B-IPV vaccine (35,36); 2) confusion and uncer­
tainty about selection o f  vaccine com binations and schedules 
for subsequent doses, especially when vaccinations are given 
by m ultiple providers who m ight be using different products;
3) reduced im m unogenicity o f  one or more com ponents (37);
4) extra doses o f  certain antigens in the fixed product (e.g., a 
provider who uses DTaP-hepatitis B-IPV vaccine will give an 
extra dose o f  hepatitis B com ponent); and 5) a shorter shelf- 
life than  the individual com ponent vaccines. T he economic 
im pact o f  the use o f  com bination vaccines is unclear because 
com bination products have the potential for either increased 
or decreased costs com pared w ith single-antigen com ponent 
vaccines. T h e  price o f  a com bination vaccine m ight exceed the 
total price o f  separate vaccines containing the same antigens. 
However, com bination vaccines might represent a better overall 
economic value if the direct and indirect costs o f  extra injec­
tions, delayed or missed vaccinations, and additional handling 
and storage are taken into consideration (38).
Licensed Combination Vaccines
In this report, a com bination vaccine is defined as a prod­
uct containing com ponents that can be divided equally into 
independently  available routine vaccines. A dash ( - ) between 
vaccine products indicates that products are supplied in their 
final form by the m anufacturer and do not require mixing 
or reconstitution by the user. A  slash ( / ) indicates that the 
products m ust be mixed or reconstituted by the user. Seven
com bination vaccines for w hich separate antigens or antigen 
com binations exist have been licensed by FD A  since 1996 in 
the U nited States (Table 2) (39—45). In the future, com bina­
tion vaccines m ight include increasing num bers o f  components 
in different arrays to protect against these and other diseases. 
(The status o f licensure and recom m endations for new vac­
cines is available at http ://aapredbook.aappublications.org/ 
new s/vaccstatus.shtm l.) T h e  use o f  a com bination  vaccine 
generally is preferred over separate injections o f  the equivalent 
com ponent vaccines. Considerations should include provider 
assessment,§ patient preference, and the potential for adverse 
events. A n exception is the first dose o f  MMRV. Unless the 
parent or caregiver expresses a preference for M M R V  vaccine, 
M M R  and varicella vaccine should be administered for the 
first dose for children aged 12—47 m onths (35).
Situations m ight arise in  w hich one com ponent o f  a com ­
bination vaccine is specifically preferred to another com po­
nent in that same vaccine. Future research considerations for 
newly licensed com bination vaccines should focus on safety 
o f  doses that are not needed because a patient is already vac­
cinated against the agents, w hether the com bination vaccine 
will im prove the tim eliness o f  vaccination, and poten tia l 
reduced costs from disease prevention resulting from timely 
vaccination.
Combination Vaccines and FDA Licensure
O nly  com bination vaccines licensed by FDA should be used. 
Vaccination providers should not com bine separate vaccines 
into the same syringe to adm inister together unless mixing is 
indicated for the patien t’s age and is explicitly specified on the 
FDA-approved product label inserts. O nly  two com bination 
vaccines (D TaP-IPV /H ib vaccine, marketed as Pentacel, and 
D T aP/H ib, m arketed as T riH ibit) contain separate antigen 
com ponents for w hich FD A  approves m ixing by the user. 
T he safety, im m unogenicity, and effectiveness of unlicensed 
com binations are unknow n.
Interchangeability of Formulations
FD A  generally licenses a com bination  vaccine based on 
studies dem onstrating that the product’s im m unogenicity (or 
efficacy) and safety are comparable or equivalent to m onova­
lent or com bination products licensed previously (46). FDA 
licensure also generally indicates that a com bination vaccine 
may be used interchangeably w ith monovalent formulations 
and other com bination  products w ith  sim ilar com ponent 
antigens produced by the same m anufacturer to continue the 
vaccination series. For example, DTaP, D T aP/H ib, and future
'' Provider assessment should include num ber o f  injections, vaccine availability, 
like lihood  o f  im proved coverage, like lihood o f  patient re turn, and storage and 
cost considerations.
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DTaP vaccines that contain similar acellular pertussis antigens 
from  the same m anufacturer may be used interchangeably if 
licensed and indicated for the patient’s age (45).
Interchangeability of Combination Vaccines from  
Different Manufacturers
Licensure o f  a vaccine by FD A  does no t necessarily indicate 
that the vaccine is interchangeable w ith products from  other 
manufacturers. Such data are ascertained and interpreted more 
readily for diseases w ith  know n correlates o f protective im m u­
nity  (e.g., specific serologic markers). For diseases w ithout 
such surrogate laboratory markers, prelicensure field vaccine 
efficacy (phase III) trials or postlicensure surveillance generally 
are required to determ ine protection (47). A CIP prefers that 
doses o f  vaccine in a series come from the same manufacturer; 
however, if this is no t possible or if  the m anufacturer of doses 
given previously is unknow n, provid ers should adm inister the 
vaccine that they have available.
Vaccine Supply
A lthough  vaccination  providers should stock sufficient 
quantities o f  com bination and monovalent vaccines needed to 
vaccinate children, adolescents, and adults against all diseases 
for w hich vaccines are recom m ended (20,28), all available 
types or brand-nam e products need no t be stocked. Potential 
advantages o f  stocking a lim ited num ber o f  vaccines include 
1) reducing confusion and potential errors w hen staff m em ­
bers m ust handle redundant products and form ulations, 2) 
m inim izing waste w hen less com m only used products expire, 
3) decreasing cold storage capacity requirements, and 4) m ini­
mizing administrative costs related to  accounting, purchasing, 
and handling.
Extra Doses of Vaccine Antigens
A dm inistering extra antigens contained in a com bination 
vaccine should be avoided in m ost situations. Using com bina­
tion vaccines containing certain antigens not indicated at the 
tim e o f adm inistration to a patient m ight be justified when 
1) the extra antigen is not contraindicated, 2) products that 
contain only the needed antigens are not readily available, 
and 3) potential benefits to the patient outweigh the potential 
risk for adverse events associated w ith the extra antigens. An 
extra dose o f m any live-virus vaccines and H ib or hepatitis B 
vaccine has no t been found to be harm ful (48). However, the 
risk for an adverse event m ight increase w hen extra doses are 
administered at an earlier time than the recom m ended interval 
for certain vaccines (e.g., tetanus toxoid vaccines and PPSV)
(16,24,49).
A vaccination provider m ight not have vaccines available 
that contain only the antigens needed as indicated by a child’s
vaccination history. Alternatively, although the indicated vac­
cines m ight be available, the provider m ight prefer to use a 
com bination vaccine to red uce the required num ber o f  injec­
tions. In such cases, the benefits and risks o f  adm inistering the 
com bination vaccine w ith an unneeded antigen should be care­
fully considered and discussed w ith the patient or parent.
W hen  inactivated (i.e., killed), or particularly subunit vac­
cines (which are often adsorbed to alum inum -salt adjuvants), 
are adm inistered, the reactogenicity o f the vaccine m ust be 
considered in balancing the benefits and risks o f  extra doses. 
Because clinical experience suggests low reactogenicity, an extra 
dose o f  H ib or hepatitis B vaccine may be adm inistered as part 
o f  a com bination vaccine to complete a vaccination series for 
another com ponent o f  the com bination. A dm inistration o f 
extra doses o f  tetanus toxoid vaccines earlier than the recom ­
m ended intervals can increase the risk for hypersensitivity 
reactions (16,24,50). Examples o f  such vaccines include DTaP, 
D TaP/H ib, D T  (for children),T d (for adolescents and adults), 
and Tdap. Extra doses o f  tetanus-toxoid—containing vaccines 
m ight be appropriate for certain patients, including for children 
who previously received D T  o rT d  vaccine and need protec­
tion  from pertussis (in DTaP or Tdap) or for im m igrants w ith 
uncertain vaccination histories.
Conjugate Vaccine Carrier Proteins
Certain carrier proteins in  existing conjugated H ib  vaccines 
also are used as com ponents o f  other vaccines (e.g., pneum o­
coccal and meningococcal vaccines) (51). Protein conjugates 
used in H ib conjugate vaccines produced in the U nited States 
include an outer m em brane protein complex from  Neisseria 
meningitidis (in PR P-O M P), and tetanus toxoid (in PRP-T). 
Sim ultaneous adm inistration o f quadrivalent meningococcal 
conjugate vaccine (M CV 4), PCV, and T dap, all o f w hich con­
tain diphtheria toxoid, is not associated w ith reduced im m u­
nogenicity or an increase in local adverse events (24,51).
Nonsimultaneous Administration
There is no evidence that inactivated vaccines interfere w'ith 
the im m une response to o ther inactivated vaccines or to live 
vaccines. Any inactivated vaccine can be adm inistered either 
sim ultaneously or at any tim e before or after a different inac­
tivated vaccine or live vaccine (Table 3).
Limited data are available regarding interference between live 
vaccines used in the U nited States. T he im m une response to 
one live-virus vaccine m ight be impaired if administered within 
28 days (i.e., 4 weeks) o f another live-virus vaccine (52,53). In 
a study conducted in two U.S. health m aintenance organiza­
tions, the risk for varicella vaccine failure (i.e., varicella d isease 
in a vaccinated person) am ong persons wrho received varicella
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vaccine w ith in  28 days o f  M M R  vaccination was threefold 
higher than am ong persons who received varicella vaccine >28 
days after M M R  vaccination (54). A nother study determ ined 
that the response to yellow fever vaccine is not affected by 
m onovalent measles vaccine adm inistered 1—27 days earlier 
(18). T he  effect ofnonsim ultaneous adm inistration o f  rubella, 
m um ps, varicella, and yellow fever vaccines is unknow n.
To m inim ize the potential risk for interference, injectable 
or nasally adm inistered live vaccines not adm inistered on the 
same day should be adm inistered >4 weeks apart (Table 3). If  
injectable or nasally adm inistered live vaccines are separated 
by <4 weeks, the second vaccine adm inistered should no t be 
counted as a valid dose and should be repeated. T he repeat dose 
should be adm inistered >4 weeks after the last invalid dose. 
O ral vaccines (Ty21a typhoid vaccine and rotavirus) can be 
adm inistered sim ultaneously or at any interval before or after 
other live vaccines (injectable or intranasal) if  indicated.
Spacing of Vaccines and 
Antibody-Containing Products
Live Vaccines
Ty21a typhoid, yellow fever, LAIV, zoster, and rotavirus 
vaccines may be adm inistered at any tim e before, concurrent 
w ith, or after adm inistration o f any im m une globulin, hyper­
im m une globulin, or intravenous im m une globulin (IGIV) 
(55). Blood (e.g., whole blood, packed red blood cells, and 
plasma) and other antibody-containing blood products (e.g., 
im m une globulin, hyperim m une globulin, and IG IV ) can 
inhibit the im m une response to measles and rubella vaccines 
for >3 m onths. T he effect o f blood and im m une globulin 
preparations on the response to m umps and varicella vaccines is 
unknown; however, commercial im m une globulin preparations 
contain antibodies to these viruses. Blood prod ucts available in 
the U nited States are unlikely to contain a substantial am ount 
of antibody to yellow fever vaccine virus. T he length o f  time 
that interference w ith injectable live-virus vaccine (other than 
yellow' fever) can persist after the antibody-containing product 
is a function of the am ount o f  antigen-specific antibody con­
tained in the product (56—58). Therefore, after an antibody- 
containing product is received, live vaccines (other than yellow 
fever, oralTy21a typhoid, LAIV, zoster, and rotavirus) should 
be delayed until the passive antibody has degraded (Table 4). 
I f  a dose o f  injectable live-virus vaccine (other than yellow 
fever and zoster) is adm inistered after an antibody-containing 
product but at an interval shorter than recom m ended in this 
report, the vaccine dose should be repeated unless serologic 
testing is feasible and indicates a response to the vaccine. T he 
repeat dose or serologic testing should be perform ed after
the interval indicated for the antibody-containing product 
(Table 5).
A lthough passively acquired antibodies can interfere w ith 
the response to rubella vaccine, the low dose o f  anti-R ho(D ) 
globulin adm inistered to postpartum  w om en has not been 
dem onstrated to reduce the response to the RA27/3 strain 
rubella vaccine (59). Because o f  the im portance o f  rubella 
and varicella im m unity  am ong w om en o f  child-bearing age 
(4,60), the postpartum  vaccination o f women w ithout evidence 
o f im m unity  to rubella or varicella w ith M M R , varicella, or 
M M R V  vaccines should not be delayed because o f  receipt o f 
anti-R ho(D ) globulin or any other blood product during the 
last trim ester o f  pregnancy or at delivery. These w om en should 
be vaccinated im m ediately after giving birth  and, if possible, 
tested >3 m onths later to ensure im m unity  to  rubella and, if  
appropriate, to measles (2).
Interference m ight occur if  adm inistration o f  an antibody- 
containing product becomes necessary after adm inistration o f 
M M R  or varicella vaccines. Usually, vaccine virus replication 
and stim ulation o f  im m unity  occurs 1—2 weeks after vaccina­
tion. If the interval between adm inistration o f  any o f  these vac­
cines and subsequent adm inistration o f  an antibody-containing 
product is <14 days, vaccination should be repeated after the 
recom m ended interval (Tables 4 and 5) unless serologic testing 
indicates a protective antibody response.
A  hum anized mouse m onoclonal antibody product (palivi- 
zumab) is available as prophylaxis for serious lower respiratory 
tract disease from respiratory syncytial virus am ong infants and 
young children. This product contains only antibody to respi­
ratory syncytial virus and does not interfere w ith the im m une 
response to licensed live or inactivated vaccines.
Inactivated Vaccines
A ntibody-containing products interact less w ith  inactivated 
vaccines, toxoids, recom binant subunit, and polysaccharide 
vaccines than w ith live vaccines (61). Therefore, adm inistering 
inactivated vaccines and toxoids either sim ultaneously w ith or 
at any interval before or after receipt o f  an antibody-containing 
product should no t substantially im pair developm ent o f  a 
protective antibody response (Table 4). T he vaccine or toxoid 
and antibody preparation should be adm inistered at different 
sites using the standard recom m ended dose. Increasing the 
vaccine dose volume or num ber o f  vaccinations is not indicated 
or recom m ended.
Interchangeability of Single-Component 
Vaccines from Different Manufacturers
C ertain  vaccines that provide protection  from the same 
diseases are available from  different m anufacturers, and these
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vaccines usually are not identical in antigen content or in 
am ount or method o f  form ulation. M anufacturers use differ­
ent production processes, and their products m ight contain 
different concentrations o f  antigen per dose or a different 
stabilizer or preservative.
Available data indicate that infants who receive sequential 
doses o f  different H ib conjugate, hepatitis B, and hepatitis 
A  vaccines produce a satisfactory antibody response after a 
com plete prim ary series (62—65)- All brands o f  H ib conju­
gate, hepatitis B ,î hepatitis A, rotavirus,** and quadrivalent 
meningococcal conjugate vaccines are interchangeable w ithin 
their respective series. I f  different brands o f a particular vaccine 
require a different num ber o f  doses for series com pletion (e.g., 
H ib  and rotavirus vaccines) and a provider mixes brands, the 
higher num ber o f  doses is recom m ended for series com pletion 
(e.g., 3 doses o f  either rotavirus or H ib vaccines).
Limited data are available about the safety, immunogenicity, 
and efficacy of using acellular pertussis (e.g., DTaP) vaccines 
from  different manufacturers for successive doses o f  the per­
tussis series. D ata from  one study indicate that for the first 3 
doses of the DTaP series, 1 - 2  doses ofTripedia (Sanofi Pasteur) 
followed by Infanrix (GlaxoSmithKline) for the remaining dose 
(or doses) is comparable to 3 doses ofTripedia w ith regard to 
im m unogenicity, as m easured by antibodies to diphtheria, 
tetanus, and pertussis toxoids, and filamentous hem agglutinin 
(66). However, in the absence o f a clear serologic correlate o f  
protection for pertussis, the relevance o f  these im m unogenic­
ity data for protection against pertussis is unknow n. W hen  
feasible, the same brand o f  DTaP vaccine should be used for 
all doses of the vaccination series. I f  vaccination providers do 
no t know  or have available the type o f DTaP vaccine previ­
ously adm inistered to a child, any DTaP vaccine may be used 
to continue or complete the series. For a child who needs 2 
doses o f  influenza vaccine (T IV  or LAIV), it is preferable to 
use the same type o f  vaccine for both doses. However, if  the 
child is eligible for either T IV  or LAIV, and the type o f  vaccine 
used for the first dose is not available, either vaccine can be 
used for the second dose. For vaccines in general, vaccination 
should not be deferred because the brand used for previous 
doses is no t available or is unknow n (23,67).
Lapsed Vaccination Schedule
Vaccination providers should adm inister vaccines as close 
to the recom m ended intervals as possible. However, intervals 
between doses that are longer than recom m ended typically do
J The exception is the 2-dose hepatitis B vaccination series fo r adolescents aged 
11—15 years. O n ly  Recombivax H B  (M erck Vaccine D iv is ion) should be used 
in  th is schedule. Engerix-B (G laxoSm ithK line) is no t approved by F D A  fo r 
th is  schedule.
**  Based on expert op in ion.
not reduce final antibody concentrations, although protection 
m ight not be attained until the recommended num ber o f  doses 
has been administered. W ith  exception o f  oral typhoid vaccine, 
an in terruption  in the vaccination schedule does not require 
restarting the entire series o f  a vaccine or toxoid or addition 
o f extra doses.
Unknown or Uncertain Vaccination Status
Vaccination providers frequently encounter persons who do 
not have adequate docum entation o f  vaccinations. W ith  the 
exception o f  influenza vaccine and PPSV, providers should 
only accept w ritten, dated records as evidence o f vaccination; 
self-reported doses o f  influenza vaccine and PPSV are accept­
able (49,68). A lthough vaccinations should not be postponed 
if  records cannot be found, an attem pt to locate missing records 
should be made by contacting previous health-care providers, 
reviewing state or local IISs, and searching for a personally held 
record. If records cannot be located w ithin a reasonable time, 
these persons should be considered susceptible and started on 
the age-appropriate vaccination sched ule. Serologic testing for 
im m unity  is an alternative to vaccination for certain antigens 
(e.g., measles, rubella, hepatitis A, and tetanus). However, 
commercial serologic testing m ight not always be sufficiently 
sensitive or standardized for detection o f  vaccine-induced 
im m unity (with the exception o f  hepatitis B vaccination at 1—2 
m onths after the final dose), and research laboratory testing 
m ight not be readily available.
Contraindications and Precautions
C ontraindications and precautions to vaccination are con­
ditions under w hich vaccines should not or likely should not 
be adm inistered. Because the m ajority o f  contraindications 
and precautions are tem porary, vaccinations often can be 
adm inistered later i f  one or more exist. A contraindication is 
a condition in a recipient that increases the risk for a serious 
adverse reaction. A vaccine should not be adm inistered when 
a contraind ication  is present; for example, M M R  vaccine 
should not be adm inistered to severely im m unocom prom ised 
persons. In contrast, certain conditions are com m only mis- 
perceived as contraindications (i.e., are not valid reasons to 
defer vaccination).
N ational standards for pediatric vaccination practices have 
been established and include descriptions o f  valid contraindica­
tions and precautions to vaccination. Persons who adm inister 
vaccines should  screen patien ts for contraindications and 
precautions to  the vaccine before each dose o f  vaccine is 
adm inistered (Table 6). Screening is facilitated by consistent 
use o f screening questionnaires, w hich are available from certain
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sta te  v acc ina tion  program s and  o th e r sources (e.g., the  
Immunization Action Coalition, http://www.immunize.org).
T he only contraindication  applicable to  all vaccines is a 
history o f  a severe allergic reaction (i.e., anaphylaxis) after a 
previous dose o f vaccine or to a vaccine com ponent (unless the 
recipient has been desensitized; see Special Situations section). 
In addition, severely im m unocom prom ised persons generally 
should not receive live vaccines. C hildren who experienced 
encephalopathy w ithin 7 days after adm inistration o f  a pre­
vious dose o f d iphtheria and tetanus toxoids and whole-cell 
pertussis vaccine (D TP), DTaP, or T dap no t attributable to 
another identifiable cause should no t receive additional doses 
of a vaccine that contains pertussis. Because of the theoreti­
cal risk to the fetus, w om en know n to be pregnant generally 
should not receive live, attenuated virus vaccines (see Special 
Situations section).
A precaution is a condition in a recipient that m ight increase 
the risk for a serious adverse reaction or that m ight compromise 
the ability o f  the vaccine to produce im m unity  (e.g., adm in­
istering measles vaccine to a person w ith passive im m unity  to 
measles from a blood transfusion or adm inistering influenza 
vaccine to someone w ith a history o f Guillain-Barre syndrom e 
w ithin 6 weeks o f  a previous influenza vaccination). A  person 
m ight experience a more severe reaction to the vaccine than 
would have otherwise been expected; however, the risk for this 
happening is less than the risk expected w ith a contraindication. 
In general, vaccinations should be deferred w hen a precaution 
is present. However, a vaccination m ight be indicated in the 
presence o f  a precaution if the benefit o f  protection from the 
vaccine outweighs the risk for an adverse reaction. For example 
a dose o f D TaP should be considered for a person in a com ­
m unity  w ith a pertussis outbreak even if  that person previously 
developed Guillain-Barre syndrom e after a dose.
T he presence o f  a m oderate or severe acute illness w ith or 
w ithout a fever is a precaution to adm inistration of all vaccines 
(Table 6). A  personal or family history o f  seizures is a precaution 
for M M R V  vaccination. A recent study found an increased risk 
for febrile seizures in children who receive M M R V  compared 
w ith M M R  and varicella vaccine (35).
Clinicians or other health-care providers might misperceive 
certain conditions or circumstances as valid contraindications or 
precautions to vaccination when they actually do not preclude 
vaccination (Table 7). These misperceptions result in missed 
opportunities to administer recommended vaccines (69). Among 
the most com m on conditions mistakenly considered to be con­
traindications are diarrhea, m inor upper respiratory tract illnesses 
(including otitis media) with or without fever, mild to moderate 
local reactions to a previous dose of vaccine, current antimicrobial 
therapy, and being in the convalescent phase o f  an acute illness.
T he decision to adm inister or delay vaccination because 
o f  a current or recent acute illness depends on the severity 
o f  sym ptom s and etiology o f  the condition. T he safety and 
efficacy o f vaccinating persons who have m ild illnesses have 
been docum ented (70—73). Vaccination should not be delayed 
because o f  the presence o f m ild respiratory tract illness or 
other acute illness w ith or w ithout fever. Vaccination should 
be deferred for persons w ith a moderate or severe acute illness. 
This precaution avoids causing diagnostic confusion between 
m anifestations o f  the underlying illness and possible adverse 
effects o f  vaccination or superim posing adverse effects o f  the 
vaccine on the underlying illness. After screening them  for 
contraind ications, persons w ith  m oderate or severe acute 
illness should be vaccinated as soon as the acute illness has 
improved. Studies indicate that failure to vaccinate children 
w ith m inor illnesses can im pede vaccination efforts (74—76). 
Am ong persons whose compliance w ith medical care cannot 
be ensured, use o f  every opportunity  to adm inister appropriate 
vaccines is critical.
Routine physical examinations and procedures (e.g., measur­
ing temperatures) are no t prerequisites for vaccinating persons 
who appear to be healthy. T he provider should ask the parent 
or guardian if  the child is ill. I f  the child has a m oderate or 
severe illness, the vaccination should be postponed.
Preventing and Managing 
Adverse Reactions
Benefit and Risk Communication
Parents, guardians, legal representatives, and adolescent and 
adult patients should be informed about the benefits of and 
risks from vaccines in  language that is culturally sensitive and 
at an appropriate educational level. O pportun ity  for questions 
should be provided before each vaccination. Discussion o f  the 
benefits o f  and risks from vaccination is sound medical practice 
and is required by law.
T he N ational C h ildhood Vaccine In ju ry  Act o f  1 9 8 6 : : 
requires that vaccine inform ation materials be developed for 
each vaccine covered by the act. These materials, know n as 
vaccine inform ation statem ents (VI Ss), m ust be provided by 
all public and private vaccination providers each time a vaccine 
is adm inistered. Copies ofV ISs are available from  state health 
authorities responsible for vaccination and from C D C  (h ttp :// 
www.cdc.gov/vaccines). Translations o fV IS s into languages 
o ther than  English are available from  certain state vaccination 
programs and from the Im m unization Action Coalition website
W N ationa l C h ildhood  Vaccine In ju ry  A c t o f  1986. 42  U.S.C. Sect. 300aa-26
(1986).
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(http://w w w .im m unize.org). T he act does not require that a 
signature be obtained; however, docum entation o f  consent 
m ight be recom m ended or required by certain state or local 
health authorities or school authorities.
C ertain parents or patients question the need for or safety 
o f  vaccinations and w ant to discuss the risks from and benefits 
o f certain vaccines. Some refuse certain vaccines or reject all 
vaccinations for personal or religious reasons. H aving a basic 
understanding of how  patients and parents o f patients view vac­
cine risk and developing effective approaches to address vaccine 
safety concerns are imperative for vaccination providers.
Each person understands and reacts to vaccine inform ation 
on the basis o f  different factors, including previous experience, 
education, personal values, m ethod o f data presentation, per­
ceptions o f  the risk for disease and perceived ability to control 
these risks, and risk preference. Increasingly, decisions about 
vaccination are based on inaccurate inform ation about risk 
provided by the m edia and certain websites. W ebsites and 
other sources o f  vaccine inform ation m ight be inaccurate or 
incomplete. Health-care providers can be a pivotal source o f 
science-based credible inform ation by discussing w ith parents 
and patients the risks from and benefits o f  vaccines, w hich 
helps patients make inform ed decisions.
W hen  a parent or patient initiates a discussion about a per­
ceived vaccine adverse reaction, the health-care provider should 
discuss the specific concerns and provide factual inform ation, 
using appropriate language. Effective, em pathetic vaccine risk 
com m unication is essential in responding to m isinform ation 
and concerns, w'ith health-care providers recognizing that risk 
assessment and decision-making can be difficult and confusing. 
Certain vaccines might be acceptable to a parent who is resistant 
to other vaccines. This partial acceptance can be used to facilitate 
additional communication. Their concerns can be addressed using 
the VIS and offering other resource materials (e.g., vaccination 
information from C D C : http://www.cdc.gov/vaccines).
T he Am erican Academy o f Pediatrics (AAP) does not rec­
om m end that providers exclude from their practice patients 
whose parents or guardians question or refuse vaccination. A 
limited num ber o f  providers m ight exclude patients on this 
basis; however, an effective public health strategy is to identify 
com m on ground and discuss measures that need to be followed 
if  the decision is to defer vaccination. Health-care providers 
should reinforce key points about each vaccine, including 
safety, and emphasize risks for disease am ong unvaccinated 
children. Parents should be advised o f  state laws regarding 
entry to schools or child-care facilities, w hich m ight require 
that unvaccinated children be excluded from the facility dur­
ing outbreaks. These discussions should be docum ented in the 
patient’s medical record, including the refusal to receive certain 
vaccines (i.e., inform ed refusal).
Preventing Adverse Reactions
Vaccines are intended to produce active im m unity  to spe­
cific antigens. A n adverse reaction is an undesirable side effect 
that occurs after a vaccination. Vaccine adverse reactions are 
classified as 1) local, 2) systemic, or 3) allergic (additional 
inform ation available at http://www.fda.gov). Local reactions 
(e.g., redness) are usually the least severe and most frequent. 
Systemic reactions (e.g., fever) occur less frequently than local 
reactions, and severe allergic reactions (e.g., anaphylaxis) are the 
least frequent reactions. Severe adverse reactions are rare.
Syncope (vasovagal or vasodepressor reaction) can occur 
after vaccination and is m ost com m on am ong adolescents and 
young adults. In 2005, the Vaccine Adverse Event Reporting 
System (VAERS) began detecting a trend o f increasing syncope 
reports that coincided w ith the licensure o f  three vaccines for 
adolescents: hum an papillomavirus (HPV), M C V 4, and Tdap 
(77). O f particular concern am ong adolescents has been the 
risk for serious secondary injuries, including skull fracture and 
cerebral hemorrhage. O f 463 VAERS reports o f  syncope during 
January 1, 2005, to July 31, 2007, a total o f  41 listed syncope 
w ith secondary injury w ith inform ation on the tim ing after 
vaccination, and the m ajority o f  these syncope reports (76%) 
occurred am ong adolescents. Am ong all age groups, 80%  o f 
reported syncope episodes occur w ithin 15 m inutes o f  vaccine 
adm inistration  (additional inform ation available at h ttp :// 
www.cdc.gov/vaccinesafety/concern/syncope.htm). Providers 
should take appropriate measures to prevent injuries if  a patient 
becomes weak or dizzy or loses consciousness. Adolescents 
and adults should be seated or lying dow n during vaccination. 
Vaccine providers, particularly w hen vaccinating adolescents, 
should consider observing patients (with patients seated or 
lying down) for 15 m inutes after vaccination to decrease the 
risk for injury should they faint (77). I f  syncope develops, 
patients should be observed until the sym ptom s resolve.
Managing Acute Vaccine Reactions
A lthough anaphylactic reactions are rare after vaccination, 
their im m ediate onset and life-threatening nature require that 
all personnel and facilities providing vaccinations have proce­
dures in  place for anaphylaxis m anagem ent. All vaccination 
providers should be familiar w ith the office emergency plan 
and be currently certified in cardiopulm onary resuscitation. 
Epinephrine and equipm ent for m aintaining an airway should 
be available for im m ediate use.
A naphylaxis usually  begins w ith in  m inu tes o f  vaccine 
adm inistration (78—80). Rapid recognition and initiation o f  
treatm ent are required to prevent possible progression to car­
diovascular collapse. If flushing, facial edema, urticaria, itching, 
swelling o f the m outh  or throat, wheezing, dyspnea, or other
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signs or sym ptom s o f anaphylaxis occur, the patient should be 
placed in a recum bent position w ith the legs elevated if possible 
(81,82). A dm inistration o f  epinephrine is the m anagem ent o f 
choice. Additional drugs also m ight be indicated (Table 8) (83). 
M aintenance o f  the airway and oxygen administration m ight be 
necessary. After the patient is stabilized, arrangements should 
be made for im m ediate transfer to an emergency facility for 
additional evaluation and treatm ent.
Reporting Adverse Events 
After Vaccination
M odern vaccines are safe and effective; however, adverse 
events have been reported after adm inistration o f  all vaccines 
(84). M ore com plete inform ation about adverse reactions to a 
specific vaccine is available in the package insert for each vac­
cine and from  C D C  at http://www.cdc.gov/vaccines/vac-gen/ 
side-effects.htm . An adverse event is an untoward event that 
occurs after a vaccination that m ight be caused by the vaccine 
product or vaccination process. These events range from com ­
m on, minor, local reactions to rare, severe, allergic reactions 
(e.g., anaphylaxis). Establishing evidence for cause and effect 
on the basis o f  case reports and case series alone is usually not 
possible because health problems that have a tem poral associa­
tion w ith vaccination do not necessarily indicate causality.
M any adverse events require more detailed epidemiologic 
studies to compare the incidence o f the event am ong vaccinees 
to the incidence am ong unvaccinated persons. R eporting  
adverse events, including serious events, to VAERS is a key 
m echanism  for identifying potential vaccine safety concerns. 
Potential causal associations between reported adverse events 
after vaccination can be assessed through epidemiologic or 
clinical studies.
T h e  N atio n a l C h ild h o o d  V accine In ju ry  A ct requires 
health-care providers and vaccine m anufacturers to report to 
VAERS specific adverse events that occur after vaccination. 
T he reporting requirements are different for manufacturers and 
health-care providers. M anufacturers are required to report all 
adverse events that occur after vaccination to VAERS, whereas 
health-care providers are required to report events that appear 
in the reportable events table on the VAERS website at http:/./ 
vaers.hhs.gov/reportable.htm .
In addition to the m andated reporting o f  events listed on 
the reportable events table, health-care providers should report 
to VAERS all events listed in product inserts as contraindica­
tions, as well as all clinically significant adverse events, even if 
they are uncertain that the adverse event is related causally to 
vaccination. Persons other than health-care providers also can 
report adverse events to VAERS.
There are three ways to report to VAERS:
1. Subm it the report online via a secure website at h ttps:// 
vaers. hhs. gov/ esub/s tep 1,
2. Fax a com pleted VAERS form  to 877-721-0366, or
3. Mail a completed VAERS form: VAERS, PO . Box 1100, 
Rockville, M D  20849-1100.
A VAERS form  can be downloaded from the VAERS web­
site at http://vaers.hhs.gov/resources/vaers_form .pdf. VAERS 
forms also can be requested by e-mail (info@vaers.org), tele­
phone (800-822-7967), or fax (877-721-0366).
National Vaccine Injury 
Compensation Program
T h e N ationa l Vaccine In ju ry  C om pensa tion  Program , 
established by the N ational C hildhood Vaccine In jury  Act o f  
1986, is a no-fault system in w hich persons thought to have 
experienced an injury or to have died as a result o f adm inistra­
tion o f  a covered vaccine can seek com pensation. The program 
became operational on O ctober 1, 1988, and is intended as an 
alternative to civil litigation under the traditional tort system 
in that negligence need not be proven. Claims arising from 
covered vaccines m ust first be adjudicated through the program 
before civil litigation can be pursued.
T he program  relies on the Vaccine In jury  Table, w hich lists 
the vaccines covered by the program and the injuries (including 
death), disabilities, illnesses, and conditions for w hich com ­
pensation m ight be awarded. The table defines the tim e during 
which the first sym ptom  or substantial aggravation o f an injury 
m ust appear after vaccination to be eligible. Successful claim­
ants receive a legal presum ption o f causation if a condition listed 
in the table is proven, thus avoiding the need to prove actual 
causation in an individual case. C laim ants also can prevail for 
conditions not listed in the reportable events table if they prove 
causation for covered vaccines. A dditional inform ation is avail­
able from the H ealth Resources and Services A dm inistration 
(HRSA) (h ttp ://w w w .hrsa.gov/vaccinecom pensation , tele­
phone: 800-338-2382). Persons who would like to file a claim 
for vaccine injury should contact the U.S. C ourt of Federal 
Claims (717 M adison Place, N .W ., W ashington, D C  20005; 
telephone: 202-357-6400).
Vaccine Administration 
Infection Control and Sterile Technique
General Precautions
Persons adm inistering vaccinations should follow appropri­
ate precautions to minimize risk for spread o f  disease. Hands
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should be cleansed w ith an alcohol-based waterless antiseptic 
hand rub or washed w ith  soap and water before preparing the 
vaccine and between each patient contact {85)- O ccupational 
Safety and H ealth  A dm inistration (OSHA) regulations do not 
require gloves to be w orn w hen adm inistering vaccinations, 
unless persons adm inistering vaccinations are likely to come 
into contact w ith potentially infectious body fluids or have 
open lesions on their hands. I f  gloves are worn, they should 
be changed between patients.
Needles and Syringes
Needles and syringes used for vaccine injections m ust be 
sterile and disposable. A separate needle and syringe should 
be used for each injection. Changing needles between draw­
ing vaccine from a vial and injecting it into a recipient is not 
necessary unless the needle has been damaged or contam i­
nated. Different vaccines should never be mixed in the same 
syringe unless specifically licensed for such use, and no attem pt 
should be made to transfer between syringes. Single-dose vials 
and manufacturer-filled syringes are designed for single-dose 
adm inistration and should be discarded if  vaccine has been 
withdraw n or reconstituted and subsequently not used w ithin 
the tim e frame specified by the manufacturer. This typically is 
no longer than the same clinic day (typically recom m ended as 
a m axim um  for inactivated vaccines).
Sometimes providers prefill syringes themselves. A C IP dis­
courages the routine practice o f  prefilling syringes because o f 
the potential for adm inistration errors and vaccine wastage. 
Because the m ajority o f  vaccines have a similar appearance after 
being drawn into a syringe, prefilling m ight result in adm inis­
tration errors. In certain circumstances in which a single vac­
cine type is being used (e.g., in preparation for a com m unity  
influenza vaccination campaign), filling a small num ber o f 
syringes may be considered. Vaccine doses should not be drawn 
into a syringe until im m ediately before adm inistration. W hen  
syringes are filled, the type o f  vaccine, lot num ber, and date o f 
filling must be labeled on each syringe, and the doses should be 
adm inistered as soon as possible after filling. U nused syringes 
filled by the end user (i.e., not filled by the manufacturer) 
should be discarded at the end o f  the vaccination session. In 
addition to adm inistration errors, prefilling o f  syringes is a 
concern because FDA does not license adm inistration syringes 
for vaccine storage. Unused syringes that are prefilled by the 
m anufacturer and activated (i.e., syringe cap removed or needle 
attached) should be discarded at the end o f the clinic day. 
W hen  in doubt about the appropriate handling o f a vaccine, 
vaccination providers should contact the manufacturer.
B loodborne diseases (e.g., hepatitis B, hepatitis C , and 
hu m an  im m unodeficiency virus [H IV ]) are occupational 
hazards for clinicians and other health-care providers. T he
Needlestick Safety and Prevention Act was enacted in 2000 
to reduce the incidence o f needle-stick injury and the con­
sequent risk for bloodborne diseases acquired from patients. 
T he act directed O SH A  to strengthen its existing bloodborne 
pathogen standards. T he revised standards became effective 
in 2001 (86). These federal regulations require that safety- 
engineered injection devices (e.g., needle-shielding syringes 
or needle-free injectors) be used for injectable vaccination in 
all clinical settings. T he regulations also require m aintenance 
o f  records docum enting injuries caused by needles and other 
medical sharp objects and that nonm anagerial employees be 
involved in the evaluation and selection o f  safety-engineered 
devices before they are procured.
Safety-engineered needles and syringes or needle-free injec­
tion devices are preferred and should be encouraged to reduce 
risk for injury. To prevent inadvertent needle-stick injury or 
reuse, safety mechanisms should be deployed after use and 
needles and syringes should  be discarded im m ediately  in 
labeled, puncture-proof containers located in the same room  
w'here the vaccine is adm inistered. Used needles should never 
be recapped .
Needle-shielding or needle-free devices that m ight satisfy 
the occupational safety regulations for administering injectable 
vaccines are available in the U nited States (87—89). Additional 
inform ation about im plem entation and enforcem ent of these 
regulations is available from O SH A  (http://www.osha.gov).
Route of Administration
Oral Route
Rotavirus and oral typhoid vaccines are the only vaccines 
administered orally in the U nited States. Oral typhoid capsules 
should be adm inistered as directed by the m anufacturer. T he 
capsules should not be opened or mixed w ith any other sub­
stance. Rotavirus vaccines are licensed for infants. There are 
two brands o f  rotavirus vaccine, and they have different types 
o f applicators. Providers should consult the package insert for 
details. A dose of rotavirus vaccine need not be repeated if the 
vaccine is spit up or vom ited. T he infant should receive the 
rem aining recom m ended doses o f  rotavirus vaccine following 
the routine schedule.
Intranasal Route
LAIV is licensed for healthy nonpregnant persons aged 2-A9  
years and is the only vaccine administered by the intranasal route. 
The administration device is a nasal sprayer with a dose-divider 
clip that allows introduction o f one 0.1 -m L spray into each naris. 
The tip should be inserted slightly into the naris before admin­
istration. Even if the person coughs or sneezes immediately after 
administration or the dose is expelled any other way, the vaccine
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dose need not be repeated . Introduction o f  low levels o f vaccine 
viruses into the environment likely is unavoidable when adminis­
tering LAIV; however, no instances have been reported o f illness or 
attenuated vaccine virus infections among inadvertently exposed 
health-care providers or immunocompromised patients. T he risk 
for acquiring vaccine viruses from the environment is unknown 
but is likely low; in addition, vaccine viruses are cold-adapted 
and attenuated and unlikely to cause symptomatic influenza. 
Severely immunosuppressed persons should not administer LAIV 
However, other persons at higher risk for influenza complications 
can administer LAIV. These include persons w ith underlying 
medical conditions placing them at higher risk or who are likely 
to be at risk, including pregnant women, persons with asthma, 
and persons aged >50 years (68).
Injectable Route
W ith  the exception o f  bacille C alm ette-G uérin (BCG) vac­
cine and smallpox vaccine, injectable vaccines are administered 
by the intram uscular or subcutaneous route. T h e  m ethod o f 
adm inistration o f  injectable vaccines is determ ined, in part, 
by the presence o f adjuvants in  some vaccines. An adjuvant is 
a vaccine com ponent distinct from the antigen that enhances 
the im m une response to  the antigen. Inactivated vaccines 
contain ing  an adjuvant should be injected in to  a muscle 
because adm inistration subcutaneously or intraderm ally can 
cause local irritation, induration, skin discoloration, inflam m a­
tion, and granulom a form ation. Routes o f  adm inistration are 
recom m ended by the m anufacturer for each im m unobiologic 
(Table 9). Deviation from the recom m ended route o f  adm in­
istration m ight reduce vaccine efficacy (90, 91) or increase the 
risk for local adverse reactions (92—94).
Intramuscular Injections
Needle Length
Injectable immunobiologies should be adm inistered where 
local, neural, vascular, or tissue injury is unlikely. Use o f  longer 
needles has been associated w ith less redness or swelling than 
occurs w ith shorter needles because o f  injection into deeper 
muscle mass (92). Appropriate needle length depends on age 
and body mass. Injection technique is the m ost im portant 
param eter to ensure efficient intram uscular vaccine delivery.
For all in tram uscu lar in jections, the needle shou ld  be 
long enough to reach the muscle mass and prevent vaccine 
from  seeping into subcutaneous tissue, but not so long as to 
involve underlying nerves, blood vessels, or bone (91,95—97). 
Vaccinators should be familiar w ith the anatom y o f the area 
into w hich they are injecting vaccine. Intram uscular injections 
are adm inistered at a 90-degree angle to the skin, prefer­
ably into the anterolateral aspect o f  the thigh or the deltoid
muscle o f the upper arm, depending on the age o f  the patient 
(Table 10).
A decision on needle size and site o f  injection m ust be made 
for each person on the basis o f  the size o f  the muscle, the 
thickness o f  adipose tissue at the injection site, the volum e o f 
the material to be adm inistered, injection technique, and the 
depth below the muscle surface into w hich the material is to be 
injected (Figure 1). A spiration before injection o f vaccines or 
toxoids (i.e., pulling back on the syringe plunger after needle 
insertion but before injection) is not necessary because no large 
blood vessels are present at the recom m ended injection sites, 
and a process that includes aspiration m ight be more painful 
for infants (98).
Infants (Aged <12 Months)
For the m ajority o f  infants, the anterolateral aspect o f  the 
thigh is the recom m ended site for injection because it provides 
a large muscle mass (Figure 2). In certain circumstances (e.g., 
physical obstruction to other sites and no reasonable indication 
to defer doses), the gluteal muscle can be used. I f  the gluteal 
muscle m ust be used, care should be taken to define the ana­
tom ic la n d m a rk s .In je c tio n  technique is the most im portant 
param eter to ensure efficient intram uscular vaccine delivery. I f  
the subcutaneous and muscle tissue are bunched to minimize 
the chance o f  striking bone (95), a 1-inch needle is required to 
ensure intram uscular adm inistration in infants aged >1 m onth. 
For the m ajority o f  infants, a 1-inch, 22- to 25-gauge needle 
is sufficient to penetrate the thigh muscle. For neonates (first 
28 days o f  life) and preterm  infants, a % -inch needle usually 
is adequate if  the skin is stretched flat between the thum b and 
forefinger and the needle is inserted at a 90-degree angle to 
the skin (97).
Toddlers (Aged 12 M o n th s-2  Years)
For toddlers, the anterolateral thigh muscle is preferred, and 
if  used, the needle should be at least 1 inch long. T he deltoid 
muscle can be used if  the muscle mass is adequate. A %-inch 
needle is adequate only for the deltoid muscle and only i f  the 
skin is stretched flat between thum b and forefinger and the 
needle is inserted at a 90-degree angle to  the skin.
Children (Aged 3 -1 8  Years)
T he deltoid muscle is preferred for children aged 3—18 years 
(Figure 3); the needle size for deltoid site injections can range 
from 22 to 25 gauge and from Vs to 1 inch on the basis o f  tech­
nique. Knowledge o f  body mass can be useful for estim ating
'N 'N I f  the gluteal muscle is chosen, in jec tion  should be administered lateral and 
superior to  a line  between the posterior superior iliac spine and the greater 
trochanter or in  the ventrogluteal site, the center o f  a triangle bounded by the 
anterior superior iliac spine, the tubercle o f  the iliac crest, and the upper border 
o f  the greater trochanter.
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the appropriate needle length (99)', however, neither a physical 
exam ination nor m easurem ent o f  body mass is necessary to 
adm inister vaccines. M ost children in this age range require a 
%- or 1-inch needle (or interm ediate size, if  available).
Adults (Aged >19 Years)
For adults, the deltoid muscle is recom m ended for routine 
intram uscular vaccinations. T he anterolateral thigh also can 
be used. For m en and w om en who weigh <130 lbs (<60 kg), 
a % -inch needle is sufficient to ensure intram uscular injection 
in the deltoid muscle if the injection is made at a 90-degree 
angle and the tissue is not bunched. For men and w om en who 
weigh 130—152 lbs (60—70 kg), a 1-inch needle is sufficient. 
For w om en who weigh 152—200 lbs (70—90 kg) and m en 
who weigh 152—260 lbs (70—118 kg), a 1- to 1 Vi -inch needle 
is recom m ended. For w om en who weigh >200 lbs (>90 kg) 
or m en who weigh >260 lbs (>118 kg), a 1 Vi-inch needle is 
recom m ended (Table 10) (96).
Subcutaneous Injections
Subcutaneous injections are adm inistered at a 45-degree 
angle, usually into the thigh for infants aged <12 m onths and 
in the upper-outer triceps area o f  persons aged >12 m onths. 
Subcutaneous injections may be adm inistered into the upper- 
outer triceps area o f  an infant if  necessary. A  % -inch, 23- to 
25-gauge needle should be inserted into the subcutaneous 
tissue (Figures 4 and 5).
Multiple Injections
I f  m ultiple vaccines are administered at a single visit, adm in­
ister each preparation at a different anatom ic site. For infants 
and younger children, if  more than two vaccines are injected 
in a single limb, the thigh is the preferred site because o f  the 
greater muscle mass; the injections should be sufficiently sepa­
rated (i.e., >1 inch if  possible) so that any local reactions can 
be differentiated (92,100). For older children and adults, the 
deltoid muscle can be used for more than one intram uscular 
injection. I f  a vaccine and an im m une globulin preparation 
are adm inistered sim ultaneously (e.g., T d /T d ap  and tetanus 
im m une globulin [TIG], hepatitis B and hepatitis B im m uno­
globulin [HBIG]), separate anatomic sites (i.e., different limbs) 
should be used for each injection. T he location o f  all injection 
sites should be docum ented in the patient’s medical record. 
H ealth-care practices should consider using a vaccination site 
map so that all persons adm inistering vaccines routinely use a 
particular anatom ic site for each different vaccine.
Jet Injections
Jet injectors are needle-free devices that pressurize liquid 
m edication, forcing it through a nozzle orifice into a narrow'
stream capable o f  penetrating skin to deliver a drug or vac­
cine into intraderm al, subcutaneous, or intram uscular tissues 
(101,102). Jet injectors prevent needle-stick injuries to health­
care providers (86) and can overcome improper, unsterile reuse 
and other drawbacks o f  needles and syringes in developing 
countries (87,103—104). Im m une responses generated by jet 
injectors against both  attenuated and inactivated viral and 
bacterial antigens are usually equivalent to, and occasionally 
greater than, im m une responses induced by needle injection. 
However, local reactions or injuries are sometimes more fre­
quent on delivery o f  vaccine by jet injectors com pared w'ith 
needle injection, depending on the inherent irritability o f  the 
vaccine and operator technique (102). Jet injectors that use 
the same nozzle for consecutive injections w ithout intervening 
sterilization were used in mass vaccination campaigns from the 
1950s through the 1990s (102); however, these were found to 
be unsafe because o f  the possibility o f bloodborne pathogen 
transmission (105—108) and should not be used. A new gen­
eration o f  jet injectors w ith disposable cartridges and syringes 
has been developed since the 1990s. W ith  a new, sterile dose 
cham ber and nozzle for each patient and correct use, these 
devices do not have the same safety concerns as multiple-use 
nozzle jet injectors. Several o f the newer devices have been 
approved by FD A  for sale in the United States (102).
Methods for Alleviating Discomfort 
and Pain Associated with Vaccination
C om fort measures, such as distraction (e.g., playing music 
or p retending  to blow away the pain), ingestion o f  sweet 
liquids, breastfeeding, cooling of the injection site, and topi­
cal analgesia, can help infants or children cope w ith the dis­
com fort associated w ith vaccination (109,110). Pretreatm ent 
(30—60 m inutes before injection) w ith a 5% topical lidocaine- 
prilocaine em ulsion m ight decrease the pain o f  vaccination by 
causing superficial anesthesia (111,112). Evidence indicates 
that this cream does no t interfere w ith the im m une response 
to M M R  (113). Topical lidocaine-prilocaine em ulsion should 
not be used on infants aged <12 m onths who are receiving 
treatm ent w ith m ethem oglobin-inducing agents because o f 
the possible developm ent o f  m ethem oglobinem ia (114). Use 
o f a topical refrigerant (vapocoolant) spray immediately before 
vaccination can reduce the short-term  pain associated w ith 
injections and can be as effective as lidocaine-prilocaine cream 
(115). Evidence does no t support use o f  antipyretics before or 
at the tim e o f  vaccination; however, they can be used for the 
treatm ent o f  fever and local discom fort that m ight occur fol­
lowing vaccination. Studies o f  children w ith previous febrile 
seizures have no t dem onstrated antipyretics to be effective in 
the prevention o f  febrile seizures (116).
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Nonstandard Vaccination Practices
Recommendations for route, site, and dosage o f immunobiolog­
ies are derived from data from clinical trials, practical experience, 
normal periodicity o f  health-care visits, and theoretical consider­
ations. ACIP discourages variations from the recommend ed route, 
site, volume, or num ber o f doses o f  any vaccine.
Variation from the recommended route and site can result in 
inadequate protection. In adults (but not in infants) (117), the 
immunogenicity o f hepatitis B is substantially lower when the 
gluteal rather than the deltoid site is used for administration 
(90). Hepatitis B administered intradermally might result in a 
lower seroconversion rate and final titer of hepatitis B surface 
antibody than when administered by the deltoid intramuscular 
route (118,119). Hepatitis B administered by any route other 
than intramuscular, or in adults at any site other than the deltoid 
or anterolateral thigh, should not be counted as valid and should 
be repeated. Similarly, doses o f rabies vaccine administered in 
the gluteal site should not be counted as valid doses and should 
be repeated (120). M CV 4 should be administered intramuscu­
larly; however, revaccination is not necessary if a vaccine dose is 
administered subcutaneously (121). Inactivated influenza vaccine 
is immunogenic when administered in a lower than standard 
dose by the intradermal route to healthy adult volunteers (122). 
However, the im m unogenicity for persons aged >60 years is 
inadequate, and varying the recommended route and dose is not 
recommended.
Live, attenuated injectable vaccines (e.g., M M R , varicella, and 
yellow fever) and certain inactivated vaccines (e.g., meningococ­
cal polysaccharide) are recommended by the manufacturers to 
be administered by subcutaneous injection. PPSV and IPV are 
recommended by the manufacturer to be administered by the 
subcutaneous or intramuscular route. Response to vaccines rec­
ommended by the subcutaneous route are unlikely to be affected 
if  the vaccines are administered by the intramuscular rather than 
subcutaneous route. Repeating doses o f vaccine administered 
by the intramuscular route when recommended to be by the 
subcutaneous route is not necessary.
Administering volumes smaller than recommended (e.g., inap­
propriately divided doses) might result in inadequate protection. 
Using reduced doses administered at multiple vaccination visits 
that equal a full dose or using smaller divided doses is not recom­
mended. Any vaccination using less than the standard dose should 
not be counted, and the person should be revaccinated according 
to age unless serologic testing indicates that an adequate response 
has developed. If less than a full recommended dose o f a parenteral 
vaccine is administered because o f  syringe or needle leakage, the 
dose should be repeated. Using larger than recommended dosages 
can be hazardous because o f excessive local or systemic concentra­
tions of antigens or other vaccine constituents.
Storage and Handling 
of Immunobiologies
Failure to adhere to recom m ended specifications for storage 
and handling o f  im m unobiologies can reduce or destroy their 
potency, resulting in inadequate or no im m une response in the 
recipient. Recom m endations in the product package inserts, 
including m ethods for reconstitution o f the vaccine, should be 
followed carefully. M aintenance o f vaccine quality is the shared 
responsibility o f  all handlers o f vaccines from the time a vaccine 
is m anufactured until adm inistration. All vaccines should be 
inspected on delivery and m onitored during storage to ensure 
that the recom m ended storage tem peratures are m aintained. 
Vaccines should continue to be stored at recom m ended tem ­
peratures im m ediately on receipt until use. Inadequate vaccine 
storage also can result in the loss o f  thousands o f  dollars w orth  
o f  vaccine inventory and the cost o f  inventory replacement.
Storage Temperature
Vaccines licensed for refrigerator storage should be stored at 
35°F—46°F (2°C—8°C). Liquid vaccines containing an alum i­
num  adjuvant perm anently lose potency when exposed to freez­
ing tem peratures. Live, attenuated virus vaccines that should 
be frozen lose potency w'hen exposed to higher tem peratures 
because the viruses degrade more quickly at storage tem pera­
tures that are warm er than recom m ended (Table 11).
Storage Units
Refrigerators and freezers used for vaccine storage m ust 
maintain the required tem perature range year-round, be large 
enough to hold the year’s largest inventory, and be dedicated 
to storage o f vaccines. Vaccine storage units m ust be carefully 
selected, used properly, and consistently m onitored to ensure 
that recommended tem peratures are m aintained. Refrigerators 
w ithout freezers and stand-alone freezers (either manual defrost 
or automatic defrost) are usually the m ost effective at m aintain­
ing the precise tem peratures required for vaccine storage. Such 
single-purpose units sold for hom e use are less expensive alter­
natives to medical specialty equipm ent (123) and are preferable 
to com bination units. A com bination refrigerator-freezer unit 
sold for hom e use m ight be adequate for storing lim ited quan­
tities o f vaccines if the refrigerator and freezer com partm ents 
have separate external doors. Before using the refrigerator for 
vaccine storage, the tem perature should be allowed to stabilize 
and then be measured in various locations w ithin the refrigera­
tor com partm ent to docum ent that a consistent tem perature 
can be m aintained w ithin the com partm ent (Table 11) (124). 
N ew  units might need >2 days o f  operation to establish a stable 
operating temperature; vaccine should not be stored in the unit
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until the un it maintains an appropriate and stable storage tem ­
perature. Refrigerator tem peratures are m ost reflective o f  the 
actual com partm ent tem perature after the door has remained 
closed and undisturbed for several hours (e.g., overnight). 
T h e  refrigerator tem perature should be set at the m idpoint 
o f  the recom m ended range (i.e., 40°F [5°C]) (125,126). A  
storage un it should be sufficiently sized so that vaccines can 
be placed away from the walls in the part o f  the unit best able 
to m aintain the constant, required tem perature. C om bination 
units, w ith separate com partm ents o f  smaller size, can only be 
used to store lim ited quantities o f  vaccines. Frequent opening 
and closing o f  doors can cause fluctuations in com partm ent 
tem perature; food, beverages, and clinical specimens should 
not be stored in vaccine storage units. I f  it becomes necessary 
to store clinical specimens in the same unit as vaccines, the 
clinical specimens should be on a shelf below the vaccine to 
prevent contam ination should the specimen leak.
Temperature Monitoring
Temperature m onitoring is a critical com ponent o f  tem pera­
ture m anagem ent. All office and clinical staff members should 
be aware o f  vaccine vulnerabilities and storage requirements. 
Assigning one person in the office the primary responsibility for 
m aintaining and reviewing tem perature logs (Figure 6) gener­
ally is m ost effective, w ith a second person assigned as backup. 
Temperatures for both the refrigerator and freezer should be 
docum ented twice a day and recorded. T he backup person 
should review the log at least once each week. Temperature 
logs should be m aintained for 3 years unless state or local 
authorities require a longer time. An autom ated m onitoring 
system that alerts staff w hen a tem perature deviation occurs 
is optim al. However, even if  an autom ated m onitoring system 
is used, tem peratures still should be m anually checked and 
recorded twice each day.
Therm om eters should be placed in each com partm ent near 
the vaccines. D ifferent types o f therm om eters can be used, 
including standard  fluid-filled, m in im um -m axim um , and 
continuous chart recorder therm om eters (Table 12). Standard 
fluid-filled therm om eters are the simplest and least expensive 
products. Product tem perature therm om eters are encased in 
biosafe liquids and generally reflect refrigerator tem perature 
m ore accurately than standard  fluid-filled therm om eters. 
M inim um -m axim um  therm om eters m onitor the tem perature 
range. C ontinuous chart recorder therm om eters m onitor tem ­
perature range and duration. All therm om eters used for m oni­
toring vaccine storage tem peratures should be calibrated and 
certified by an appropriate agency (e.g., N ational Institute o f 
Standards and Technology or the American Society for Testing 
and Materials). Because all therm om eters are calibrated as part
o f the m anufacturing process, this recom m endation refers to 
a second calibration process that occurs after m anufacturing 
but before m arketing and is docum ented w ith  a certificate 
that comes w ith the product. Some products (e.g., continuous 
chart recorder therm om eters) usually include a m anufacturer- 
defined schedule for additional recalibration. For m any types 
o f therm om eters, replacem ent m ight be less expensive than 
recalibration. Therm om eters that require batteries need to have 
the batteries changed; review the docum entation that comes 
w ith the product for guidance.
Response to Out-of-Range 
Temperature Reading
An o u t-o f-ran g e  tem p era tu re  read ing  shou ld  p ro m p t 
im m ediate action. A plan should be d eveloped ahead o f time 
to address various types o f  emergencies that m ight require 
removal o f  vaccine from the original storage unit. Transfer o f  
vaccines to a predesignated alternative emergency storage site 
m ight be necessary if  a temperature problem cannot be resolved 
im m ediately (e.g., plugging in an unplugged unit or closing a 
door that has been left open). Vaccine should be m arked “do 
not use” and moved to the alternate site after verifying that 
the alternate un it is at the proper tem perature. After the vac­
cine has been moved, determ ine w hether the vaccine is still 
useable by contacting the state or local health departm ent or 
m anufacturer. Damage to the im m unogenicity o f  a vaccine 
exposed to tem peratures outside o f  the recom m ended range 
m ight not be apparent visually. As a general rule, vaccines that 
have been stored at inappropriate tem peratures should not 
be administered. I f  such vaccines already have been adm inis­
tered, guidance is available from the state health departm ent 
or C D C . Vaccine exposed to inappropriate tem peratures that 
is inadvertently adm inistered should generally be repeated. 
Clinicians should consult w ith state or local health depart­
m ents in these situations.
Expiration Dates and Windows
All vaccines have an expiration date determ ined by the 
m anufacturer that m ust be observed. Providers should record 
the vaccine expiration dates and lot num bers on a stock or 
inventory record for each vaccine vial w hen a shipm ent is 
received. W hen  vaccines are removed from storage, clinicians 
and other health-care providers should note whether an expira­
tion window exists for vaccine stored at room  tem perature or at 
an interm ediate tem perature. For example, single-com ponent 
varicella vaccine that is stored frozen m ust be discarded after 
72 hours o f  storage at refrigerator tem perature. Vaccine trans­
port between the storage site and the adm inistration clinic is
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discouraged unless the cold chain is m aintained, and vaccine 
transport by the patien t (e.g., transporting  zoster vaccine 
from  a pharm acy to a clinic) is particularly discouraged. An 
expiration w indow  also applies to vaccines that have been 
reconstituted. For example, after reconstitution, M M R  vac­
cine should be kept at refrigerator tem perature and m ust be 
administered w ithin 8 hours. Doses o f  expired vaccines that are 
adm inistered inadvertently generally should not be counted as 
valid and should be repeated. Inactivated vaccines should be 
repeated as soon as possible. Live vaccines should be repeated 
after a 28-day interval from the invalid dose to reduce the 
risk for interference from interferon on the subsequent doses. 
A dditional inform ation about expiration dates is available at 
http://www.cdc. gov/ vaccines/recs/storage.
Multidose Vials
C ertain  vaccines (i.e., quadrivalent meningococcal poly­
saccharide vaccine [M PSV4], PPSV, TIV, IPV, and yellow 
fever) are available in multidose vials. Because several doses 
are w ithdraw n from  the same vial, proper technique m ust be 
followed to prevent contam ination. For m ultidose vials that 
do not require reconstitution, doses that remain after w ith­
drawal of a dose can be administered until the expiration date 
prin ted  on the vial or vaccine packaging if  the vial has been 
stored correctly and the vaccine is not visibly contam inated, 
unless otherwise specified by the manufacturer. M ultidose vials 
that require reconstitution m ust be used w ith in  the interval 
specified by the m anufacturer. After reconstitution, the new 
expiration date should be w ritten on the vial.
Altered Immunocompetence 
General Principles
Altered im m unocom petence, a term  often used synony­
mously w ith im m unosuppression and im m unocom prom ise, 
can be classified as prim ary or secondary. Primary im m unodefi­
ciencies generally are inherited and include conditions defined 
by an absence or quantitative deficiency o f  cellular or hum oral 
com ponents or both that provide immunity. Examples include 
congenital im m unodeficiency diseases such as X-linked agam­
maglobulinem ia, severe com bined im m unodeficiency disease, 
and chronic granulom atous disease. Secondary im m unodefi­
ciency generally is acquired and is defined by loss or qualitative 
deficiency in cellular or hum oral im m une com ponents that 
occurs as a result o f a disease process or its therapy. Examples 
o f  secondary  im m unodefic iency  inc lude  H IV  infec tion , 
hem atopoietic malignancies, treatm ent w ith radiation, and 
treatm ent w ith immunosuppressive drugs including alkylating
agents and antimetabolites. T he degree to w hich im m unosup­
pressive drugs cause clinically significant im m unodeficiency 
generally is dose related and varies by drug. Prim ary and sec­
ondary im m unodeficiencies m ight include a com bination o f  
deficits in both cellular and hum oral im m unity. In this report, 
the general term  altered im m unocom petence also is used to 
include conditions such as asplenia and chronic renal disease, 
and treatm ents w ith therapeutic monoclonal antibodies (spe­
cifically, the tum or necrosis factor inhibitors) (127—132) and 
prolonged adm inistration o f  high-dose corticosteroids.
D eterm ination  o f  altered im m unocom petence is im por­
tant to the vaccine provider because incidence or severity o f  
some vaccine-preventable diseases is higher in persons w ith 
altered im m unocom petence; therefore, certain vaccines (e.g., 
inactivated influenza vaccine and pneum ococcal vaccines) 
are recom m ended specifically for persons w ith these diseases 
(28,68). Vaccines m ight be less effective during the period o f  
altered im m unocom petence. Live vaccines m ight need to be 
deferred until im m une function has improved. Inactivated 
vaccines administered during the period o f altered im m uno­
competence m ight need to be repeated after im m une function 
has improved. In addition , persons w ith altered im m uno­
com petence m ight be at increased risk for an adverse reaction 
after adm inistration o f  live, attenuated vaccines because o f 
uninhibited replication.
The degree o f altered im m unocompetence in a patient should 
be determined by a physician. T he challenge for clinicians and 
other health-care providers is assessing the safety and effective­
ness o f  vaccines for conditions associated w ith prim ary or sec­
ondary immunodeficiency, especially when new therapeutic 
modalities are being used and inform ation about the safety and 
effectiveness o f  vaccines has not been characterized fully in 
persons receiving these drugs (Table 13). Laboratory studies can 
be useful for assessing the effects o f a disease or drug on the 
im m une system. Tests useful to assess humoral im m unity include 
im m unoglobulin (and im m unoglobulin subset) levels and spe­
cific antibody levels (e.g., tetanus and diphtheria). Tests that 
demonstrate the status of cellular im m unity include lymphocyte 
num bers (i.e., a complete blood count with differential), a test 
that delineates concentrations and proportions o f  lymphocyte 
subsets (i.e., B and T  lymphocytes, C D 4 + T  versus CD8+ T  
lymphocytes), and tests that measure T-cell proliferation in 
response to specific or nonspecific stimuli (e.g., lymphocyte 
proliferation assays) (133,134). The ability to characterize a drug 
or disease condition as affecting cellular or hum oral im m unity 
is only the first step; using this inform ation to draw inferences 
about w hether particular vaccines are indicated or w hether cau­
tion is advised with use o f live or inactivated vaccines is more 
complicated and might require consultation w ith an infectious 
disease or im m unology specialist.
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Altered Immunocompetence 
as an Indication to Receive a Vaccine
Persons w ith  altered im m unocom petence  generally are 
advised to receive T IV  and age-appropriate polysaccharide- 
based vaccines (PCV, PPSV, M C V 4, M PSV 4, and Hib) on 
the basis o f  dem onstrated effectiveness or an increased risk for 
disease if  the vaccine is w ithheld.
Pneumococcal Vaccines
Two types o f vaccine against invasive pneumococcal disease are 
available in the United States: PCV and PPSV. PCV  is recom­
mended routinely for all children beginning at age 2 months. 
PCV  is recommended routinely up to age 59 m onths for healthy 
children and up to 71 months for children with conditions that 
place them at high risk for invasive disease from Streptococcus 
pneumoniae. PPSV is licensed for persons aged >2 years and 
recommended for persons with certain underlying medical condi­
tions (including altered immunocompetence) and for all persons 
aged >65 years. Complete recommendations on use o f PCV  and 
PPSV are available in the Recommended Immunization Schedules 
fo r  Persons Aged 0 Through 18 Years and the Recommended Adult 
Immunization Schedule (25,49).
Influenza Vaccines
Two types o f  influenza vaccine are used in the United States: 
T IV  and LAIV. Vaccination with T IV  is recom m ended specifi­
cally for persons w ith  altered im m unocom petence, including 
H IV  infection. LAIV usually is contraindicated for persons 
w ith altered im m unocom petence, although healthy persons 
w ith anatom ic or functional asplenia and household and other 
close contacts o f  persons w ith altered im m unocom petence can 
receive this vaccine {68).
Meningococcal Vaccines
Two types o f m eningococcal vaccine are licensed in the 
U nited States: M C V 4 and M PSV4. Persons w ith  asplenia, 
C3 com plem ent deficiency {51), or persistent com plem ent 
com ponent deficiency are at increased risk for meningococcal 
disease and should receive M C V 4 or M PSV4. Q uadrivalent 
M C V 4 is licensed for persons aged 2—55 years; persons aged 
>56 years should receive M PSV4.
Hib Vaccines
H ib conjugate vaccines are available in single or com bined 
antigen preparations. H ib  vaccine is recom m ended routinely 
for all children through age 59 m onths. However, a single 
dose o f  H ib vaccine also may be considered for asplenic older
children, adolescents, and adults w ho did no t receive the 
vaccine series in childhood. Clinicians and other health-care 
providers m ight consider use o f H ib  vaccine for persons w ith 
H IV  infection who did not receive the vaccine during infancy 
or childhood.
Vaccination of Contacts of Persons 
with Altered Immunocompetence
Household contacts and other close contacts o f persons w ith 
altered im m unocom petence may receive all age-appropriate 
vaccines, w ith  the exception o f  sm allpox vaccine. M M R , 
varicella, and rotavirus vaccines should be adm inistered to 
susceptible household contacts and other close contacts o f 
im m unocom prom ised patients w hen indicated. M M R  vac­
cine viruses are not transm itted to contacts, and transmission 
o f  varicella vaccine is rare {2,4,135). N o specific precautions 
are needed unless the varicella vaccine recipient has a rash 
after vaccination, in w hich case direct contact w ith susceptible 
household contacts should be avoided until the rash resolves 
{4,135). All m em bers o f  the household should wash their 
hands after changing the diaper o f  an infant. This minimizes 
rotavirus transmission, for an undeterm ined num ber o f  weeks 
after vaccination, from an infant who received rotavirus vaccine 
{136). H ousehold and other close contacts o f  persons w ith 
altered im m unocom petence should receive annual influenza 
vaccination. LAIV may be adm inistered to healthy household 
and other close contacts of persons w ith altered im m unocom ­
petence {68).
Vaccination with Inactivated Vaccines
All inactivated vaccines can be adm inistered safely to per­
sons w ith altered im m unocom petence w hether the vaccine is 
a killed whole-organism or a recom binant, subunit, toxoid, 
polysaccharide, or polysaccharide protein-conjugate vaccine. 
If  inactivated vaccines are indicated for persons w ith altered 
im m unocom petence, the usual doses and schedules are rec­
om m ended. However, the effectiveness o f  such vaccinations 
m ight be suboptim al.
Except for inactivated influenza vaccine, vaccination during 
chem otherapy or radiation therapy should be avoided if  pos­
sible because antibody response m ight be suboptim al. Patients 
vaccinated w ithin 14 days before starting im m unosuppressive 
therapy or while receiving im m unosuppressive therapy should 
be considered unim m unized and should be revaccinated at least 
3 m onths after therapy is discontinued if im m une competence 
has been restored.
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Vaccination with Live, Attenuated 
Viral and Bacterial Vaccines
Severe complications have followed vaccination w ith live, 
attenuated viral and live, attenuated bacterial vaccines am ong 
persons w ith  altered im m unocom petence (137—145)- Persons 
w ith most forms o f altered im m unocom petence should not 
receive live vaccines (M M R, varicella, M M R V  LAIV, zoster, 
yellow fever, Ty21a oral typhoid, BCG , and rotavirus).
Children w ith defects in phagocyte function (e.g., chronic 
granulom atous disease or m yeloperoxidase deficiency) can 
receive live, attenuated viral vaccines in addition to inactivated 
vaccines but should no t receive live, attenuated bacterial vac­
cines (e.g., BCG orTy21aoral typhoid vaccines). Children with 
deficiencies in com plem ent or w ith asplenia can receive live, 
attenuated viral and live, attenuated bacterial vaccines.
Persons w ith  severe ce ll-m ed ia ted  im m u n o d efic ien cy  
should not receive live, attenuated viral or bacterial vaccines. 
However, two factors support vaccination o f  HIV-exposed 
or HIV-infected infants: 1) the H IV  diagnosis m ight no t be 
established in infants born to HIV-infected mothers before 
the age o f the first rotavirus vaccine dose (only 1.5%  to 3% o f 
HIV-exposed infants in the U nited States will be determ ined 
to be H IV-infected), and 2) vaccine strains o f rotavirus are 
considerably attenuated (136,146).
Children w ith H IV  infection are at increased risk for com ­
plications from varicella and herpes zoster com pared w ith 
im m unocom petent children (145,147). Limited data am ong 
H IV -infected children (specifically C D C  class N , A, or B 
w ith age-specific C D 4 + T-lym phocyte percentages o f  > 15%) 
indicate that varicella vaccine is im m unogenic, effective, and 
safe (4,147). Varicella vaccine should be considered for chil­
dren w'ho meet these criteria. Eligible children should receive 
2 doses o f  varicella vaccine w ith a 3-m onth  interval between 
doses (4,147). Doses separated by <3 m onths are invalid for 
persons w ith altered im m unocom petence.
Persons w ith H IV  infection are at increased risk for severe 
complications if  infected w ith measles. N o severe or unusual 
adverse events have been reported after measles vaccination 
am ong HIV-infected persons who did not have evidence o f 
severe im m unosuppression (148—151). Therefore, M M R  vac­
cination is recom m ended for all asym ptom atic HIV-infected 
persons who do not have evidence o f severe im m unosuppres­
sion (age-specific C D 4 + T-lym phocyte percentages o f  >15%) 
and for w hom  measles vaccination would otherwise be indi­
cated. Similarly, M M R  vaccination should be considered for 
m ildly sym ptom atic HIV-infected persons (pediatric category 
A1 or A2 or adolescent/adult category A) who do not have
evidence o f  severe im m unosuppression (age-specific C D 4 + 
T-lym phocyte percentages >15%) for w'hom measles vaccina­
tion  would otherwise be indicated (2,146). M M R V  (licensed 
only through age 12 years) should not be adm inistered to 
children or adolescents w ith H IV  infection (35).
HIV-infected persons who are receiving regular doses o f  
IG IV  m ight not respond to varicella vaccine or M M R  vac­
cine because o f  the continued presence o f  passively acquired 
antibody. However, because o f the potential benefit, M M R  
and varicella vaccines should be considered approximately 14 
days before the next sched uled dose o f  IG IV  (if not otherwise 
contraindicated), although an optimal im m une response might 
not occur depending on the dose and interval since the previous 
dose of IGIV. Unless serologic testing indicates that specific 
antibodies have been produced, vaccination should be repeated 
(if no t otherwise contraindicated) after the recom m ended 
interval (Table 5). In m ost cases, this is after the therapy has 
been discontinued. An additional dose o f  IG IV  should be con­
sidered for persons receiving m aintenance IG IV  therapy who 
are exposed to measles or varicella >3 weeks after adm inister­
ing a standard dose (100-400  m g/kg body weight) o f IGIV. 
Patients w ith  leukem ia, lym phom a, or o ther malignancies 
whose disease is in remission, who have restored im m unocom ­
petence, and whose chem otherapy has been discontinued for 
at least 3 m onths can receive live-virus vaccines. Persons w ith 
impaired hum oral im m unity  (e.g., hypogam m aglobulinem ia 
or dysgammaglobulinemia) may be vaccinated w ith varicella 
vaccine (4). However, most persons w ith these disorders also 
receive periodic doses o f  IGIV. Appropriate spacing should be 
m aintained between adm inistration o f  IG IV  and varicella vac­
cine to prevent an inadequate response to vaccination caused 
by the presence o f  neutralizing antibodies from  the IGIV. 
H ousehold m embers should no t receive smallpox vaccine.
Zoster incidence is higher in persons w ith altered im m uno­
com petence (55). Ad ults w ith most types o f  altered im m uno­
com petence are expected to m aintain residual im m unity  to 
varicella-zoster virus because o f previous infection that protects 
against prim ary varicella bu t provides incom plete protection 
against zoster. Zoster vaccine is contraindicated in persons w ith 
prim ary or acquired im m unodeficiency (e.g., lym phom a, leu­
kemia, tum ors involving bone marrow, and patients receiving 
chem otherapy) and some patients w ith AIDS (55). A CIP has 
no recom m endation for or against vaccination o f  persons w ith 
H IV  infection w ith C D 4 + T-lymphocyte counts >200 cells/«!.. 
Zoster vaccine may be adm inistered to certain persons w ith 
altered im m unocom petence, such as persons w ith H IV  infec­
tion who have C D 4 + T-lym phocyte counts >200 cells/^L.
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Recipients of Hematopoietic 
Cell Transplants
A hem atopoietic cell transplant (H C T ) results in im m u­
nosuppression because o f the hem atopoietic ablative therapy 
adm inistered before the transplant, drugs used to prevent or 
treat graft-versus-host disease, and, in some cases, from  the 
underlying disease process necessitating transplantation (152— 
154). H C T  involves ablation o f  the bone m arrow  followed by 
reim plantation o f the persons own stem cells or stem cells from 
a donor. A ntibody titers to vaccine-preventable diseases (e.g., 
tetanus, poliovirus, measles, m um ps, rubella, and encapsulated 
bacteria) decrease 1—4 years after autologous or allogeneic 
H C T  if  the recipient is not revaccinated. H C T  recipients o f 
all ages are at increased risk for certain vaccine-preventable 
diseases, including diseases caused by encapsulated bacteria 
(i.e., pneum ococcal, m eningococcal, and H ib  infections). 
As a result, H C T  recipients should be revaccinated routinely 
after H CT, regardless o f  the source o f  the transplanted stem 
cells (152—154). M ost inactivated vaccines should be initiated 
6 m onths after the H C T  (154) Inactivated influenza vaccine 
should be adm inistered beginning at least 6 m onths after 
H C T  and annually thereafter for the life o f the patient. A 
dose o f  inactivated influenza vaccine can be given as early as 4 
m onths after H C T , bu t a second dose should be considered in 
this situation (154). A  second dose is recom m ended routinely 
for all children receiving influenza vaccine for the first time. 
Sequential adm inistration of 3 doses o f  pneum ococcal con­
jugate vaccine is recom m ended, beginning 3—6 m onths after 
the transplant, followed by a dose o f  PPSV (152). A  3-dose 
regimen o f H ib  vaccine should be administered beginning 6 
m onths after transplant; at least 1 m onth  should separate the 
doses (154). M M R  vaccine should be administered 24 m onths 
after transplant if  the H C T  recipient is im m unocom petent. 
Because o f insufficient experience using varicella vaccine 
am ong H C T  recipients, physicians should assess the im m une 
status o f  each recipient on a case-by-case basis and determ ine 
the risk for infection before using the vaccine. I f  a decision is 
made to vaccinate w ith varicella vaccine, the vaccine should be 
adm inistered a m inim um  o f 24 m onths after transplantation 
if  the H C T  recipient is presum ed to be im m unocom petent 
(152,153).
Conditions or Drugs that Might 
Cause Immunodeficiencies
Asplenia and use o f  corticosteroids or certain drugs have the 
potential to be im m unosuppressive and are presum ed to cause 
some degree o f altered im m unocom petence.
Anatomic or Functional Asplenia
Persons w ith anatom ic asplenia (e.g., surgical removal or 
congenital absence o f  the spleen) or functional asplenia (as 
occurs in persons w ith sickle cell disease) are at increased risk 
for infection by encapsulated bacteria, especially by S. pneu­
moniae (pneum ococcus), N . meningitidis (meningococcus), 
and H ib (22,49,51). Children aged <5 years w ith anatom ic 
or functional asplenia should receive an age-appropriate series 
o f  PCV. Persons aged >2 years should receive 2 doses o f  PPSV 
separated by 5 years (20,25,28,49).
M eningococcal vaccine is recom m ended for persons w ith 
anatom ic or functional asplenia. A specific M C V 4 (Menactra), 
is approved for persons aged 2—55 years and is the recom­
mended vaccine for this age group unless a contraindication 
exists. A nother M C V 4 (Menveo) is approved only for ages 
11—55 years. Persons aged >56 years should receive M PSV4. 
T he duration o f  im m unity  after meningococcal vaccination 
is not certain; however, on the basis o f  serologic testing w ith 
recently licensed assays, revaccination is recom m ended for 
persons at continued high risk. A 3-year interval to the next 
dose is recom m ended for children at high risk who receive 
their first dose at ages 2—6 years. A 5-year interval is recom ­
m ended for persons at high risk who receive their first dose 
at age >7 years.
No efficacy data are available on which to base a recom m en­
dation for use o f  H ib vaccine for older children and adults with 
the chronic conditions that are associated w ith an increased 
risk for H ib disease. A dm inistering 1 dose o f H ib  vaccine to 
these patients who have not previously received H ib vaccine 
is not contraindicated.
Pneumococcal, meningococcal, and H ib vaccinations should 
be adm inistered at least 14 days before elective splenectomy, 
if possible. If the vaccinations are no t adm inistered before 
surgery, they should be adm inistered after the procedure as 
soon as the patien t’s condition is stable.
Corticosteroids
The am ount o f  systemically absorbed corticosteroids and the 
duration o f adm inistration needed to suppress the im m une 
system o f  an otherwise im m unocom petent person are not well 
defined. Corticosteroid therapy usually is not a contraindica­
tion to adm inistering live-virus vaccine w hen adm inistration 
is 1) short term  (i.e., <14 days); 2) a low to m oderate dose 
(<20 m g o f prednisone or equivalent per day); 3) long-term , 
alternate-day treatm ent w ith  short-acting  preparations; 4) 
maintenance physiologic doses (replacement therapy); or 5) 
topical (skin or eyes), inhaled, or by intraarticular, bursal, or 
tendon injection (154). N o evidence o f  more severe reactions 
to live, attenuated viral vaccines has been reported am ong 
persons receiving corticosteroid therapy by aerosol, and such
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therapy is no t a reason to delay vaccination. A lthough the 
im m unosuppressive effects o f  steroid trea tm en t vary, the 
m ajority  o f  clinicians consider a dose equivalent to either 
>2 m g/kg o f  body weight or >20 m g/day o f  prednisone or 
equivalent for persons who weigh >10 kg w hen adm inistered 
for >14 days as sufficiently immunosuppressive to raise concern 
about the safety o f  vaccination w ith live-virus vaccines (154). 
Corticosteroids used in greater than physiologic doses also can 
reduce the im m une response to vaccines. Vaccination providers 
should defer live-virus vaccination for at least 1 m onth  after 
discontinuation of high-dose systemically absorbed corticos­
teroid therapy adm inistered for >14 days.
Other Immunosuppressive Drugs
W hen feasible, clinicians should administer all indicated vac­
cines to all persons before initiation o f chemotherapy, before 
treatm ent w ith other im m unosuppressive drugs, and before 
radiation or splenectomy. Persons receiving chem otherapy or 
radiation for leukemia and other hem atopoietic malignancies, 
for solid tum ors, or after solid organ transplant should be 
assumed to have altered im m unocom petence. Live, attenu­
ated vaccines should not be adm inistered for at least 3 m onths 
after such im m unosuppressive therapy. Inactivated vaccines 
adm inistered during chem otherapy should be readministered 
after im m une com petence is regained. C hildren  receiving 
chem otherapy for leukemia, lym phom a, other malignancies, 
or radiation generally are thought to retain im m une m em ory 
after treatm ent, although revaccination w ith the com m on 
childhood vaccines after chem otherapy for acute lymphoblastic 
leukemia might be indicated (155). In general, revaccination o f 
a person after chem otherapy or radiation therapy is considered 
unnecessary if  the previous vaccination occurred before therapy 
and not during therapy, w ith the exception o f  recipients o f 
H C T, who should be revaccinated as recommended previously. 
D eterm ination o f  the level o f im m une m em ory and the need 
for revaccination should be made by the treating physician.
Inactivated vaccines may be adm inistered during low-dose 
in term itten t or m aintenance therapy w ith im m unosuppres­
sive drugs. T he safety and efficacy o f  live, attenuated vaccines 
during such therapy is unknow n. Physicians should carefully 
weigh the risks for and benefits o f providing injectable live vac­
cines to adult patients receiving low-dose therapies for chronic 
autoim m une disease. T he safety and efficacy o f  live, attenuated 
vaccines adm inistered concurrently w ith recom binant hum an 
im m une mediators and im m une m odulators are unknow n. 
Evidence th a t use o f  th e rap eu tic  m o n o clo n a l a n tib o d y  
preparations, especially the an titum or necrosis factor agents 
adalim um ab, infliximab, and etanercept, causes reactivation 
o f  latent tuberculosis infection and tuberculosis disease and 
predisposes persons to other opportunistic infections suggests
caution in the use o f  live vaccines in patients receiving these 
drugs (127—132). U ntil additional inform ation becomes avail­
able, avoidance o f  live, attenuated vaccines during interm it­
tent or low-dose chem otherapy or other immunosuppressive 
therapy is prudent, unless the benefit o f  vaccination outweighs 
the hypothetical increased risk for an adverse reaction after 
vaccination.
Special Situations
Concurrent Administration 
of Antimicrobial Agents and Vaccines
W ith  a few exceptions, use o f  an antim icrobial agent is not 
a contraindication to vaccination. Antibacterial agents have no 
effect on the response to live, attenuated vaccines, except live 
o ra lT y 2 la  typhoid vaccine, and have no effect on inactivated, 
recom binant subunit, or polysaccharide vaccines or toxoids. 
T y 2 la  typhoid vaccine should not be adm inistered to persons 
receiving antimicrobial agents until 24 hours after the last dose 
o f antim icrobial (14). I f  feasible, to avoid a possible reduction 
in vaccine effectiveness, antibacterial drugs should not be 
started or resumed until 1 week after the last dose ofTy21a.
A n tiv ira l d rugs used for tre a tm e n t or p rophylax is o f  
influenza virus infections have no effect on the response to 
inactivated influenza vaccine (68). However, live, attenuated 
influenza vaccine should not be adm inistered until 48 hours 
after cessation o f  therapy w ith  antiviral influenza drugs. If 
feasible, to avoid possible reduction in vaccine effectiveness, 
antiviral m edication should not be adm inistered for 14 days 
after LAIV adm inistration (68). Antiviral drugs active against 
herpesviruses (e.g., acyclovir or valacyclovir) m ight reduce the 
efficacy o f  live, attenuated varicella and zoster vaccines (4,55). 
These drugs should be discontinued at least 24 hours before 
adm inistration o f  vaccines containing varicella zoster virus, 
including zoster vaccine, if  possible. Delay use or resum ption 
o f  antiviral therapy for 14 days after vaccination. No data exist 
to suggest that com m only used antiviral drugs have an effect 
on rotavirus vaccine or M M R.
Tuberculosis Screening 
and Skin Test Reactivity
Measles illness, severe acute or chronic infections, H IV  
infection, and m alnutrition  can create a relatively anergic state 
during which the tuberculin skin test (TST) might have a false- 
negative reaction (156—158). A lthough any live, attenuated 
measles vaccine theoretically can suppress T S T  reactivity, the 
degree o f  suppression is likely less than that occurring from 
acute infection from wild-type measles virus. A lthough routine
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T S T  screening o f all children is no longer recom m ended, 
T S T  screening is sometimes needed (e.g., for well child care, 
school entrance, or employee health reasons) at the same time 
as adm inistration o f  a measles-containing vaccine.
T he T S T  and measles-containing vaccine can be adm in­
istered at the same visit (preferred option). Simultaneously 
adm inistering the T S T  and measles-containing vaccine does 
not interfere w ith reading the T S T  result at 4 8 -7 2  hours and 
ensures that the person has received measles vaccine.
I f  the m easles-containing vaccine has been adm inistered 
recently, T S T  screening should be delayed for at least 4 weeks 
after vaccination. A  delay in perform ing the T S T  removes the 
concern o f  any theoretical but transient suppression o f  T S T  
reactivity from the vaccine.
T S T  screening can be perform ed and read before adm inis­
tration of the measles-containing vaccine. This option is the 
least favored because it delays receipt o f the measles-containing 
vaccine. If a person is suspected to have tuberculosis, not only 
should the M M R  vaccine be w ithheld before the TST, it should 
be w ithheld until after treatm ent has been initiated because a 
person w ith active tuberculosis who is m oderately or severely 
ill should not receive M M R  vaccine. In a general screening 
situation in w hich tuberculosis is not suspected, a T S T  may 
be adm inistered sim ultaneously w ith live vaccines or should 
be deferred for 28 days after vaccination.
N o data exist regarding the potential degree o f  T S T  sup­
pression that m ight be associated w ith other live, attenuated 
virus vaccines (e.g., varicella or yellow fever). However, in the 
absence o f  data, following guidelines for measles-containing 
vaccine w hen scheduling T S T  screening and adm inistering 
other live, attenuated virus vaccines is prudent. I f  the oppor­
tun ity  to vaccinate m ight be missed, vaccination should not 
be delayed only because o f these theoretical considerations. 
Because o f  similar concerns about smallpox vaccine and T S T  
suppression, a T S T  should not be performed until 4 weeks 
after smallpox vaccination ( 1.59).
A more specific test for diagnosis o f  tuberculosis or latent 
tuberculosis infection was licensed in 2005- T he interferon­
gamma release assay (IGRA) requires only one visit to complete 
and is less sensitive to the effects o f  previous BCG  vaccination 
(160). T he  same tim ing guidelines that apply to the interval 
between a live vaccine and T S T  apply to IG R A  (i.e., 28 days 
between live vaccine and IGRA if they do not occur on the 
same day), because IG R A  (like TST) m ight be suppressed 
through im m unologic mechanisms.
T he potential for T S T  to cause boosting o f  results should be 
considered in adults who m ight have latent tuberculosis and 
have a negative in itia lT S T  (160). T he  two-step tuberculin test 
is recom m ended for certain situations (160). Because this test 
consists o f  two TSTs (or a T S T  followed by IGRA) separated
by an interval o f  1—3 weeks, there is a greater w indow  o f time 
during which live vaccine replication could suppress reactivity. 
If a live vaccine is administered, the first dose o f a two-step TST 
should be delayed for 4 weeks, and if additional doses of live 
vaccines are indicated thereafter, they should be delayed until 
the second T S T  (or the IGRA after an initial TST).
TST  or IGRA reactivity in the absence o f  tuberculosis disease 
is no t a contraindication to adm inistration o f  any vaccine, 
including live, attenuated virus vaccines. Tuberculosis disease 
is not a contraindication to vaccination, unless the person is 
m oderately or severely ill. A lthough no studies have reported 
on the effects o f  M M R  vaccine on persons w ith untreated 
tuberculosis, a theoretical basis exists for concern that measles 
vaccine m ight exacerbate tuberculosis disease (2). As a result, 
before adm inistering M M R  to persons w ith untreated active 
tuberculosis, initiating antituberculosis therapy is advisable (2). 
Considering w hether concurrent im m unosuppression (e.g., 
im m unosuppression caused by H IV  infection) is a concern 
before adm inistering live, attenuated vaccines also is prudent.
Severe Allergy to Vaccine Components
Vaccine com ponents can cause allergic reactions am ong 
certain recipients. These reactions can be local or systemic 
and can include anaphylaxis or anaphylactic-like responses 
(e.g., generalized urticaria or hives, wheezing, swelling o f  the 
m outh and throat, dyspnea, hypotension, and shock). Allergic 
reactions m ight be caused by the vaccine antigen, residual 
animal protein, antim icrobial agents, preservatives, stabiliz­
ers, or o ther vaccine com ponents (161). C hildren who have 
had an apparent severe allergic reaction to a vaccine should be 
evaluated by an allergist to determ ine the responsible allergen 
and to make recom m endations regarding future vaccination. 
C om ponents o f  each vaccine are listed in the respective pack­
age insert. An extensive list o f  vaccine com ponents and their 
use, as well as the vaccines that contain each com ponent, has 
been published (162) and also is available from  C D C  (h ttp :// 
www.cdc. gov/ vaccines).
T he m ost com m on animal protein allergen is egg protein, 
w hich is found in influenza and yellow fever vaccines because 
they are prepared using em bryonated chicken eggs. Ordinarily, 
persons who are able to eat eggs or egg products safely can 
receive these vaccines; persons who have had an anaphylactic 
or anaphylactic-like allergy to eggs or egg proteins generally 
should not receive these vaccines. Asking persons if  they can eat 
eggs w ithout adverse effects is a reasonable way to determ ine 
which persons m ight be at risk for allergic reactions from  yel­
low fever and influenza vaccines. A  regimen for adm inistering 
influenza vaccine to children w ith egg hypersensitivity and 
severe asthm a has been developed (163,164)
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Measles and m um ps vaccine viruses are grown in chick 
em bryo fibroblast tissue culture. However, persons w ith a 
severe egg allergy can receive measles- or m um ps-containing 
vaccines w ithou t skin testing or desensitization to egg protein 
(2). Rubella and varicella vaccines are grown in hum an diploid 
cell cultures and can safely be adm inistered to persons w ith a 
severe allergy to eggs or egg proteins. T he rare severe allergic 
reactions after measles or m um ps vaccination or M M R  are 
not thought to be caused by egg antigens but to other com po­
nents o f  the vaccine (e.g., gelatin) (165—168). M M R , MMRV, 
and other vaccines contain hydrolyzed gelatin as a stabilizer. 
Extreme caution should be used when adm inistering vaccines 
that contain gelatin to persons who have had an anaphylactic 
reaction to gelatin or gelatin-containing products.
C ertain vaccines contain trace am ounts o f  antim icrobial 
agents or other preservatives (e.g., neom ycin or thimerosal) 
to w hich patients m ight be allergic, although such allergies 
are rare. T he inform ation provided in vaccine package inserts 
should be reviewed carefully before deciding w hether a patient 
w ith such allergies should receive the vaccine. N o licensed vac­
cine contains penicillin or penicillin derivatives.
Persons who have had anaphylactic reactions to neom ycin 
should not receive vaccines containing neomycin. M ost often, 
a neomycin allergy is a contact derm atitis, a m anifestation o f 
a delayed-type (cell-mediated) im m une response rather than 
anaphylaxis (169,170). A  history o f  delayed-type reactions 
to neom ycin is no t a contraindication for adm inistration o f 
these vaccines.
Thim erosal, an organic mercurial com pound in use since 
the 1930s, is added to certain im m unobiologies as a preserva­
tive. Since m id-2001, vaccines routinely recom m ended for 
young infants have been m anufactured w ithout thimerosal as 
a preservative. Live, attenuated vaccines have never contained 
thimerosal. Thimerosal-free form ulations o f  inactivated influ­
enza vaccine are available. Inactivated influenza vaccine also 
is available in form ulations w ith trace thimerosal, in w hich 
thimerosal remains as a m anufacturing residual but does not 
function as a preservative, and in form ulations that contain 
thim erosal as a preservative. T him erosal at a preservative 
concentration is present in certain o ther vaccines that can 
be adm inistered to children (e.g., T d  and D T ). Inform ation 
about the thimerosal content o f  vaccines is available from FDA 
(http://w w w .fda.gov/cber/vaccine/thim erosal.htm ).
O n  the basis o f  lim ited scientific data, some investigators 
have asserted that receiving thim erosal-containing vaccines 
m ight induce an allergy. Allergies to thimerosal usually have 
been described as local delayed-type hypersensitivity reactions 
(171—173). Thim erosal elicits positive delayed-type hyper­
sensitivity patch tests in 1%—18% o f persons tested; however, 
these tests have lim ited or no clinical relevance (174,175)- The
m ajority o f  persons do no t experience reactions to thimerosal 
adm inistered as a com ponent o f  vaccines even w hen patch or 
intradermal tests for thimerosal indicate hypersensitivity (175)- 
A  local or delayed-type hypersensitivity reaction to thimerosal 
is not a contraindication to receipt o f  a vaccine that contains 
thimerosal.
Latex Allergy
Latex is sap from the commercial rubber tree. Latex contains 
naturally occurring im purities (e.g., p lant proteins and pep­
tides) that m ight be responsible for allergic reactions. Latex is 
processed to form natural rubber latex and dry, natural rubber. 
Natural rubber latex and dry, natural rubber m ight contain the 
same plant im purities as latex bu t in lesser am ounts. N atural 
rubber latex is used to produce medical gloves, catheters, 
and other products. Dry, natural rubber is used in the tip o f 
syringe plungers, the tip on prefilled syringes, vial stoppers, 
and injection ports on intravascular tubing. Synthetic rubber 
and synthetic latex also are used in medical gloves, syringe 
plungers, and vial stoppers. Synthetic rubber and synthetic 
latex do not contain natural rubber or natural latex and do not 
contain im purities linked to allergic reactions. Latex or dry, 
natural rubber used in vaccine packaging generally is noted in 
the m anufacturers’ package inserts.
The most com m on type o f latex sensitivity is a contact-type 
(type 4) allergy, usually as a result o f prolonged contact with 
latex-containing gloves (176). However, latex allergies associated 
with injection procedures have been described among patients 
with diabetes mellitus (177—179)- Allergic reactions (including 
anaphylaxis) after vaccinations are rare. A review o f reports to 
VAERS identified only 28 cases o f  possible immediate-type 
anaphylactic reactions among more than 160,000 vaccine adverse 
event reports (180).
If  a person reports a severe (anaphylactic) allergy to latex, 
vaccines supplied in vials or syringes that contain natural 
rubber latex should not be adm inistered unless the benefit o f  
vaccination clearly outweighs the risk for a potential allergic 
reaction. In these cases, providers should be prepared to treat 
patients who are having an allergic reaction. For latex allergies 
other than anaphylactic allergies (e.g., a history o f  contact 
allergy to latex gloves), vaccines supplied in vials or syringes 
that contain dry, natural rubber or natural rubber latex may 
be administered.
Vaccination of Preterm Infants
In the m ajority o f cases, preterm  infants (infants born before 
37 weeks’ gestation), regardless o f  b irth  weight, should be 
vaccinated at the same chronological age and according to the 
same schedule and using the same precautions as for full-term
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infants and children. B irth w eight and size are not factors 
in deciding w hether to vaccinate a clinically stable preterm  
infant (181-185), except for hepatitis B vaccination. T he full 
recom m ended dose o f each vaccine should be used. Divided 
or reduced doses are not recom m ended.
Decreased seroconversion rates m ight occur am ong certain 
preterm  infants (i.e., w ith  low  b irth  weights [<2,000 g]) 
after adm inistration  o f hepatitis B vaccine at b irth  (186). 
However, by the chronological age of 1 m onth , all preterm  
infants, regardless o f  initial birth  weight, are likely to respond 
as adequately as larger infants (187—189). Preterm  infants 
born to HBsAg-positive m others and m others w ith unknow n 
HBsAg status m ust receive im m unoprophylaxis w ith hepatitis 
B vaccine w ithin 12 hours after birth. T he initial vaccine dose 
should not be counted toward com pletion o f the hepatitis B 
series, and 3 ad d itional doses o f hepatitis B vaccine should be 
adm inistered, beginning when the infant is aged 1 m onth. 
For m others w ith unknow n HBsAg status, attem pts should be 
made to determ ine HBsAg status. T he infant m ust be given 
H B IG  w ithin 12 hours o f b irth  unless the m other is found to 
be HBsAg negative (26). Infants weighing <2,000 g born  to 
HBsAg-negative m others should receive the first dose o f  the 
hepatitis B series at chronological age 1 m onth  or at hospital 
discharge.
I f  a child aged at least 6 weeks has been in the hospital since 
birth, deferral o f  rotavirus vaccine is recom m ended until the 
tim e of discharge (136). T he  rotavirus vaccine series should 
not be initiated for infants aged >15 weeks, 0 days.
Breastfeeding and Vaccination
N either inactivated nor live-virus vaccines adm inistered to a 
lactating w om an affect the safety o f  breastfeeding for wom en 
or their infants. A lthough live viruses in vaccines can replicate 
in vaccine recipients (i.e., the m other), the m ajority o f live 
viruses in vaccines have been dem onstrated not to be excreted 
in hum an milk. Varicella vaccine virus has not been found in 
hum an milk (190). A lthough rubella vaccine virus m ight be 
excreted in hum an milk, the virus usually does not infect the 
infant. If  infection does occur, it is well tolerated because the 
virus is attenuated (191). Inactivated, recom binant, subunit, 
polysaccharide, and conjugate vaccines, as well as toxoids, pose 
no risk for m others who are breastfeeding or for their infants. 
Breastfeeding is a contraindication for smallpox vaccination 
o f  the m other because o f  the theoretical risk for contact trans­
mission from  m other to infant. Yellow fever vaccine should be 
avoided in breastfeeding w om en (19). However, when nursing 
m others cannot avoid or postpone travel to areas endem ic for 
yellow fever in w hich risk for acquisition is high, these women 
should be vaccinated.
Limited data indicate that breastfeeding can enhance the 
response to certain vaccine antigens (192). There are no data 
to suggest that passive transfer o f antibodies in hum an milk 
can affect the efficacy o f live-virus vaccines. Breastfed infants 
should be vaccinated according to the recom m ended schedule 
(193-195).
Vaccination During Pregnancy
Risk to a developing fetus from  vaccination o f the m other 
during pregnancy is theoretical. N o evidence exists o f  risk to 
the fetus from vaccinating pregnant w om en w ith inactivated 
virus or bacterial vaccines or toxoids (196,197). Live vaccines 
adm inistered to a pregnant w om an pose a theoretical risk to 
the fetus; therefore, live, attenuated virus and live bacterial vac­
cines generally are contraindicated during pregnancy. Benefits 
o f  vaccinating pregnant w om en usually outweigh potential 
risks when the likelihood o f disease exposure is high, when 
infection would pose a risk to the m other or fetus, and when 
the vaccine is unlikely to cause harm . Recom m endations for 
vaccination during  pregnancy are developed using A C IP ’s 
Guiding Principles fo r  Development o fA C IP  Recommendations 
fo r  Vaccination D uring Pregnancy and  Breastfeeding (198).
Pregnant w om en who received the last dose o f  tetanus- 
toxoid—containing vaccine >10 years previously should gener­
ally receive T d  rather than  T dap while they are pregnant (16), 
although Tdap is not contraindicated during pregnancy. A dose 
o f  T d  during pregnancy ensures adequate tetanus im m unity  
in the m other and prevents disease in both m other and infant. 
In specific situations, the dose o f  T d  can be withheld if  the 
provider is confident the pregnant wom an is im m une to tetanus 
(199). Regardless o f  a recent T d  vaccination, pregnant w om en 
who have not already received T dap  should receive a dose o f  
Tdap as soon as possible after delivery to ensure pertussis 
im m unity and reduce the risk for transmission to the newborn. 
Pregnant w om en who are no t vaccinated or are only partially 
vaccinated against tetanus should com plete the prim ary series 
(16). W om en for w hom  T d is indicated bu t who did not 
complete the recom m ended 3-dose series during pregnancy 
should receive follow-up after delivery to ensure the series is 
completed . Because T dap  is recom m ended as a one-tim e dose, 
pregnant w om en who previously have received T dap  should 
receive Td if  indicated.
W om en in the second and third trimesters o f pregnancy are 
at increased risk for hospitalization from  influenza (68,200). 
Because vaccinating against influenza before the season begins 
is critical, and because predicting exactly when the season will 
begin is impossible, routine influenza vaccination is recom ­
m ended for all w om en who are or will be pregnant (in any
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trimester) during influenza season, w hich in the U nited States 
is usually early O ctober through late M arch (68).
IPV  can be adm inistered to pregnant w om en who are at 
risk for exposure to  w ild-type poliovirus infection (201). 
H epatitis A, pneum ococcal polysaccharide, m eningococcal 
conjugate, and meningococcal polysaccharide vaccines should 
be considered for wom en at increased risk for those infections 
(49,51,202). Pregnant w om en who m ust travel to areas where 
the risk for yellow fever is high should receive yellow fever 
vaccine because the lim ited theoretical risk from vaccination 
is outweighed substantially by the risk for yellow fever infec­
tion (19,203). H epatitis B vaccine is no t contraindicated in 
pregnancy and should be given to a pregnant w om an who has 
an indication for hepatitis B vaccine (26,204).
Pregnancy is a contraindication for smallpox (vaccinia) vac­
cine and measles-, m um ps-, rubella-, and varicella-containing 
vaccines. Smallpox vaccine is the only vaccine know n to harm  
a fetus w hen adm inistered to a pregnant wom an. In addition, 
smallpox vaccine should not be adm inistered to a household 
contact o f  a pregnant w om an (159). D ata from  studies o f 
children born to m others vaccinated w ith  rubella vaccine 
during  pregnancy dem onstrate  rubella an tibody  levels in 
unvaccinated infants. This could represent passive transfer o f 
m aternal antibody or a fetal antibody response to vaccine virus 
infection in the fetus. N o cases o f  congenital rubella or vari­
cella syndrom e or abnormalities attributable to fetal infection 
have been observed am ong infants born to susceptible wom en 
who received rubella or varicella vaccines during pregnancy 
(205—207). Because o f  the im portance o f  protecting wom en 
o f childbearing age against rubella and varicella, reasonable 
practices in any vaccination program  include asking wom en 
if  they are pregnant or m ight become pregnant in the next 4 
weeks; not vaccinating wom en who state that they are or plan 
to become pregnant; explaining the theoretical risk for the 
fetus if  M M R , varicella, or M M R V  vaccine were administered 
to a w om an who is pregnant; and counseling w om en who are 
vaccinated not to become pregnant during the 4 weeks after 
M M R , varicella, or M M R V  vaccination (2 ,5 9 ,2 0 5 —207)■ 
M M R V  is an unlikely option  for a pregnant w om an because 
the vaccine is only licensed through 12 years o f  age. Routine 
pregnancy  testing  o f  w om en  o f  ch ildbearing  age before 
adm inistering a live-virus vaccine is no t recom m ended (2,4). 
I f  a pregnant w om an is inadvertently vaccinated or becomes 
pregnant w ithin 4 weeks after M M R  or varicella vaccination, 
she should be counseled about the theoretical basis o f  concern 
for the fetus; however, M M R  or varicella vaccination d uring 
pregnancy should not be considered a reason to term inate 
pregnancy (2,4,207).
Persons who receive M M R  vaccine do no t transm it the vac­
cine viruses to contacts (2). Transmission o f  varicella vaccine
virus to contacts is rare (4). M M R  and varicella vaccines 
should be adm inistered when indicated to children and other 
household contacts o f  pregnant w om en (2,4). Infants living in 
households w ith pregnant wom en should be vaccinated w ith 
rotavirus vaccine according to the same schedule as infants in 
households w ithout pregnant women.
Pregnant women should be evaluated for im m unity to rubella 
and varicella and be tested for the presence o f HBsAg during 
every pregnancy (2 ,26,60). W om en susceptible to rubella 
and varicella should be vaccinated im m ediately after delivery. 
A w om an found to be HBsAg positive should be m onitored 
carefully to ensure that the infant receives H B IG  and begins 
the hepatitis B vaccine series no later than 12 hours after birth 
and that the infant completes the recom m ended hepatitis B 
vaccine series on schedule (26). N o know n risk exists for the 
fetus from  passive im m unization o f  pregnant w om en w ith 
im m une globulin preparations.
Persons Vaccinated Outside 
the United States
Clinicians have a lim ited ability to determ ine w hether per­
sons are protected on the basis o f  their country  o f  origin and 
their records alone. Vaccines adm inistered outside the United 
States generally can be accepted as valid if the schedule (i.e., 
m inim um  ages and intervals) is similar to that recom m ended 
in the United States. W ith  the exception o f  the influenza 
vaccine and PPSV, only written docum entation should be 
accepted as evidence o f  previous vaccination. W ritten  records 
are more likely to predict protection if  the vaccines, dates o f  
adm inistration, intervals between doses, and age at the time 
o f vaccination are com parable to U.S. recom m endations. 
A lthough vaccines w ith  inadequate potency have been pro­
duced in other countries (208,209), the m ajority o f  vaccines 
used worldwide are produced w ith adequate quality control 
standards and are potent.
T he num ber o f  U.S. families adopting children from outside 
the U nited States has increased substantially in the last decade
(209). A dopted children’s b irth  countries often have vaccina­
tion schedules that differ from the recom m ended childhood 
vaccination schedule in the U nited States. Differences in the 
U.S. schedule and those used in o ther countries include the 
vaccines adm inistered, the recom m ended ages o f  adm inistra­
tion, and the num ber and tim ing o f  doses.
D ata are inconclusive regarding the extent to which an inter­
nationally adopted child’s vaccination record reflects the child’s 
protection. A  child’s record m ight indicate adm inistration o f  
M M R  vaccine w hen only single-antigen measles vaccine was 
administered. A study o f  children adopted from  orphanages in 
the People’s Republic o f  China, Russia, and countries in Eastern
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Europe determ ined that 67%  o f children w ith docum entation 
o f  >3 doses o f  D T P  before adoption had nonprotective titers 
to these antigens (209 )■ In contrast, children adopted from 
these countries w ho received vaccination in the com m unity  
(not only from orphanages) and had docum entation o f >1 
doses of D T P  exhibited protective titers 67%  o f the time (209). 
However, antibody testing was performed by using a hem ag­
glutination assay, w hich tends to underestim ate protection 
and cannot directly be compared w ith antibody concentration
(210). D ata are likely to rem ain limited for areas other than 
the People’s Republic o f  C hina, Russia, and Eastern Europe. 
Health-care providers should ensure that household contacts o f 
international adoptees are vaccinated adequately, particularly 
for measles, hepatitis A, and hepatitis B (211).
H ealth-care providers m ay use one o f  m ultiple approaches 
if  the im m unogenicity o f  vaccines adm inistered to persons 
outside the United States is in question. Repeating the vaccina­
tions is an acceptable option that usually is safe and prevents 
the need to obtain and interpret serologic tests. If  avoiding 
unnecessary injections is desired, judicious use o f  serologic 
testing m ight help determ ine which vaccinations are needed. 
For some vaccines, the m ost readily available serologic tests 
cannot docum ent protection against infection. These recom ­
m endations provide guidance on possible approaches to evalu­
ation and revaccination for each vaccine recom m ended in the 
U nited States (Table 14).
DTaP Vaccine
Vaccination providers can revaccinate children w ith DTaP 
vaccine w ithout regard to recorded doses; however, data indi­
cate increased rates o f  local adverse reactions after the fourth 
and fifth doses o f  DTaP (67). I f  a revaccination approach is 
adopted and a severe local reaction occurs, serologic testing 
for specific IgG antibody to tetanus and diphtheria toxins can 
be measured before adm inistering additional doses. Protective 
concen tra tion^  indicates that additional doses are unnecessary 
and subsequent vaccination should occur as age-appropriate. 
N o established serologic correlates exist for protection against 
pertussis.
For a child whose record indicates receipt o f  >3 doses o f 
D T P  or DTaP, serologic testing for specific IgG antibody to 
both  d iphtheria and tetanus toxin before additional doses is a 
reasonable approach. If a protective concentration is present, 
recorded doses are considered valid, and the vaccination series 
should be com pleted as age appropriate. An indeterm inate 
antibody concentration m ight indicate im m unologic m em ory
Enzyme immunoassay tests are available. Physicians should contact the labora­
to ry  perform ing the test fo r interpretive standards and lim itations. Protective 
concentrations fo r antibody to  d iph theria  and tetanus toxins are defined as
>0.1 IU /m L .
but w aning antibody; serologic testing can be repeated after a 
booster dose if  the vaccination provider wants to avoid revac­
cination w ith a complete series.
Alternately, for a child whose records indicate receipt o f  >3 
doses, a single booster dose can be adm inistered followed by 
serologic testing after 1 m onth  for specific IgG antibody to 
both diphtheria and tetanus toxins. I f  the child has a protective 
concentration, the recorded doses are considered valid, and 
the vaccination series should be completed as age appropriate. 
C hildren w ith an indeterm inate concentration after a booster 
dose should be revaccinated w ith a com plete series.
Hepatitis A Vaccine
Children aged 12—23 m onths w ithout docum entation  o f  
hepatitis A  vaccination or serologic evidence o f  im m unity  
should be vaccinated on arrival in the U nited States (202). 
Persons who have received 1 dose should receive the second 
dose if  6—18 m onths have passed since the first dose was 
administered.
Hepatitis B Vaccine
Persons no t know n to be vaccinated for hepatitis B should 
receive an age-appropriate series o f  hepatitis B vaccine. A per­
son whose records indicate receipt o f  >3 doses o f  vaccine are 
considered protected, and additional doses are not needed if  > 1 
dose was adm inistered at age >24 weeks. Persons who received 
their last hepatitis B vaccine dose at an age <24 weeks should 
receive an additional dose at age >24 weeks. People who have 
received <3 doses o f vaccine should com plete the series at the 
recom m ended intervals and ages.
All foreign-born persons and immigrants, refugees, and interna­
tionally adopted children born in Asia, the Pacific Islands, Africa, 
and other regions o f  high or intermediate endemicity should be 
tested for HBsAg, regardless o f vaccination status (212). Those 
determ ined to be HBsAg-positive should be m onitored for 
development o f liver disease. Household members o f  HBsAg- 
positive children or adults should be vaccinated if they are not 
already immune.
Hib Vaccine
Interpretation o f  a serologic test to verify w hether children 
w'ho were vaccinated >2 m onths previously are protected 
against H ib  bacteria can be difficult. Because the num ber o f  
vaccinations needed for protection decreases w ith age and 
because adverse events are rare (22), age-appropriate vaccina­
tion should be provided. H ib  vaccination is not recom m ended 
routinely for persons aged >5 years (20).
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MMR Vaccine
T he simplest approach to resolving concerns about M M R  
vaccination is to revaccinate w ith 1 or 2 doses o f M M R  vac­
cine, depending on age. Serious adverse events after M M R  
vaccinations are rare (2). N o evidence indicates that adm in­
istering M M R  vaccine increases the risk for adverse reactions 
am ong persons who are already im m une to measles, m um ps, 
or rubella as a result of previous vaccination or natural disease. 
Doses o f  measles-containing vaccine adm inistered before the 
first birthday should not be counted as part o f the series (2). 
Alternatively, serologic testing for IgG antibody to vaccine 
viruses indicated on the vaccination record can be considered. 
Serologic testing is widely available for measles and rubella IgG 
antibody. A person whose record indicates receipt o f m on­
ovalent measles or measles-rubella vaccine on or after the first 
birthday and who has protective antibody against measles and 
rubella should receive 1 or 2 doses o f  M M R  or M M R V  as age 
appropriate to ensure protection against m um ps and varicella 
(and rubella if  measles vaccine alone had been administered). 
I f  a person whose record indicates receipt o f  M M R  at age >12 
m onths has a protective concentration o f antibody to measles, 
no additional vaccination is needed unless a second dose is 
required for school entry.
Pneumococcal Vaccines
M any industrialized countries are now routinely using pneu­
mococcal vaccines. A lthough recom m endations for pneum o­
coccal polysaccharide vaccine also exist in m any countries, the 
vaccine m ight no t be routinely adm inistered. PC V  and PPSV 
should be adm inistered according to age-appropriate vaccina­
tion schedules or as ind icated by the presence o f  und erlying 
medical conditions {25,49).
Poliovirus Vaccine
T he simplest approach to vaccinating with poliovirus vaccine 
is to revaccinate persons aged <18 years w ith IPV according 
to the U.S. schedule. Adverse events after IPV  are rare {201). 
Children appropriately vaccinated w ith 3 doses o f  O P V  in 
econom ically developing countries m ight have suboptim al 
seroconversion, including to type 3 poliovirus {201). Serologic 
testing for neutralizing antibody to poliovirus types 1, 2, and 
3 can be obtained commercially and at certain state health 
departm ent laboratories. Persons w ith protective titers against 
all three types do not need to repeat doses but should complete 
the schedule as age appropriate.
Rotavirus Vaccine
Rotavirus vaccination should not be initiated for infants aged 
>15 weeks, 0 days. Infants who began the rotavirus vaccine 
series outside the U nited States but who did no t complete
the series and who are still aged <8 m onths, 0 days, should 
follow the routine schedule and receive doses to com plete the 
series. I f  the brand o f  a previously adm inistered dose is RV5 
or unknow n, a total o f  3 doses o f  rotavirus vaccine should 
be docum ented for series com pletion. All doses should be 
adm inistered by age 8 m onths, 0 days.
Td and Tdap Vaccines
Children aged >7 years who need the prim ary series doses o f 
tetanus-toxoid—containing vaccine should receive T d  or T dap 
as age appropriate.
Varicella Vaccine
Varicella vaccine is not available in the m ajority o f  countries. 
A person who lacks reliable evidence o f  varicella im m unity  
should be vaccinated as age appropriate {4,20).
Zoster Vaccine
Zoster vaccination is recommended for all persons aged >60 
years who have no contraindications, including persons who 
report a previous episode o f zoster or who have chronic medical 
conditions. The vaccine should be offered at the patients first 
clinical encounter with the health-care provider. T he vaccine is 
administered as a single 0.65-mL subcutaneous dose. Zoster vac­
cination is not indicated to treat acute zoster, to prevent persons 
with acute zoster from developing postherpetic neuralgia, or to 
treat ongoing postherpetic neuralgia. Before administration o f 
zoster vaccine, patients do not need to be asked about their history 
o f varicella or to have serologic testing conducted to determine 
zoster immunity.
Vaccinating Persons 
with Bleeding Disorders
Because o f the risk for hem atom a form ation after injections, 
intram uscular injections are often avoided am ong persons w ith 
bleeding disorders by using the subcutaneous or intraderm al 
routes for vaccines that norm ally are adm inistered intram us­
cularly. In one study, hepatitis B vaccine was adm inistered 
intram uscularly to 153 persons w ith hem ophilia. T he vac­
cination was administered w ith a 23-gauge or smaller caliber 
needle, followed by application o f  steady pressure to the site 
for 1—2 m inutes. T h e  vaccinations resulted in a low (4%) 
bruising rate, and no patients required factor supplem entation 
{213). W hether antigens that produce more local reactions 
(e.g., pertussis) would produce an equally low rate o f  bruising 
is unknow'n.
W hen  hepatitis B or any other intram uscularly administered 
vaccine is indicated for a patient w ith a bleeding disorder, the 
vaccine should be adm inistered intram uscularly if  a physician
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familiar w ith the patien ts bleeding risk determ ines that the 
vaccine can be adm inistered by this route w ith  reasonable 
safety I f  the patient receives antihem ophilia or similar therapy 
intram uscularly adm inistered vaccinations can be scheduled 
shortly after such therapy is adm inistered. A fine-gauge needle 
(23 gauge or smaller caliber) should be used for the vaccina­
tion, followed by firm pressure on the site, w ithout rubbing, 
for at least 2 m inutes. T he patient or family should be given 
inform ation on the risk for hem atom a from the injection. 
Patients receiving anticoagulation therapy presum ably have 
the same bleeding risk as patients w ith clotting factor disor­
ders and should follow the same guidelines for intram uscular 
adm inistration.
Vaccination Records 
Records of Health-Care Providers
A ppropriate and timely vaccination docum entation helps 
ensure not only that persons in need o f  recom m ended vac­
cine doses receive them  bu t also that adequately vaccinated 
patients do not receive excess doses. C urtailing the num ber o f 
excess doses administered to patients controls costs incurred by 
patients, providers, insurers, vaccination programs, and other 
stakeholders. In add ition, excess doses o f  inactivated vaccines 
m ight increase the risk for an adverse reaction. Health-care 
providers who adm inister vaccines covered by the N ational 
C hildhood Vaccine Injury Act are required to ensure that the 
perm anent medical record o f  the recipient (or a perm anent 
office log or file) indicates the date the vaccine was adm inis­
tered, the vaccine manufacturer, the vaccine lot num ber, and 
the name, address, and title of the person adm inistering the 
vaccine. In addition, the provider is required to record the 
edition date of the VIS distributed and the date those m ateri­
als were provided. T he act considers a health-care provider 
to be any licensed health-care professional, organization, or 
institution, w hether private or public (including federal, state, 
and local departm ents and agencies), under whose authority  
a specified vaccine is adm inistered. This inform ation should 
be kept for all vaccines, not just for those required by the act. 
Providers and staff m embers also should systematically update 
patient’s perm anent medical records to reflect any docum ented 
episodes of adverse events after vaccination and any serologic 
test results related to vaccine-preventable diseases (e.g., those 
for rubella screening and antibody to HBsAg).
Personal Records of Patients
Official childhood vaccination records have been adopted 
by every state and territory and the D istrict o f C olum bia to
encourage uniform ity o f  records and to facilitate assessment 
o f vaccination status by schools and child-care centers. T he 
records also are key tools in vaccination education programs 
aimed at increasing parental and patient awareness o f  the need 
for vaccines. A perm anent vaccination record card should be 
established for each new born infant and m aintained by the 
parent or guardian. T he parent or guardian should be educated 
about the im portance o f  keeping the record up to date and 
instructed to keep the record indefinitely as part o f  the child’s 
perm anent medical record. These cards should be distributed to 
new mothers before discharge from the hospital. Using vaccina­
tion record cards for adolescents and adults also is encouraged. 
Standardized adult vaccination records are available at h ttp :// 
www.im m unize.org.
Immunization Information Systems
IISs (formerly referred to as im m unization registries) are 
confidential, population-based, com puterized inform ation 
systems that collect and consolidate vaccination data from 
m ultiple health-care providers w ith in  a geographic area. IISs 
are a critical tool that can increase and sustain vaccination 
coverage by consolidating vaccination records from m ultiple 
providers, generating rem inder and recall vaccination notices 
for each person, and providing official vaccination forms and 
vaccination coverage assessments (214).
C hanging vaccination providers during the course o f  an 
individual’s vaccination series is com m on in the U nited States. 
T he 2007 National H ealth Interview Survey Sum m ary Health 
Statistics for U.S. Children docum ented that 95%  o f children 
have a usual place o f  health care; 6% go to more than one health 
venue most o f  the time. Individual eligibility for M edicaid and 
resulting enrollm ent in M edicaid managed-care health plans 
tends to be sporadic, w ith an average duration  o f 9 m onths 
and a m edian o f <12 m onths in 2000 (215). In addition to 
changes in providers, the vaccination records of persons who 
have changed vaccination providers often are unavailable 
or incom plete or m ight not have been entered into an IIS 
(214). Missing or inaccurate inform ation regarding vaccines 
received previously m ight preclude accurate determ ination o f  
w hich vaccines are indicated at the tim e o f a visit, resulting in 
adm inistration o f  extra doses.
A fully operational IIS also can prevent duplicate vaccinations, 
lim it missed appointm ents, reduce vaccine waste, and reduce 
staff tim e required to produce or locate vaccination records 
or certificates. M ost IISs have additional capabilities, such 
as vaccine m anagem ent, m aintenance o f lifetime vaccination 
histories, and interoperability w ith other health inform ation 
systems. T he National Vaccine Advisory C om m ittee strongly 
encourages developm ent of com m unity- or state-based IISs
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and recommends that vaccination providers participate in these 
systems w hen possible. O ne o f  the national health objectives 
for 2010 was 95%  participation o f  children aged <6 years in a 
fully operational population-based IIS (objective 20.1) (216). 
Participating in an IIS means having two or more vaccinations 
recorded in the IIS. 2008 IIS data indicate that approximately 
75%  o f children aged <6 years w ith two or more vaccinations 
were participating in IISs (2 1 /). Inclusion o f adults into IISs 
also would be worthwhile. A new national health objective 
for 2020 is 80% o f adolescents (aged 11—18 years) w ith  two 
or more age-appropriate vaccinations recorded in IISs (h ttp :// 
www.healthypeople.gov/hp2020/objectives/topicarea.aspx?id=3 
O&topicarea=immunization+and+infectious+diseases).
Vaccination Programs
In the U nited States, vaccination programs have eliminated 
many vaccine-preventable diseases and reduced the incidence o f 
several others (218). Because infants and young children were 
the principle recipients o f  most vaccines developed during the 
tw entieth century (e.g., poliovirus vaccine), m any persons in 
the United States m ight believe that vaccinations are solely for 
the young; however, vaccinations are recommended for persons 
o f  all ages (20,28). Improved vaccination coverage can result in 
additional reductions in the incidence o f  vaccine-preventable 
diseases and decrease associated m orb id ity  and m ortality. 
Universal vaccination is a critical part o f  quality health care 
and should be accomplished through routine and catch-up 
vaccination provided in physicians’ offices, public health  
clinics, and other appropriate com plem entary settings. Every 
patient encounter represents an opportun ity  to review and, 
w hen needed, improve a patient’s vaccination status through 
adm inistration o f  recom m ended vaccines.
Vaccination of Children and Adolescents
Physicians and other pediatric vaccination providers should 
adhere to the standards for child and adolescent vaccination 
practices (8). These standards were published by the N ational 
Vaccine Advisory C om m ittee and define appropriate vaccina­
tion practices for both public and private sectors. T he standards 
provide guidance on practices that eliminate barriers to vaccina­
tion, including eliminating unnecessary prerequisites for receiv­
ing vaccinations, eliminating missed opportunities to vaccinate, 
im proving procedures to assess vaccination needs, enhancing 
knowledge about vaccinations am ong parents and providers, 
and improving m anagem ent and reporting of adverse events. 
In addition, the standards address the im portance o f  recall and 
rem inder systems and using assessments to m onitor clinic or 
office vaccination coverage levels. Health-care providers should
sim ultaneously adm inister as many vaccine doses as possible 
as indicated on the Recommended Im m unization Schedules fo r  
Persons Aged 0 Through 18 Years (20).
C om m unity  health-care providers, as well as staff members 
at both  state and local vaccination programs, should coordi­
nate w ith  partners to maximize outreach to populations at 
risk for undervaccination and vaccine-preventable diseases. 
For example, the Special Supplem ental N u trition  Program 
for W om en, Infants, and C hildren  (W IC) is a categorical 
federal grant program  adm inistered by the U.S. D epartm ent 
o f A griculture th rough state health departm ents. T he pro­
gram provides supplem ental foods, health-care referrals, and 
nutrition  education to low-income pregnant, breastfeeding, 
or postpartum  w om en, as well as to infants and children 
aged <5 years. M ore than  8.7 m illion people participated in 
this program  in 2008 (http://w w w .fns.usda.gov/pd/w icm ain. 
h tm ). In collaboration, W IC  and state vaccination programs 
should assess regularly the vaccination coverage levels o f  W IC  
participants and develop new strategies and aggressive outreach 
procedures in sites w ith coverage levels <90% . Vaccination 
programs and private providers are encouraged to refer eligible 
children to obtain W IC  nutritional services (219).
Adolescents
Vaccinations are recom m ended throughout life, including 
during adolescence. T he age range for adolescence is defined as 
11—21 years by m any professional associations, including the 
American Academy o f  Pediatrics and the American Medical 
Association (220,221). D efinitions o f these age cutoffs differ 
depending on the source o f  the definition and the source’s 
purpose for creating a definition. Vaccination o f adolescents 
is critical for preventing diseases for w hich adolescents are at 
particularly high or increasing risk, such as m eningococcal 
disease and hum an papillomavirus infection. Three vaccines 
recom m ended for adolescents have been licensed since 2005: 
M C V 4, HPV, and theT dap  vaccine. A  second dose o f  varicella 
vaccine is recom m ended for persons who received 1 dose o f  
varicella vaccine after age 12 m onths, and this group includes 
m any adolescents. In addition, annual seasonal influenza vac­
cination is recommended for persons aged >6 m onths who have 
no contraindications. To ensure vaccine coverage, clinicians and 
other health-care providers who treat adolescents m ust screen 
for a complete vaccination history on every occasion that an 
adolescent has an office visit.
N ational goals for vaccination coverage for adolescents aged 
13—15 years were included in Healthy People 2 0 1 0  (216). 
Targets for 90%  coverage were specified for established vaccine 
recom m endations including those for 3 doses o f  hepatitis B 
vaccine, 1 dose o f M M R  vaccine, 1 dose o f  varicella vaccine 
(excluding persons w ith a history o f  varicella), and 1 dose o f
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T d  vacc in e . R esu lts  o f  the  p u b lish e d  2 0 0 8  N a tio n a l 
Im m unization Survey— Teen indicate that, for the first time, 
coverage targets for hepatitis B and M M R  vaccines were met. 
For >1 dose o f  varicella, coverage increased to 86% . However, 
coverage for >1 dose o f  either T d  or T dap was unchanged at 
71% , rem aining below the coverage target o f  90% . Coverage 
for M C V 4 is 42% . N ew  objectives from Healthy People 2020  
include 1 dose o f  T dap  and >2 doses o f  varicella vaccine 
(excluding persons who have had varicella disease) (http://www. 
healthypeople.gov/hp2020/objectives/topicarea.aspx?id=30&  
topicarea=immunization+and+infectious+diseases).
Ensuring adolescents receive routine and catch-up vaccina­
tion and increasing vaccination coverage in this age group pres­
ent challenges. In general, adolescents do not visit health-care 
providers frequently. H ealth-care providers should prom ote 
annual preventive visits (217), including one specifically for 
adolescents aged 11 and 12 years. T he annual visits should be 
used as opportunities to provide routinely recom m ended vac­
cine doses, additional catch-up doses needed for lapsed vaccine 
series, vaccines recom m ended for high-risk groups, additional 
doses that m ight have been recently recom m ended, and other 
recom m ended health-care services.
All vaccine doses should be adm inistered according to A CIP 
vaccine-specific statements and w ith the most recent schedules 
for both  routine and catch-up vaccination. Before leaving any 
visit for medical care, adolescents should be encouraged to 
schedule return visits for any additional vaccine doses needed. 
D uring visits that occur outside o f  influenza season, providers 
should discuss and recom m end seasonal influenza vaccination 
and make explicit plans for vaccination, including tim ing and 
anticipated setting (e.g., health-care provider’s office, school, or 
pharmacy). C atch-up vaccination w ith m ultidose adolescent 
vaccines generally can occur according to the routine dosing 
schedule for these vaccines, although in some circumstances the 
clinician or health-care provider m ight use m inim um  intervals 
for vaccine doses. These circumstances include an outbreak 
that increases risk for disease or the likelihood that doses will 
be missed in the future (e.g., because o f  an im pending loss o f 
health-care coverage or transportation  challenges). Because 
o f  lack o f  efficacy data for H P V  vaccine adm inistration using 
m inim um  intervals, providers are encouraged, w hen possible, 
to use routine dosing intervals for females aged 11—26 years 
who have not yet received 3 H P V  vaccine doses as recom ­
mended (20,28).
O ne o f the challenges o f adolescent vaccination is ensur­
ing that current, com plete vaccination histories are available. 
Insurers, covered services, or reim bursem ent levels can change, 
and these changes m ight affect reimbursement for vaccine doses 
and vaccination services directly while also causing disruptions
in an adolescent’s access to vaccination providers or venues. 
In circumstances in which a vaccination record is unavailable, 
vaccination providers should attem pt to obtain this inform a­
tion  from various sources (e.g., parent, previous providers, or 
school records). M ore detail about how  to obtain these records 
is available at from  C D C  at http://w w w .cdc.gov/vaccines/ 
recs/im m uniz-records.htm . W ith  the exception o f influenza 
and pneum ococcal polysaccharide vaccines, if docum enta­
tion  o f  a vaccine dose is not available, the adolescent should 
be considered unvaccinated for that dose. Regardless o f  the 
venue in w hich an adolescent receives a dose o f  vaccine, that 
vaccine dose should be docum ented in the patient’s chart or 
in an office log, and the inform ation should be entered into 
an IIS. T he adolescent also should be provided w ith a record 
card that docum ents the vaccination history.
Adult Vaccination
T h e incidence o f  vaccine-preventable diseases in adults in 
the United States is high. Approximately 45,000 adults die 
each year from vaccine-preventable diseases, the majority from 
influenza (222). In 2008, an estimated 44,000 cases ofinvasive 
pneumococcal disease were reported w ith approximately 4,500 
deaths, the m ajority occurring am ong persons aged >35 years 
(http://www.cdc.gov/abcs/survreports/spneu08.htm ). Because 
o f recent licensure o f  new vaccines approved for ad ults and 
new A CIP recom m endations for the use o f  m any vaccines 
in adults, providers o f  adult health care now  share a greater 
responsibility for putting these recommendations into practice. 
In 2009, an estimated 4,070 deaths were caused by infection 
w ith the H P V  strains causing the m ajority o f  cervical cancers 
in this country that are preventable w ith H P V  vaccine and 
routine Papanicolaou smear testing (http://www.cancer.org/ 
docroot/hom e/index.asp). Herpes zoster causes considerable 
m orbidity  in adults aged >50 years (55). A painful complica­
tion o f  herpes zoster infection is postherpetic neuralgia, w hich 
is characterized by severe pain that can persist for up to a year 
after the herpes zoster rash has subsided. A vaccine to prevent 
herpes zoster was licensed in 2006.
In 2003, the N ational Vaccine Advisory C om m ittee pub­
lished standards for adult vaccination (222). These standards 
include ensuring vaccine availability, review o f records, com ­
m unicating the risks and benefits o f  vaccination, use o f  stand­
ing orders, and recom m ending sim ultaneous adm inistration 
o f all indicated doses according to the Recommended A dult 
Im m unization Schedule (28).
Vaccination w ith vaccines recommended for all adults or for 
those in specific age groups is generally cost-effective, if not cost- 
saving, for society. T he National Commission on Prevention 
Priorities (NCPP) ranked clinical preventive services based on
32 MMWR /  January 28, 2011 /  Vol. 60 /  No. 2
Recommendations and Reports
clinically preventable disease effects and cost-effectiveness (223)■ 
In the N C P P  report, influenza vaccination for adults aged >50 
years and pneumococcal vaccination for adults aged >65 years 
ranked high, with 8 o f 10 possible points in the scoring system 
used. Most other studies have found influenza vaccination reduces 
or minimizes health care, societal, and individual costs or the pro­
ductivity losses and absenteeism associated with influenza illness 
{224—226). Economic analyses among adults aged >65 years have 
found influenza vaccination to be cost-effective (225—227).
A  2008 study of the cost-effectiveness of PPSV demonstrated 
that vaccination resulted in a gain o f $3,341 per quality-adjusted 
life year; the result is sensitive to vaccine uptake assumptions 
(228). PPSV administered at ages 50—65 years might be clini­
cally favorable and, depending on cost-effectiveness criteria used, 
economically favorable (228).
Hepatitis B vaccine is no t recom m ended routinely for all 
adults. However, m ultiple studies have established the cost- 
effectiveness o f providing hepatitis B vaccinations at counseling 
and testing sites for H IV  and other sexually transm itted dis­
eases, correctional institutions, drug-abuse treatm ent centers, 
and other settings serving adults at risk for hepatitis B virus 
infection (229—230).
Four studies have estimated the cost-effectiveness o f  a rou­
tine herpes zoster vaccination program  o f im m unocom petent 
persons aged >60 years (231—234). At a vaccine cost o f  $150 
per dose, the societal costs o f  routinely vaccinating im m u­
nocom petent persons aged >60 years range from $27,000 to 
$ 112,000 per quality-adjusted life year gained (231—234). The 
estim ated cost per quality-adjusted life year for zoster vaccina­
tion covers a wide range that appears acceptable compared with 
either standard thresholds or other established interventions 
but is at the interm ediate to high end o f that range.
Vaccination rates in adults are considered suboptimal (235— 
238). Healthy People 2010  goals for adult vaccination coverage with 
influenza and pneumococcal polysaccharide vaccines are 90% for 
each vaccine. For the 2007—2008 season, influenza vaccination 
coverage among adults aged 50—64 years was 34% , and cover­
age among adults aged >65 years was 66% (67). In 2008, 60% 
of adults aged >65 years received a dose o f PPSV (http://www 
cdc.gov/nchs/data/hestat/vaccine_coverage.htm). New Healthy 
People2020  goals for influenza and pneumococcal polysaccharide 
vaccines include specific subsets o f adults, including institutional­
ized adults aged >18 years (for both influenza and pneumococcal 
polysaccharide vaccines) and noninstitutionalized adults at high 
risk aged >18 years (for pneumococcal polysaccharide vaccine) 
(http://www.healthypeople.gov/hp2020/objectives/topicarea.aspx 
?id=30&topicarea=immunization+and+infectious+diseases).
T he most substantial barrier to vaccination coverage is lack o f 
knowledge about these vaccines among adult patients and adult
providers. O ther barriers are cost (lack o f  additional insurance 
to Medicare) (239) and the lack o f  financing mechanisms for 
newly licensed and recom m ended vaccines.
A  com m on challenge for health-care providers is vaccinating 
adults w ith unknown vaccination records. In general (except for 
influenza and pneumococcal polysaccharide vaccines), adults 
should receive a vaccine dose if  the dose is recommended and no 
record o f previous administration exists. If  an adult has a record of 
military service and does not have records available, providers can 
assume that the person has received all vaccines recommended by 
the military at the time o f service entry. Serologic testing might be 
helpful in clarifying im m une status if questions remain because 
at different times and depending on military assignments, there 
might be interservice and individual differences.
Evidence-Based Interventions 
to Increase Vaccination Coverage
T he independent, nonfederal Task Force on C om m unity  
Preventive Services, whose m embership is appointed by C D C , 
provides public health  decision-makers w ith  recom m enda­
tions on population-based interventions to prom ote health 
and prevent disease, in ju ry  disability, and prem ature death. 
T he recommend ations are based on systematic reviews o f  the 
scientific literature about effectiveness and cost-effectiveness o f 
these interventions. In addition, the task force identifies criti­
cal inform ation about the other effects o f  these interventions, 
the applicability to specific populations and settings, and the 
potential barriers to im plem entation. A dditional inform ation, 
including updates o f  published reviews, is available from The 
Community Guide at http://w w w .thecom m unityguide.org.
Beginning in 1996, the task force systematically reviewed 
published evidence on the effectiveness and cost-effectiveness o f 
population-based interventions to increase coverage o f vaccines 
recommended for routine use among children, adolescents, and 
adults. A total o f  197 articles were identified that evaluated 
a relevant intervention, met inclusion criteria, and were pub­
lished during 1980—1997. Reviews o f 17 specific interventions 
were published in 1999 (235—238). Using the results o f  their 
review, the task force made recom m endations about the use 
o f  these interventions (238). Several interventions were iden­
tified and recom m ended on the basis o f  published evidence. 
Follow-up reviews were published in 2000, and a review o f  
interventions to improve the coverage o f adults at high risk 
was conducted in 2005 (238,239). T he  interventions and the 
recom m endations are sum m arized in this report (Table 15).
In 1997, the task force categorized as a recom m ended strat­
egy vaccination requirements for child care, school, and college 
(236). W hen appropriate, health agencies should take necessary 
steps to develop and enforce these requirements.
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A 2008 update o f  the original task force systematic review 
o f the evidence on the effectiveness o f provider assessment and 
feedback for increasing coverage rates found that this strategy 
remains an effective intervention. A later update reviewed 
19 new studies published during 1997—2007. T he updated 
review supports the original task force recom m endation for 
use o f  assessment and feedback based on strong evidence o f 
effectiveness. T he task force reviewed studies o f  assessment and 
feed back as a strategy that were conducted in a range o f  set­
tings, including private practice, m anaged care, public health, 
com m unity health settings, and academic centers. Studies have 
assessed the effectiveness o f  this intervention to improve cover­
age w ith M M R , DTP, DTaP, H ib, influenza, pneumococcal, 
and T d  vaccines (237). T he m ost updated inform ation on this 
review is available at h ttp ://w w w .thecom m unityguide.org/ 
vaccines/universally/providerassessm ent.htm l. As recognized 
by the task force, routine assessment and feedback o f  vaccina­
tion rates obtained at the provider site is one o f the m ost effec­
tive strategies for achieving high, sustainable vaccine coverage. 
Since 1995, all states receiving federal funds for vaccination 
programs have been required to conduct annual assessments 
of vaccination rates both in public health clinics and in pri­
vate provider offices. Primarily to aid local and state health 
departm ents in their efforts to conduct assessments and assist 
providers, C D C  has developed numerous software applications 
to measure vaccination rates in provider practices.
Other General Programmatic Issues
Program m atic challenges, evolving issues, and effective 
in terventions related to adu lt and adolescent vaccination 
programs have been described by other advisory groups and 
expert groups. Ad ditional evidence-based approaches are being 
developed for certain issues (e.g., settings for adolescent vac­
cination delivery) through ongoing research and evaluation. 
Am ong current program m atic challenges, vaccine financing is 
especially difficult because certain problems and solutions differ 
markedly from one state to another. Practitioners interested in 
beginning or continuing to provide vaccinations to patients 
are encouraged to consult w ith local and state public health 
vaccination programs to learn about publicly funded programs 
that m ight be available in their areas for patients who need vac­
cination but have insufficient health insurance coverage and no 
financial resources. I f  no t already participating, providers wrho 
care for adolescents and children aged <19 years should enroll 
in the Vaccines for Children Program (http://www.cdc.gov/ 
vaccines/program s/vfc/default.htm ). T hrough  this program ’s 
provision o f  ACIP-recommended, federally purchased vaccines, 
participating providers are able to fully vaccinate eligible chil­
dren whose parents m ight not otherwise be able to afford the
vaccinations. Interested providers are encouraged to work with 
insurers, state and specialty-specific medical organizations, vac­
cine manufacturers, and other stakeholders to address financial 
barriers to achieving high vaccination coverage. W ith  avail­
ability o f  safe and effective vaccines for 17 vaccine-preventable 
diseases, the capacity for realizing the potential benefits o f  these 
products in the United States depends on reaching children, 
adolescents, and adults through dedicated, knowledgeable vac­
cination providers and efficient, strong vaccination programs 
at local, state, and federal levels.
Vaccine Information Sources
In addition to these general recom m endations, the following 
sources contain specific and updated vaccine inform ation.
CDC-INFO Contact Center
T he C D C -IN F O  contact center is supported by C D C  and 
provides public health-related inform ation, including vaccina­
tion inform ation, for health-care providers and the public, 24 
hours a day, 7  days a week (telephone [English and Spanish]: 
800-232-4636; telephone [TTY]: 800-232-6348).
CDC's National Center for immunization 
and Respiratory Diseases
C D C ’s N ational C enter for Im m unization and Respiratory 
Diseases website provides direct access to vaccination recom­
m endations o f  ACIP, vaccination schedules, autom ated child 
schedulers, an adult im m unization scheduler, vaccine safety 
inform ation, publications, provider education and training, 
and links to other vaccination-related websites (http://www. 
cdc. gov/ vaccines) .
M M W R
A CIP recom m endations regarding vaccine use, statem ents 
o f vaccine policy as they are developed, and reports o f  specific 
disease activity are published by C D C  in the M M W R  series and 
can be found at http://www.cdc.gov/vaccines/pubs/ACIP-list. 
h tm . Electronic subscriptions are free (http://www.cdc.gov/ 
m m w r/m m w rsubscribe.htm l). Subscriptions to prin t versions 
also are available from the Superintendent o f Docum ents, U.S. 
G overnm ent Printing Office, W ashington, D .C . 20402-9235 
(telephone: 202-512-1800).
American Academy of Pediatrics (AAP)
Every 3 years, AAP issues the Red Book: Report o f  the 
Committee on Infectious Diseases, w hich contains a composite 
sum m ary o f  AAP and A CIP recom m endations concerning 
infectious diseases and vaccinations for infants, children, and
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adolescents (telephone: 888-227-1770; website: http://www. 
aap.org).
American Academy of Family Physicians (AAFP)
Inform ation from the professional organization o f family 
physicians is available at http://w w w .aafp.org.
Immunization Action Coalition
T he Im m unization Action C oalition provides extensive free 
provider and patient inform ation, including translations o f 
VISs into m ultiple languages. Printed materials are reviewed 
by C D C  for technical accuracy (http://w w w .im m unize.org 
and http://w w w .vaccineinform ation.org).
National Network for Immunization Information
T his N ational N etw ork for Im m unization  Inform ation is 
an affiliation o f the Infectious Diseases Society o f  America, 
the Pediatric Infectious Diseases Society, AAP, the American 
N urses A ssociation , AAFP, the N a tio n a l A ssociation  o f  
P ed iatric  N urse  P rac titio n ers , the  A m erican  C ollege o f  
O bstetricians and G ynecologists, the U niversity o f  Texas 
M edical Branch, the Society for Adolescent M edicine, and 
the American M edical Association. T his source provides the 
public, health professionals, policy makers, and the media 
w ith up-to-date, scientifically valid inform ation (http://w w w . 
im m unizationinfo.org).
Vaccine Education Center
Located at the C hildren’s H ospital o f  Philadelphia, the 
Vaccine Education C enter provides patient and provider vac­
cine inform ation (http://w w w .vaccine.chop.edu).
Institute for Vaccine Safety
Located at Johns H opkins U niversity School o f  Public 
H ealth, the Institute for Vaccine Safety provides inform ation 
about vaccine safety concerns and objective and tim ely infor­
mation to physicians and health-care providers and parents 
(http://www.vaccinesafety.edu).
Group on Immunization Education of the Society 
of Teachers of Family Medicine
T h e G roup on Im m unization Education o f  the Society o f  
Teachers o f  Family M edicine provides inform ation for clini­
cians, including the free program  Shots. Shots includes the 
childhood, adolescent, and adult schedules for iPhone, Palm, 
and W indow s devices, as well as online versions (http://www. 
im m unizationed.org).
State and Local Health Departments
State and local health departm ents provide technical advice 
th rough hotlines, e-mail, and websites, including p rin ted  
inform ation regarding vaccines and im m unization schedules, 
posters, and other educational materials.
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TABLE 1. Recommended and minimum ages and intervals between vaccine doses*'1'
Recommended Recommended
Vaccine and dose number age for this dose Minimum age for this dose interval to next dose Minimum interval to next dose
HepB-15 Birth Birth 1-4 months 4 weeks
HepB-2 1-2 months 4 weeks 2-17 months 8 weeks
HepB-311 6-18 months 24 weeks — —
DTaP-15 2 months 6 weeks 2 months 4 weeks
DTaP-2 4 months 10 weeks 2 months 4 weeks
DTaP-3 6 months 14 weeks 6-12 months 6 months**-11'
DTaP-4 15-18 months 12 months 3 years 6 months**
DTaP-5 4-6  years 4 years — —
Hib-1 s-§§ 2 months 6 weeks 2 months 4 weeks
Hib-2 4 months 10 weeks 2 months 4 weeks
H il> 3 " 6 months 14 weeks 6-9 months 8 weeks
Hib-4 12-15 months 12 months — —
IPV-1 ® 2 months 6 weeks 2 months 4 weeks
IPV-2 4 months 10 weeks 2-14 months 4 weeks
IPV-3 6-18 months 14 weeks 3-5 years 6 months
IPV-4*** 4-6  years 4 years — —
PCV-155 2 months 6 weeks 8 weeks 4 weeks
PCV-2 4 months 10 weeks 8 weeks 4 weeks
PCV-3 6 months 14 weeks 6 months 8 weeks
PCV-4 12-15 months 12 months — —
MMR-1f t t 12-15 months 12 months 3-5 years 4 weeks
MMR-2t t t 4 -6  years 13 months — —
Varicella-1+tt 12-15 months 12 months 3-5 years 12 weeks555
Varicella-2t t t 4 -6  years 15 months — —
HepA-1 12-23 months 12 months 6-18 months** 6 months**
HepA-2 2:18 months 18 months — —
Influenza, inactivated111111 a6 months 6 months**** 1 month 4 weeks
LAIV (intranasal)111111 2-49 years 2 years 1 month 4 weeks
MCV4-1t t t t 11-12 years 2 years 5 years 8 weeks
MCV4-2 16 years 11 years (+8 weeks) — —
MPSV4-lt+ tt — 2 years 5 years 5 years
MPSV4-2 — 7 years — —
Td 11-12 years 7 years 10 years 5 years
Tdap5555 >11 years 7 years — —
PPSV-1 — 2 years 5 years 5 years
PPSV-211111111 — 7 years — —
HPV-1***** 11-12 years 9 years 2 months 4 weeks
HPV-2 11-12 years (+2 months) 9 years (+4 weeks) 4 months 12 weeks1"1"1"1"1
HPV-3+tt+t 11-12 years (+6 months) 9 years (+24 weeks) — —
Rotavirus-155555 2 months 6 weeks 2 months 4 weeks
Rotavirus-2 4 months 10 weeks 2 months 4 weeks
Rotavirus-31111111111 6 months 14 weeks — —
Herpes zoster****** >60 years 60 years — —
See table footnotes on page 37
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TABLE 1. (Continued) Recom mended and m inim um  ages and intervals betw een vaccine doses*-'1'
Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis; HepA = hepatitis A; HepB = hepatitis B; Hib = Haemophilus influenzae type b; IHPV = 
human papillomavirus; IPV = inactivated poliovirus; LAIV= live, attenuated influenza vaccine; MCV4 = quadrivalent meningococcal conjugate vaccine; MMR = measles, 
mumps, and rubella; MMRV= measles, mumps, rubella, and varicella; MPSV4 = quadrivalent meningococcal polysaccharide vaccine; PCV= pneumococcal conjugate 
vaccine; PPSV = pneumococcal polysaccharide vaccine; PRP-OMB = polyribosylribitol phosphate-meningococcal outer membrane protein conjugate; Td = tetanus 
and diphtheria toxoids;TIV = trivalent inactiated influenza vaccine;Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; Var = varicella vaccine. 
* Combination vaccines are available. Use of licensed combination vaccines is generally preferred to separate injections o f their equivalent component vaccines. 
When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components; the minimum interval 
between doses is equal to the greatest interval o f any of the individual components. 
f  Information on travel vaccines, including typhoid, Japanese encephalitis, and yellow fever, is available at http://www.cdc.gov/travel. Information on other vaccines 
that are licensed in the United States but not distributed, including anthrax and smallpox, is available at http://www.bt.cdc.gov.
5 Combination vaccines containing the hepatitis B component are available (see Table 2). These vaccines should not be administered to infants aged <6 weeks 
because of the other components (i.e., Hib, DTaP, HepA^and IPV).
HepB-3 should be administered at least 8 weeks after HepB-2 and at least 16 weeks after HepB-1 and should not be administered before age 24 weeks.
** Calendar months.
+t The minimum recommended interval between DTaP-3and DTaP-4 is 6 months. However, DTaP-4need not be repeated if administered at least 4 months after DTaP-3.
55 For Hib and PCV, children receiving the first dose o f vaccine at age >7 months require fewer doses to complete the series.
1111 If PRP-OMP (Pedvax-Hib, Merck Vaccine Division) was administered at ages 2 and 4 months, a dose at age 6 months is not necessary.
*** A fourth dose is not needed if the third dose was administered at >4 years and at least 6 months after the previous dose.
1,1 Combination MMRV vaccine can be used for children aged 12 months-12 years. See text for details.
The minimum interval from Varicella-1 to Varicella-2 for persons beginning the series at age >13 years is 4 weeks.
mm one dose of influenza vaccine per season is recommended for most persons. Children aged <9 years who are receiving influenza vaccine for the first time or 
who received only 1 dose the previous season (if it was their first vaccination season) should receive 2 doses this season.
**** The minimum age for inactivated influenza vaccine varies by vaccine manufacturer. See package insert for vaccine-specific minimum ages.
t t t t  Revaccination with meningococcal vaccine is recommended for previously vaccinated persons who remain at high risk for meningococcal disease. (Source: 
CDC. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for 
meningococcal disease. MMWR 2009;58:[1042-3]).
§§§§ Only 1 dose of Tdap is recommended. Subsequent doses should be given as Td. For one brand of Tdap, the minimum age is 11 years. For management of a 
tetanus-prone wound in persons who have received a primary series of tetanus-toxoid-containing vaccine, the minimum interval after a previous dose o f any 
tetanus-containing vaccine is 5 years.
H f«  a  second dose of PPSV 5 years after the first dose is is recommended for persons aged <65 years at highest risk for serious pneumococcal infection and those 
who are likely to have a rapid decline in pneumococcal antibody concentration. (Source: CDC. Prevention of pneumococcal disease: recommendations of the 
Advisory Committee on Immunization Practices [ACIP]. MMWR 1997;46[No. RR-8]).
***** Bivalent HPV vaccine is approved for females aged 10-25 years. Quadrivalent IHPV vaccine is approved for males and females aged 9-26 years. 
f t t t t  The minimum age for l-IPV-3 is based on the baseline minimum age for the first dose (i.e., 108 months) and the minimum interval o f 24 weeks between the 
first and third dose. Dose 3 need not be repeated if it is administered at least 16 weeks after the first dose.
§§§§§ T|le  f|rst dose of rotavirus must be administered at age 6 weeks through 14 weeks and 6 days. The vaccine series should not be started for infants aged >15 
weeks, 0 days. Rotavirus should not be administered to children older than 8 months, 0 days of age regardless of the number of doses received between 6 
weeks and 8 months, 0 days o f age.
1111111111 |f 2 doses o f Rotarix (GlaxoSmithKline) are administered as age appropriate, a third dose is not necessary.
****** Herpes zoster vaccine is recommended as a single dose for persons aged >60 years.
TABLE 2. FDA-licensed combination vaccines*
Vaccine* Trade name (year licensed) Age range Routinely recommended ages
Hib-HepB Comvax (1996) 6 weeks-71 months Three-dose schedule at 2,4, and 12-15 months of age
DTaP/Hib TriHIBit (1996) 15-18 months Fourth dose o f Hib and DTaP series
HepA-HepB Twinrix (2001) >18 years Three doses on a schedule o f 0,1, and 6 months
DTaP-HepB-IPV Pediarix (2002) 6 weeks-6 years Three-dose series at 2,4 and 6 months of age
MMRV ProQuad (2005) 12 months- l 2 years Two doses, the first at 12-15 months, the second at 4-6  years
DTaP-IPV Kinrix (2008) 4-6  years Fifth dose of DTaP and fourth dose of IPV
DTaP-IPV/Hib Pentacel (2008) 6 weeks-4 years Four-dose schedule at 2,4,6, and 15-18 months of age
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular pertussis; FDA = Food and Drug Administration; HepA = 
hepatitis A; HepB = hepatitis B; Hib = Haemophilus influenzae type b; IPV = inactivated poliovirus; MMR = measles, mumps, and rubella; MMRV = measles, mumps, 
rubella, and varicella; Td = tetanus and diphtheria toxoids;Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.
Source: American Academy of Pediatrics. Passive immunization In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2009 report o f the Committee on 
Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.
* Although MMR, DTaP, DT,Td, and Tdap are combination vaccines, they are not included on this list because they are not available in the United States as single-antigen 
products.
f  A dash ( - )  between vaccine products indicates that products are supplied in their final form by the manufacturer and do not require mixing or reconstitution by 
the user. A slash ( / )  indicates that the products must be mixed or reconstituted by the user.
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TABLE 3. Guidelines for spacing o f live and inactivated antigens
Antigen combination Recommended minimum interval between doses
Two or more inactivated* May be administered simultaneously or at any interval between doses
Inactivated and live May be administered simultaneously or at any interval between doses
Two or more live injectable1 28 days minimum interval, if not administered simultaneously
Source: American Academy of Pediatrics. Pertussis. In: Pickering LK, Baker, CJ, Kimberlin DW, Long SS, eds. Red book: 2009 report o f the Committee on Infectious 
Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:22.
* Certain experts suggest a 28-day interval between tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine and tetravalent meningococcal 
conjugate vaccine if they are not administered simultaneously.
T Live oral vaccines (e.g.,Ty2la typhoid vaccine and rotavirus vaccine) may be administered simultaneously or at any interval before or after inactivated or live inject­
able vaccines.
TABLE 4. Guidelines for adm inistering antibody-contain ing products* and vaccines
Type of administration Products administered Recommended minimum interval between doses
Simultaneous (during 
the same office visit)
Nonsimultaneous
Antibody-containing products and inactivated antigen
Antibody-containing products and live antigen
Administered first
Antibody-containing products 
Inactivated antigen 
Antibody-containing products 
Live antigen
Administered second
Inactivated antigen 
Antibody-containing products 
Live antigen
Antibody-containing products
Can be administered simultaneously at different anatomic sites 
or at any time interval between doses
Should not be administered simultaneously.1' If simultaneous 
administration of measles-containing vaccine or varicella 
vaccine is unavoidable, administer at different sites and 
revaccinate or test for seroconversion after the recommend­
ed interval (see Table 5)
No interval necessary 
No interval necessary 
Dose related1-5 
2 weeks1"
* Blood products containing substantial amounts o f immune globulin include intramuscular and intravenous immune globulin, specific hyperimmune globulin (e.g., 
hepatitis B immune globulin, tetanus immune globulin, varicella zoster immune globulin, and rabies immune globulin), whole blood, packed red blood cells, plasma, 
and platelet products.
1 Yellow fever vaccine; rotavirus vaccine; oralTy2la typhoid vaccine; live, attenuated influenza vaccine; and zoster vaccine are exceptions to these recommendations. 
These live, attenuated vaccines can be administered at any time before or after or simultaneously with an antibody-containing product.
5 The duration o f interference o f antibody-containing products with the immune response to the measles component of measles-containing vaccine, and possibly 
varicella vaccine, is dose related (see Table 5).
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TABLE 5. Recom m ended intervals betw een adm inistration o f antibody-contain ing products and measles- or varicella-containing vaccine, by 
product and indication for vaccination
Product/Indication Dose (mg IgG/kg) and route*
Recommended interval before 
measles- or varicella-containing 
vaccine+ administration (months)
Tetanus IG 250 units (10 mg IgG/kg) IM 3
Hepatitis A IG
Contact prophylaxis 0.02 mL/kg (3.3 mg IgG/kg) IM 3
International travel 0.06 mL/kg (10 mg IgG/kg) IM 3
Hepatitis B IG 0.06 mL/kg (10 mg IgG/kg) IM 3
Rabies IG 20 lU/kg (22 mg IgG/kg) IM 4
Varicella IG 125 units/10 kg (60-200 mg IgG/kg) IM, maximum 625 units 5
Measles prophylaxis IG
Standard (i.e., nonimmunocompromised) contact 0.25 mL/kg (40 mg IgG/kg) IM 5
Immunocompromised contact 0.50 mL/kg (80 mg IgG/kg) IM 6
Blood transfusion
RBCs, washed 10 mL/kg, negligible IgG/kg IV None
RBCs, adenine-saline added 10 mL/kg (10 mg IgG/kg) IV 3
Packed RBCs (hematocrit 65%)5 10 mL/kg (60 mg IgG/kg) IV 6
Whole blood (hematocrit 35%-50%)5 10 mL/kg (80-100 mg IgG/kg) IV 6
Plasma/platelet products 10 mL/kg (160 mg IgG/kg) IV 7
Cytomegalovirus IGIV 150 mg/kg maximum 6
IGIV
Replacement therapy for immune deficiencies11 300-400 mg/kg IV11 8
Immune thrombocytopenic purpura treatment 400 mg/kg IV 8
Postexposure varicella prophylaxis** 400 mg/kg IV 8
Immune thrombocytopenic purpura treatment 1000 mg/kg IV 10
Kawasaki disease 2 g/kg IV 11
Monoclonal antibody to respiratory syncytial virus 15 mg/kg IM None
F protein (Synagis [Medlm m une])+t
Abbreviations: HIV= human immunodeficiency virus; IG = immune globulin; IgG = immune globulin G; IGIV = intravenous immune globulin; mg IgG/kg = milligrams 
of immune globulin G per kilogram of body weight; IM = intramuscular; IV = intravenous; RBCs = red blood cells.
* This table is not intended for determining the correct indications and dosages for using antibody-containing products. Unvaccinated persons might not be pro­
tected fully against measles during the entire recommended interval, and additional doses of IG or measles vaccine might be indicated after measles exposure. 
Concentrations of measles antibody in an IG preparation can vary by manufacturer's lot. Rates of antibody clearance after receipt o f an IG preparation also might 
vary. Recommended intervals are extrapolated from an estimated half-life of 30 days for passively acquired antibody and an observed interference with the im­
mune response to measles vaccine for 5 months after a dose o f 80 mg IgG/kg.
+ Does not include zoster vaccine. Zoster vaccine may be given with antibody-containing blood products.
5 Assumes a serum IgG concentration o f 16 mg/ml_.
11 Measles and varicella vaccinations are recommended for children with asymptomatic or mildly symptomatic HIV infection but are contraindicated for persons with 
severe immunosuppression from HIV or any other immunosuppressive disorder.
** The investigational VariZIG, similar to licensed varicella-zoster IG (VZIG), is a purified human IG preparation made from plasma containing high levels of antivaricella 
antibodies (IgG).The interval between VariZIG and varicella vaccine (Var or MMRV) is 5 months. 
t+ Contains antibody only to respiratory syncytial virus
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TABLE 6. Contraindications and precautions* to commonly used vaccines
Vaccine Contraindications Precautions
DTaP Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
Encephalopathy (e.g., coma, decreased level o f conscious­
ness, or prolonged seizures), not attributable to another 
identifiable cause, within 7 days of administration of 
previous dose of DTP or DTaP
Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, 
progressive encephalopathy; defer DTaP until neurologic status clarified and 
stabilized
Temperature o f >105°F (>40.5°C) within 48 hours after vaccination with a previous 
dose of DTP or DTaP
Collapse or shock-like state (i.e., hypotonic hyporesponsive episode) within 48 hours 
after receiving a previous dose of DTP/DTaP 
Seizure <3 days after receiving a previous dose o f DTP/DTaP 
Persistent, inconsolable crying lasting >3 hours within 48 hours after receiving a 
previous dose of DTP/DTaP 
GBS <6 weeks after previous dose of tetanus toxoid-containing vaccine 
History of arthus-type hypersensitivity reactions after a previous dose of tetanus 
toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed 
since the last tetanus toxoid-containing vaccine 
Moderate or severe acute illness with or w ithout fever
DT, Td Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
GBS <6 weeks after previous dose of tetanus toxoid-containing vaccine 
History of arthus-type hypersensitivity reactions after a previous dose of tetanus 
toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed 
since the last tetanus-toxoid-containing vaccine 
Moderate or severe acute illness with or w ithout fever
Tdap Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
Encephalopathy (e.g., coma, decreased level o f conscious­
ness, or prolonged seizures), not attributable to another 
identifiable cause, within 7 days of administration of 
previous dose of DTP, DTaP, or Tdap
GBS <6 weeks after a previous dose of tetanus toxoid-containing vaccine 
Progressive or unstable neurological disorder, uncontrolled seizures, or progressive 
encephalopathy until a treatment regimen has been established and the condition 
has stabilized
History of arthus-type hypersensitivity reactions after a previous dose of tetanus 
toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed 
since the last tetanus toxoid-containing vaccine 
Moderate or severe acute illness with or w ithout fever
IPV Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Pregnancy
Moderate or severe acute illness with or w ithout fever
MMR+'S Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
Pregnancy
Known severe immunodeficiency (e.g., from hematologic 
and solid tumors, receipt o f chemotherapy, congenital 
immunodeficiency, or long-term immunosuppressive 
therapy11 or patients with HIV infection who are severely 
immunocompromised)5
Recent (<11 months) receipt of antibody-containing blood product (specific interval 
depends on product)**
History of thrombocytopenia or thrombocytopenic purpura
Need for tuberculin skin testingf t
Moderate or severe acute illness with or w ithout fever
l i b Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
Age <6 weeks
Moderate or severe acute illness with or w ithout fever
Hepatitis B Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Infant weight <2,000 gm55
Moderate or severe acute illness with or w ithout fever
Hepatitis A Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Pregnancy
Moderate or severe acute illness with or w ithout fever
Varicella Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
Known severe immunodeficiency (e.g., from hematologic 
and solid tumors, receipt o f chemotherapy, congenital 
immunodeficiency, or long-term immunosuppressive 
therapy11 or patients with HIV infection who are severely 
immunocompromised)5 
Pregnancy
Recent (<11 months) receipt of antibody-containing blood product (specific interval 
depends on product)1111 
Moderate or severe acute illness with or w ithout fever
See table footnotes on page 41
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TABLE 6. (Continued) Contraindications and precautions* to commonly used vaccines
Vaccine Contraindications Precautions
PCV Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose (of PCV7, PCV13, or any diphtheria toxoid-contain­
ing vaccine) or to a component of a vaccine (PCV7, PCV13, 
or any diphtheria toxoid-containing vaccine)
Moderate or severe acute illness with or w ithout fever
TIV Severe allergic reaction (e.g., anaphylaxis) after previous 
dose or to vaccine component, including egg protein
GBS <6 weeks after a previous dose of influenza vaccine 
Moderate or severe acute illness with or w ithout fever
LAIV Severe allergic reaction (e.g., anaphylaxis) after previous 
dose or to vaccine component, including egg protein 
Pregnancy 
Immunosuppression 
Certain chronic medical conditions***
GBS <6 weeks after a previous dose of influenza vaccine 
Moderate of severe acute illness with or w ithout fever
PPSV Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Moderate or severe acute illness with or w ithout fever
MCV4 Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Moderate or severe acute illness with or w ithout fever
MPSV4 Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Moderate or severe acute illness with or w ithout fever
HPV Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component
Pregnancy
Moderate or severe acute illness with or w ithout fever
Rotavirus Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
SCID
Altered immunocompetence other than SCID
History of intussusception
Chronic gastrointestinal diseaset t f
Spina bifida or bladder exstrophyt t f
Moderate or severe acute illness with or w ithout fever
Zoster Severe allergic reaction (e.g., anaphylaxis) after a previous 
dose or to a vaccine component 
Substantial suppression of cellular immunity 
Pregnancy
Moderate or severe acute illness with or w ithout fever
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular pertussis; GBS = Guiiiian-Barre syndrome; IHBsAg = hepatitis 
B surface antigen; Hib = Haemophilus influenzae type b; HIV = human immunodeficiency virus; HPV = human papillomavirus; IPV= inactivated poliovirus; LAIV = live, 
attenuated influenza vaccine; MCV4 = quadrivalent meningococcal conjugate vaccine; MMRV = measles, mumps, rubella, and varicella; MPSV4 = quadrivalent menin­
gococcal polysaccharide vaccine; PCV= pneumococcal conjugate vaccine; PPSV= pneumococcal polysaccharide vaccine; SCID = severe combined immunodeficiency; 
Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis;TIV = trivalent inactivated influenza vaccine.
* Events or conditions listed as precautions should be reviewed carefully. Benefits o f and risks for administering a specific vaccine to a person under these circum­
stances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. If the benefit o f vaccination 
is believed to outweigh the risk, the vaccine should be administered. Whether and when to administer DTaP to children with proven or suspected underlying 
neurologic disorders should be decided on a case-by-case basis.
I HIV-infected children may receive varicella and measles vaccine if CD4+ T-lymphocyte count is >15%. (Source: Adapted from American Academy of Pediatrics. 
Passive immunization. In: Pickering LK, ed. Red book: 2009 report o f the committee on infectious diseases. 28th ed. Elk Grove Village, IL: American Academy of 
Pediatrics: 2009.)
5 MMR and varicella vaccines can be administered on the same day. If not administered on the same day, these vaccines should be separated by at least 28 days.
II Substantially immunosuppressive steroid dose is considered to be >2 weeks of daily receipt o f 20 mg or 2 mg/kg body weight of prednisone or equivalent.
** See text and Table 5 for details.
t f  Measles vaccination might suppress tuberculin reactivity temporarily. Measles-containing vaccine can be administered on the same day as tuberculin skin testing. 
If testing cannot be performed until after the day of MMR vaccination, the test should be postponed for >4 weeks after the vaccination. If an urgent need exists 
to skin test, do so with the understanding that reactivity might be reduced by the vaccine.
55 Hepatitis B vaccination should be deferred for infants weighing <2,000 g if the mother is documented to be HBsAg-negative at the time of the infant's birth. 
Vaccination can commence at chronological age 1 month or at hospital discharge. For infants born to HBsAg-positive women, hepatitis B immune globulin and 
hepatitis B vaccine should be administered within 12 hours after birth, regardless of weight.
1111 Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered (see Table 5).
* **  Source: CDC. Prevention and control o f seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. 
MMWR 2010;59(No. RR-8).
t t f  For details, see CDC. Prevention of rotavirus gastroenteritis among infants and children: recommendations o f the Advisory Committee on Immunization Practices. 
MMWR 2009;58(No. RR-2).
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TABLE 7. Conditions com m only misperceived as contraindications to  vaccination
Vaccine
Conditions commonly misperceived as contraindications 
(i.e., vaccination may be administered under these conditions)
General for all vaccines, including Mild acute illness with or without fever
DTaP, pediatric DT, adult Td, Mild-to-moderate local reaction (i.e., swelling, redness, soreness); low-grade or moderate fever after previous dose
adolescent-adult Tdap, IPV, MMR, Lack of previous physical examination in well-appearing person
Hib, hepatitis A, hepatitis B, Current antimicrobial therapy*
varicella, rotavirus, PCV.TIV, LAIV, Convalescent phase of illness
PPSV, MCV4, MPSV4, HPV, and Preterm birth (hepatitis B vaccine is an exception in certain circumstances)1'
herpes zoster Recent exposure to an infectious disease
History o f penicillin allergy, other nonvaccine allergies, relatives with allergies, or receiving allergen extract immunotherapy
DTaP Fever of <105°F (<40.5°C), fussiness or mild drowsiness after a previous dose o f DTP/DTaP
Family history of seizures
Family history of sudden infant death syndrome
Family history of an adverse event after DTP or DTaP administration
Stable neurologic conditions (e.g., cerebral palsy, well-controlled seizures, or developmental delay)
Tdap Fever of >105°F (>40.5°C) for <48 hours after vaccination with a previous dose of DTP or DTaP
Collapse or shock-like state (i.e., hypotonic hyporesponsive episode) within 48 hours after receiving a previous dose of DTP/ 
DTaP
Seizure <3 days after receiving a previous dose o f DTP/DTaP
Persistent, inconsolable crying lasting >3 hours within 48 hours after receiving a previous dose of DTP/DTaP
History o f extensive limb swelling after DTP/DTaP/Td that is not an arthus-type reaction
Stable neurologic disorder
History o f brachial neuritis
Latex allergy that is not anaphylactic
Breastfeeding
Immunosuppression
IPV Previous receipt o f >1 dose of oral polio vaccine
MMR5-1 Positive tuberculin skin test 
Simultaneous tuberculin skin testing**
Breastfeeding
Pregnancy of recipient's mother or other close or household contact 
Recipient is female of child-bearing age 
Immunodeficient family member or household contact 
Asymptomatic or m ildly symptomatic HIV infection 
Allergy to eggs
Hepatitis B Pregnancy
Autoimmune disease (e.g., systemic lupus erythematosis or rheumatoid arthritis)
Varicella Pregnancy of recipient's mother or other close or household contact 
Immunodeficient family member or household contact1"1' 
Asymptomatic or m ildly symptomatic HIV infection 
Humoral immunodeficiency (e.g., agammaglobulinemia)
TIV Nonsevere (e.g., contact) allergy to latex, thimerosal, or egg 
Concurrent administration of coumadin or aminophylline
LAIV Health-care providers that see patients with chronic diseases or altered immunocompetence (an exception is providers for 
severely immunocompromised patients requiring care in a protected environment)
Breastfeeding
Contacts of persons with chronic disease or altered immunocompetence (an exception is contacts o f severely immunocom­
promised patients requiring care in a protected environment)
PPSV History o f invasive pneumococcal disease or pneumonia
HPV Immunosuppression
Previous equivocal or abnormal Papanicolaou test 
Known HPV infection 
Breastfeeding 
History o f genital warts
See table footnotes on page 43.
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TABLE 7. (Continued) Conditions com m only misperceived as contraindications to  vaccination
Vaccine
Conditions commonly misperceived as contraindications 
(i.e., vaccination may be administered under these conditions)
Rotavirus Prematurity
Immunosuppressed household contacts 
Pregnant household contacts
Zoster Therapy with low-dose methotrexate (<0.4 mg/kg/week), azathioprine (<3.0 mg/kg/day), or 6-mercaptopurine 
(<1.5 mg/kg/day) for treatment of rheumatoid arthritis, psoriasis, polymyositis, sarcoidosis, inflammatory bowel 
disease, or other conditions 
Health-care providers of patients with chronic diseases or altered immunocompetence 
Contacts of patients with chronic diseases or altered immunocompetence 
Unknown or uncertain history of varicella in a U.S.-born person
Abbreviations: DT = diphtheria and tetanus toxoids; DTP = diphtheria toxoid, tetanus toxoid, and pertussis; DTaP = diphtheria and tetanus toxoids and acellular 
pertussis; HBsAg = hepatitis B surface antigen; Hib = Haemophilus influenzae type b; HPV = human papillomavirus; IPV= inactivated poliovirus; LAIV= live, attenuated 
influenza vaccine; MCV4 = quadrivalent meningococcal conjugatevaccine;MMR = measles, mumps, and rubella; MPSV4 = quadrivalent meningococcal polysaccharide 
vaccine; PCV = pneumococcal conjugate vaccine; PPSV = pneumococcal polysaccharide vaccine;Td = tetanus and diphtheria toxoids;Tdap = tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis;TIV = trivalent inactivated influenza vaccine.
* Antibacterial drugs might interfere with Ty21a oral typhoid vaccine, and certain antiviral drugs might interfere with varicella-containing vaccines and LAIV.
+ Hepatitis B vaccination should be deferred for infants weighing <2,000 g if the mother is documented to be HBsAg-negative at the time of the infant's birth. 
Vaccination can commence at chronological age 1 month or at hospital discharge. For infants born to HBsAg-positive women, hepatitis B immune globulin and 
hepatitis B vaccine should be administered within 12 hours after birth, regardless o f weight.
5 MMR and varicella vaccines can be administered on the same day. If  not administered on the same day, these vaccines should be separated by at least 28 days. 
HIV-infected children should receive immune globulin after exposure to measles. HIV-infected children can receive varicella and measles vaccine if CD4+T-lymphocyte 
count is >15%. (Source: Adapted from American Academy of Pediatrics. Passive immunization. In: Pickering LK, ed. Red book: 2009 report of the Committee on 
Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy o f Pediatrics; 2009.)
** Measles vaccination might suppress tuberculin reactivity temporarily. Measles-containing vaccine can be administered on the same day as tuberculin skin testing. 
If testing cannot be performed until after the day of MMR vaccination, the test should be postponed for at least 4 weeks after the vaccination. If an urgent need 
exists to skin test, do so with the understanding that reactivity m ight be reduced by the vaccine. 
f t  If a vaccinee experiences a presumed vaccine-related rash 7-25 days after vaccination, the person should avoid direct contact with immunocompromised persons 
for the duration of the rash.
TABLE 8. Treatm ent o f anaphylaxis in children and adults w ith  drugs adm inistered intramuscularly or orally
Drug Dosage
Children
Primary regimen
Epinephrine 1:1000 (aqueous) (1 mg/mL)* 0.01 mg/kg up to 0.5 mg (administer 0.01 mL/kg/dose up to 0.5 mL) IM repeated every 10-20 minutes
up to 3 doses
Secondary regimen
Diphenhydramine 1-2 mg/kg oral, IM, or IV, every 4-6 hours (100 mg, maximum single dose)
Hydroxyzine 0.5-1 mg/kg oral, IM, every 4-6 hours (100 mg, maximum single dose)
Prednisone 1.5-2 mg/kg oral (60 mg, maximum single dose); use corticosteroids as long as needed
Adults
Primary regimen
Epinephrine 1:1000 (aqueous)* 0.01 mg/kg up to 0.5 mg (administer 0.01 mL/kg/dose up to 0.5 mL) IM repeated every 10-20 minutes
up to 3 doses
Secondary regimen
Diphenhydramine 1-2 mg/kg up to 100 mg IM or oral, every 4-6  hours
Abbreviations: IM = intramuscular; IV = intravenous.
Sources: Adapted from American Academy of Pediatrics. Passive immunization. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS. Red book: 2009 report o f the 
Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009:66-7; Immunization Action Coalition. Medical management 
o f vaccine reactions in adult patients (available at www.immunize.org/catg.d/p3082.pdf); and Mosby's Drug Consult. St. Louis, MO: Elsevier; 2005.
* If the agent causing the anaphylactic reaction was administered by injection, epinephrine may be injected into the same site to slow absorption.
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TABLE 9. Dose and route o f adm inistration for selected vaccines
Vaccine Dose Route
DTaP, DT,Td, Tdap 0.5 mL IM
DTaP-HepB-IPV 0.5 mL IM
DTaP/Hib 0.5 mL IM
DTaP-IPV/Hib 0.5 ml_ IM
DTaP-IPV 0.5 mL IM
Hib 0.5 ml_ IM
Combination Hib/HepB 0.5 mL IM
HepA <18 years: 0.5 mL 
>19 years: 1.0 mL
IM
HepB <19 years: 0.5 mL* 
>20 years: 1.0 mL
IM
HepA-HepB >18 years: 1.0 mL IM
LAIV 0.2 mL divided dose between nares Intranasal spray
TIV 6-35 months: 0.25 mL 
>3 years: 0.5 mL
IM
MMR 0.5 mL SC
MMRV 0.5 mL SC
MCV4 0.5 mL IM
MPSV4 0.5 mL SC
PCV 0.5 mL IM
PPSV 0.5 mL IM or SC
HPV (HPV2 or HPV4) 0.5 mL IM
IPV 0.5 mL IM or SC
Rotavirus (RV1 or RV5) (1.0 mL or 2.0 mL) Oral
Varicella 0.5 mL SC
Herpes zoster 0.65 mL SC
Abbreviations: DT = diphtheria and tetanus toxoids; DTP = diphtheria toxoid, tetanus toxoid, 
and pertussis; DTaP = diphtheria and tetanus toxoids and acellular pertussis; HepA= hepatitis 
A; HepB = hepatitis 6; Hib = Haemophilus influenzae type b; HPV = human papillomavirus; 
HPV2 = bivalent HPV vaccine; HPV4 = quadrivalent HPV vaccine; IM = intramuscular; IPV = 
inactivated poliovirus; LAIV = live, attenuated influenza vaccine; MCV4 = quadrivalent menin­
gococcal conjugate vaccine; MMR = measles, mumps, and rubella; MMRV= measles, mumps, 
rubella, and varicella; MPSV4 = quadrivalent meningococcal polysaccharide vaccine; PCV = 
pneumococcal conjugate vaccine; PPSV = pneumococcal polysaccharide vaccine; SC = sub­
cutaneous; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria 
toxoid, and acellular pertussis;TIV = trivalent inactivated influenza vaccine.
Source: Adapted from Immunization Action Coalition: http://www.immunize.org.
* Persons aged 11-15 years may be administered Recombivax HB (Merck), 1.0 ml_ (adult 
formulation) on a 2-dose schedule.
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TABLE 10. Needle length and injection site o f IM injections for children aged <18 years 
(by age) and adults aged >19 years (by sex and weight)
Age group Needle length Injection site
Children (b irth -18 yrs)
Neonates* % inch (16 mm)* Anterolateral thigh
infants, 1-12 mos 1 inch (25 mm) Anterolateral thigh
Toddlers, 1-2 yrs 1-1V4inch (25-32 mm) 
5/s+— 1 inch (16-25 mm)
Anterolateral thigh5 
Deltoid muscle o f arm
Children, 3-18 yrs 5/s+— 1 inch (16-25 mm) 
1—1V4 inches (25-32 mm)
Deltoid muscle o f arm5 
Anterolateral thigh
Adults (>19 yrs)
Men and women, <60 kg (130 lbs)
Men and women, 60-70 kg (130-152 lbs) 
Men, 70-118 kg (152-260 lbs)
Women, 70-90 kg (152-200 lbs)
Men, >118 kg (260 lbs)
Women, >90 kg (200 lbs)
1 inch (25 mm)1 
1 inch (25 mm)
1-1V2 inches (25-38 mm)
1V2 inches (38 mm)
Deltoid muscle o f arm
Abbreviation: IM = intramuscular.
Source: Adapted from Poland GA, Borrud A, Jacobsen RM, et al. Determination of deltoid fat pad thickness: 
implications for needle length in adult immunization. JAMA 1997;277:1709-11.
* First 28 days o f life.
T If skin is stretched tightly and subcutaneous tissues are not bunched.
5 Preferred site.
11 Some experts recommend a %-inch needle for men and women who weigh <60 kg.
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TABLE 11. Vaccine storage temperature recommendations
Vaccines
Vaccine storage 
temperature Diluent storage temperature Comments
Nonlyophilized, aluminum-adjuvanted vaccines
Diphtheria-tetanus-containing 35°F-46°F (2°C-8°C) 
vaccines (DT, Td) or pertussis- Do not freeze, 
containing vaccines (DTaP,Tdap)
No diluent* Irreversible loss of potency occurs with 
exposure to freezing temperatures.
HepA and HepB 35°F-46°F (2°C-8°C) 
Do not freeze.
No diluent Irreversible loss of potency occurs with 
exposure to freezing temperatures.
PCV 35°F-46°F (2°C-8°C) 
Do not freeze.
No diluent Irreversible loss of potency occurs with 
exposure to freezing temperatures.
HPV+ 35°F-46°F (2°C-8°C) 
Do not freeze.
No diluent Irreversible loss of potency occurs with 
exposure to freezing temperatures.
Nonlyophilized, non-aium inum-adjuvanted vaccines
PRP-OMP Hib 35°F-46°F (2°C-8°C) No diluent —
IPV 35°F-46°F (2°C-8°C) No diluent Data on thermostability properties of 
these vaccines are lacking.
MCV4+'5 35°F-46°F (2°C-8°C) No diluent Data on thermostability properties of 
these vaccines are lacking.
PPSV 35°F-46°F (2°C-8°C) No diluent Data on thermostability properties of 
these vaccines are lacking.
TIV+ 35°F-46°F (2°C-8°C) No diluent Data on thermostability properties of 
these vaccines are lacking.
Lyophilized (nonvaricella) vaccines
PRP-THib1 35°F-46°F (2°C-8°C)11 35°F-46°F (2°C-8°C) 
Do not freeze.
—
MMR+ 35°F-46°F (2°C-8°C)1 35°F-77°F (2°C-25°C)
Can be refrigerated or stored at room temperature
Do not expose to light or temperatures 
above the recommended range.
MPSV4 35°F-46°F (2°C-8°C)11 Data are lacking on ideal pre-reconstitution storage 
requirements. After reconstitution, vaccine should be 
stored at 35°F-46°F (2°C-8°C).
Do not freeze.
Freeze dried (lyophilized) vaccine. Data 
on the effect of freezing temperatures 
on potency are lacking.
Varicella-containing vaccines
MMRV1 -58°F-5°F (-50°C to-15°C) 35°F-77°F (2°C-25°C)
Can be refrigerated or stored at room temperature
—
Varicella1 <5°F (<-15°C) 35°F-77°F (2°C-25°C)
Can be refrigerated or stored at room temperature
—
Herpes zoster1 <5°F (S-15°C) 35°F-77°F (2°C-25°C)
Can be refrigerated or stored at room temperature
—
Noninjectable vaccines
RV5 vaccine1- 35°F-46°F (2°C-8°C) 
Do not freeze.
No diluent —
RV1 vaccine1 35°F-46°F (2°C-8°C) 
Do not freeze.
The diluent may be stored at a controlled room 
temperature 20°C-25°C (68°F-77°F).
Do not freeze.
LAIV 35°F-46°F (2°C-8°C) No diluent Do not expose to temperatures above 
the recommended range.
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular pertussis; HepA = hepatitis A; HepB = hepatitis B; Hib = 
Haemophilus influenzae type b; HPV = human papillomavirus; IPV= inactivated poliovirus; LAIV = live, attenuated influenza vaccine; MCV4 = quadrivalent meningo­
coccal conjugate vaccine; MMR = measles, mumps, and rubella; MMRV= measles, mumps, rubella, and varicella; MPSV4 = quadrivalent meningococcal polysaccharide 
vaccine; PCV = pneumococcal conjugate vaccine; PPSV = pneumococcal polysaccharide vaccine; PRP-OMB = polyribosylribitol phosphate-meningococcal outer 
membrane protein conjugate; PRP-T = polyribosylribitol phosphate polysaccharide conjugated to a tetanus toxoid; RV= rotavirus; RV1 = live, attenuated monovalent 
rotavirus vaccine; RV5 = live, reassortment pentavalent rotavirus vaccine; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis;TIV= trivalent inactivated influenza vaccine.
Source: Adapted from Atkinson WL, Kroger AT, Pickering LK. General immunization practices. In: Plotkin SA, Orenstein WA, editors. Vaccines. 35th ed. Philadelphia, 
PA: Elsevier; 2008; and CDC. Guidelines for maintaining and managing the vaccine cold chain. MMVVR 2003;52:1023-5.
*  DTaP-Tripedia is sometimes used as a diluent for Actl-lib.
I  Protect from light.
5 There are two meningococcal conjugate vaccines; Menactra is nonlyophilized, and Menveo is lyophilized. Both powder and diluent should be stored at 35°F-46°F.
II The lyophilized pellet may be stored at freezer temperature; the reconstituted vaccine should be stored at refrigerator temperature.
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TABLE 12. Comparison o f therm om eters used to  m onitor vaccine tem peratures
Thermometer type Advantages Disadvantages
Continuous chart recorder Most accurate
Continuous 24-hour readings of temperature range and 
duration
Can be recalibrated at regular intervals
Most expensive
Requires most training and maintenance
Minimum-maximum Inexpensive
Monitors temperature range
Accurate within a range o f +/-1°C.
No information about the duration o f out-of-range temperature 
Cannot be recalibrated at routine intervals
Standard fluid filled Inexpensive and simple to use 
Because thermometers encased in biosafe liquids, can 
reflect vaccine temperatures more accurately than those 
directly exposed to the air
Accurate within a range o f +/-1°C
No information about duration of out-of-temperature exposure 
No information on minimum/maximum temperatures 
Cannot be recalibrated at routine intervals 
Might experience poor performance from inexpensive models
Source: Adapted from CDC. Guidelines for maintaining and managing the vaccine cold chain. MMWR 2003;52:1023-5; and Langley A, Grant S, eds. Proceedings of 
the National Vaccine Storage Workshop; June 28-30; Brisbane, Australia. Maroochydore: Queensland Health; 2004.
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TABLE 13. Vaccination o f persons w ith  prim ary and secondary imm unodeficiencies
Primary Specific immunodeficiency Contraindicated vaccines*
Risk-specific 
recommended vaccines* Effectiveness and comments
B-lymphocyte
(humoral)
Severe antibody deficiencies (e.g., X-linked 
agammaglobulinemia and common 
variable immunodeficiency)
OPV+
Smallpox
LAIV
BCG
Ty21a (live typhoid) 
Yellow fever
Pneumococcal 
Consider measles and 
varicella vaccination
The effectiveness o f any vaccine is uncertain if 
it depends only on the humoral response 
(e.g., PPSV or MPSV4).
IGIV interferes w ith  the  immune response to  
measles vaccine and possibly varicella 
vaccine.
Less severe antibody deficiencies (e.g., 
selective IgA deficiency and IgG subclass 
deficiency
OPV+
BCG
Yellow fever
Other live vaccines appear to  be safe.
Pneumococcal All vaccines likely effective; immune response 
m ight be attenuated.
T-lymphocyte 
(cell-mediated and 
humoral)
Complete defects (e.g., severe combined 
immunodeficiency [SCID] disease, 
complete DiGeorge syndrome)
All live vaccines^»** Pneumococcal Vaccines m ight be ineffective.
Partial defects (e.g., most patients w ith 
DiGeorge syndrome, Wiskott-Aldrich 
syndrome, ataxia-telangiectasia)
All live vaccines^»** Pneumococcal 
Meningococcal 
Hib (if not administered 
in infancy)
Effectiveness o f any vaccine depends on 
degree o f immune suppression.
Complement Persistent complement, properdin, or factor 
B deficiency
None Pneumococcal
Meningococcal
All routine vaccines likely effective.
Phagocytic function Chronic granulomatous disease, leukocyte 
adhesion defect, and myeloperoxidase 
deficiency.
Live bacterial vaccines^ Pneumococcal’1"1' All inactivated vaccines safe and likely 
effective.
Live viral vaccines likely safe and effective.
Secondary HIV/AIDS OPV+
Smallpox
BCG
LAIV
W ithhold MMR and varicella in 
severely immunocompromised 
persons.
Yellow fever vaccine m ight have a 
contraindication or a precaution 
depending on clinical parameters 
o f immune function***
Pneumococcal 
Consider Hib (if not 
administered in infancy) 
and meningococcal 
vaccination.
MMR, varicella, rotavirus, and all inactivated 
vaccines, including inactivated influenza, 
m ight be e ffective.^
Malignant neoplasm, transplantation, 
immunosuppressive or radiation therapy
Live viral and bacterial, depending 
on immune s ta tu s^
Pneumococcal Effectiveness o f any vaccine depends on 
degree o f immune suppression.
Asplenia None Pneumococcal 
Meningococcal 
Hib (if not administered in 
infancy)
All routine vaccines likely effective.
Chronic renal disease LAIV Pneumococcal 
Hepatitis B™
All routine vaccines likely effective.
Abbreviations: AIDS = acquired immunodeficiency syndrome; BCG = bacille Calmette-Guérin; Hib Haemophilus influenzae type  b; HIV = human immunodeficiency virus; IG = immuno­
globulin; IGIV = immune globulin intravenous; LAIV ~ live, attenuated influenza vaccine; iVliVlR- measles, mumps, and rubella; MPSV4-quadrivalent meningococcal polysaccharide vaccine; 
OPV = oral poliovirus vaccine (live); PPSV = pneumococcal polysaccharide vaccine; TIV = trivalent inactivated influenza vaccine.
Source: Adapted from American Academy of Pediatrics. Passive immunization. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS eds. Red book: 2009 report o f the Committee on Infectious 
Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:74-5.
* Other vaccines that are universally or routinely recommended should be given if not contraindicated.
+ OPV is no longer available in the United States.
5 Live bacterial vaccines: BCG and oral Ty21a Salmonella Typhi vaccine.
11 Live viral vaccines: MMR, MMRV, OPV, LAIV, yellow fever, zoster, rotavirus, varicella, and vaccinia (smallpox). Smallpox vaccine is not recommended for children or 
the general public.
** Regarding T-lymphocyte immunodeficiency as a contraindication for rotavirus vaccine, data exist only for severe combined immunodeficiency. 
t f  Pneumococcal vaccine is not indicated for children with chronic granulomatous disease beyond age-based universal recommendations for PCV. Children with 
chronic granulomatous disease are not at increased risk for pneumococcal disease.
55 HIV-infected children should receive IG after exposure to measles and may receive varicella and measles vaccine if CD4+T-lymphocyte count is >15%.
1,11 Indicated based on the risk from dialysis-based bloodborne transmission.
*** Symptomatic HIV infection or CD4+ T-lymphocyte count o f <200/mm3 or <15% o f total lymphocytes for children aged <6 years is a contraindication to yellow 
fever vaccine administration. Asymptomatic HIV infection with CD4+T-lymphocyte count of 200-499/mm3 for persons aged >6 years or 15%-24% o f total lym­
phocytes for children aged <6 years is a precaution for yellow fever vaccine administration. Details o f yellow fever vaccine recommendations are available from 
CDC. (CDC. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2010;59[No. RR-7].)
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TABLE 14. Approaches to  evaluation and vaccination o f persons vaccinated outside the  United States w ho have no (or questionable) vaccina­
tion records
Vaccine Recommended approach Alternative approach*
MMR Revaccination with MMR Serologic testing for IgG antibodies to measles, mumps, 
and rubella
Hib Age-appropriate revaccination —
Hepatitis A Age-appropriate revaccination Serologic testing for IgG antibodies to hepatitis A
Hepatitis B Age-appropriate revaccination and serologic testing for HBsAgf —
Poliovirus Revaccination with inactivated poliovirus vaccine Serologic testing for neutralizing antibody to poliovirus types 1, 
2, and 3 (limited availability)
DTaP Revaccination with DTaP, with serologic testing for specific IgG 
antibody to tetanus and diphtheria toxins in the event of a 
severe local reaction
Persons whose records indicate receipt o f >3 doses: serologic 
testing for specific IgG antibody to diphtheria and tetanus 
toxins before administering additional doses (see text), or 
administer a single booster dose o f DTaP, followed by serologi­
cal testing after 1 month for specific IgG antibody to diphtheria 
and tetanus toxins with revaccination as appropriate (see text)
Tdap Age-appropriate vaccination of persons who are candidates for 
Tdap vaccine on the basis of time since last diphtheria and 
tetanus-toxoid-containing vaccines.
Varicella Age-appropriate vaccination of persons who lack evidence of 
varicella immunity
—
Pneumococcal conjugate Age-appropriate vaccination —
Rotavirus Age-appropriate vaccination —
HPV Age-appropriate vaccination —
Zoster Age-appropriate vaccination —
Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis; HBsAg = hepatitis B surface antigen; Hib = Haemophilus influenzae type b; HPV= human 
papillomavirus; IgG = immune globulin G; MMR = measles, mumps, and rubella; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.
* There is a recommended approach for all vaccines and an alternative approach for some vaccines.
f  In rare instances, hepatitis B vaccine can give a false-positive HBsAg result up to 18 days after vaccination; therefore, blood should be drawn to test for HBsAg before 
vaccinating (Source: CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations 
o f the Advisory Committee on Immunization Practices [ACIP]; Part I: Immunization in Infants, Children, and Adolescents. MMWR 2005;54(No. RR-16.])
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TABLE 15. Recom m endations regarding interventions to im prove coverage o f vaccines recom m ended for routine use am ong children, ado­
lescents, and adults
Intervention Recommendation
Increase community demand for vaccination
Client reminder or recall systems Strongly recommended
Multicomponent interventions, including education Strongly recommended
Requirements for entry to schools, child-care facilities, and colleges Recommended
Community education alone Insufficient evidence
Clinic-based education Insufficient evidence
Patient or family incentives or sanctions Insufficient evidence
Client-held medical records Insufficient evidence
Enhance access to vaccination services
Reducing out-of-pocket costs Strongly recommended
Enhancing access through the U.S. Department of Agriculture's Women, Infants, and Children program Recommended
Home visits, outreach, and case management Recommended
Enhancing access at schools Recommended
Expanding access in health care settings Recommended as part of multicomponent interventions only
Enhancing access at child care centers Insufficient evidence
Focus on providers
Reminder or recall systems Strongly recommended
Assessment and feedback Strongly recommended
Standing orders Strongly recommended
Provider education alone Insufficient evidence
Source: Adapted from Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, ado­
lescents and adults. Am J Prev Med 2000;18:92-6, and Task Force on Community Preventive Services. Recommendations to improve targeted vaccination coverage 
among high-risk adults. Am J Prev Med 2005;28:231-7.
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FIGURE 1. Intram uscular needle insertion FIGURE 4. Subcutaneous site o f adm inistration: triceps
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90° angle ,
Derm is.
Fatty tissue . 
(subcutaneous)
Muscle tissue .
Source: Adapted from California Immunization Branch.
FIGURE 2. Intram uscular/subcutaneous site o f adm inistration: an te ­
rolateral thigh
FIGURE 5. Subcutaneous needle insertion
FIGURE 3. Intram uscular site o f adm inistration: deltoid
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FIGURE 6. Sample tem perature log
Temperature Log forVaccines (Fahrenheit) Month/Year:_ Days 1-15
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Source: Adapted from Immunization Action Coalition. Available at http://www.immunize.Org/catg.d/p3039.pdf. Accessed December 1,2010.
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Abbreviations
AAFP Am erican Academy o f  Family Physicians
AAP Am erican Academy o f  Pediatrics
A CIP Advisory C om m ittee on Im m unization Practices
D T  pediatric diphtheria-tetanus toxoid
DTaP pediatric diphtheria and tetanus toxoids and acellular pertussis
FD A  Food and D rug A dm inistration
GBS Guillain-Barré syndrom e
H B IG  hepatitis B im m une globulin
HBsAg hepatitis B surface antigen
H ib Haemophilus influenzae type b
H IV  hum an im m unodeficiency virus
H P V  hum an papillomavirus
H C T  hem atopoietic cell transplant
IgG im m unoglobulin  G
IG IV  intravenous im m une globulin
IPV  inactivated poliovirus
LAIV live, attenuated influenza vaccine
M C V 4 quadrivalent meningococcal conjugate vaccine
M M R  measles, m um ps, and rubella
M M R V  measles, m um ps, rubella, and varicella
M PSV4 quadrivalent meningococcal polysaccharide vaccine
O P V  oral poliovirus
O SH A  O ccupational Safety and H ealth  A dm inistration
PC V  pneum ococcal conjugate vaccine
P R P-O M P Haemophilus influenzae type b-polyribosylribitol phosphate-meningococcal outer membrane protein conjugate
PPSV pneum ococcal polysaccharide vaccine
RV1 live, attenuated monovalent rotavirus vaccine
RV5 live, reassortant pentavalent rotavirus vaccine
T d adult tetanus and diphtheria toxoids
T dap tetanus and reduced diphtheria toxoids and acellular pertussis (for adolescents and adults)
T IV  trivalent inactivated influenza vaccine
T S T  tuberculin skin test
VAERS Vaccine Adverse Event Reporting System
VIS vaccine inform ation statem ent
ZOS herpes zoster vaccine
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Glossary
Adverse event. An untoward event that occurs after a vaccination 
that might be caused by the vaccine product or vaccination process. 
Adverse events include those that have the following characteristics: 
1) vaccine induced (caused by the intrinsic characteristic of the 
vaccine preparation and the individual response of the vaccinee): 
these events would not have occurred without vaccination (e.g., 
vaccine-associated paralytic poliomyelitis); 2) vaccine potentiated: 
the events would have occurred anyway but were precipitated by 
the vaccination (e.g., first febrile seizure in a predisposed child); 
3) programmatic error: the event was caused by technical errors 
in vaccine preparation, handling, or administration; and 4) coin­
cidental: the event was associated temporally with vaccination by 
chance or caused by underlying illness. Special studies are needed 
to determine whether an adverse event is a reaction to the vaccine 
or the result of another cause (Sources: Chen RT. Special meth­
odological issues in pharmacoepidemiology studies of vaccine 
safety. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. Sussex, 
England: John Wiley & Sons; 2000:707-32; and Fenichel GM, 
Lane DA, Livengood JR, Horwitz SJ, Menkes JH , Schwartz JF. 
Adverse events following immunization: assessing probability of 
causation. Pediatr Neurol 1989;5:287-90).
Adverse reaction. An undesirable medical condition that has 
been demonstrated to be caused by a vaccine. Evidence for the 
causal relation is usually obtained through randomized clinical 
trials, controlled epidemiologic studies, isolation of the vaccine 
strain from the pathogenic site, or recurrence of the condition 
with repeated vaccination (i.e., rechallenge); synonyms include 
side effect and adverse effect.
A djuvant. A vaccine component distinct from the antigen that 
enhances the immune reponse to the antigen.
A ntitoxin. A solution of antibodies against a toxin. Antitoxin 
can be derived from either human (e.g., tetanus immune globulin) 
or animal (usually equine) sources (e.g., diphtheria and botulism 
antitoxin). Antitoxins are used to confer passive immunity and 
for treatment.
H y p e rim m u n e  g lo b u lin  (sp e c ific ). Special preparations 
obtained from blood plasma from donor pools preselected for a 
high antibody content against a specific antigen (e.g., hepatitis B 
immune globulin, varicella-zoster immune globulin, rabies immune 
globulin, tetanus immune globulin, vaccinia immune globulin, 
cytomegalovirus immune globulin, botulism immune globulin).
Im m une globulin. A sterile solution containing antibodies, 
which are usually obtained from hum an blood. It is obtained 
by cold ethanol fractionation of large pools of blood plasma and 
contains 15%— 18% protein. Intended for intramuscular adminis­
tration, immune globulin is primarily indicated for routine main­
tenance of immunity among certain immunodeficient persons and 
for passive protection against measles and hepatitis A.
Im m u n o b io lo g ic . Antigenic substances (e.g., vaccines and 
toxoids) or antibody-containing preparations (e.g., globulins and 
antitoxins) from human or animal donors. These prod ucts are used 
for active or passive immunization or therapy. Examples of immu­
nobiologies include antitoxin, immune globulin and hyperimmune 
globulin, monoclonal antibodies, toxoids, and vaccines.
Intravenous im m une globulin. A product derived from blood 
plasma from a donor pool similar to the immune globulin pool, 
but prepared so that it is suitable for intravenous use. Intravenous 
immune globulin is used primarily for replacement therapy in 
primary antibody-deficiency disorders, for treatment of Kawasaki 
disease, immune thrombocytopenic purpura, hypogammaglobu­
linemia in chronic lymphocytic leukemia, and certain cases of 
human immunodeficiency virus infection (Table 5).
M onoclonal antibody. An antibody product prepared from a 
single lymphocyte clone, which contains only antibody against a 
single antigen.
S im ultaneous. In the context of vaccine timing and spacing, 
occurring on the same clinic day, at different anatomic sites, and 
not combined in the same syringe.
Toxoid. A modified bacterial toxin that has been made nontoxic, 
but retains the ability to stimulate the formation of antibodies to 
the toxin.
Vaccination and im m unization. The terms vaccine and vaccina­
tion are derived from rncca, the Latin term for cow. Vaccine was the 
term used by Edward Jenner to describe material used (i.e., cowpox 
virus) to produce immunity to smallpox. The term vaccination was 
used by Louis Pasteur in the 19th century to include the physical 
act of administering any vaccine or toxoid. Immunization is a 
more inclusive term, denoting the process of ind ucing or providing 
immunity by administering an immunobiologic. Immunization 
can be active or passive. Active immunization is the production 
of antibody or other immune responses through administration 
of a vaccine or toxoid. Passive immunization means the provi­
sion of temporary immunity by the administration of preformed 
antibodies. Although persons often use the terms vaccination and 
immunization interchangeably in reference to active immunization, 
the terms are not synonymous because the administration of an 
immunobiologic cannot be equated automatically with develop­
ment of adequate immunity.
Vaccine. A suspension of live (usually attenuated) or inactivated 
microorganisms (e.g., bacteria or viruses) or fractions thereof 
administered to induce immunity and prevent infectious disease or 
its sequelae. Some vaccines contain highly defined antigens (e.g., 
the polysaccharide of Haemophilus influenzae type b or the surface 
antigen of hepatitis B); others have antigens that are complex or 
incompletely defined (e.g., Bordetella pertussis antigens or live, 
attenuated viruses).
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